

Guidance on Radiation Dose Limits for the Lens of the Eye

February 5, 2016

1 **Preface**

2

3 This Commentary has been prepared in order to provide guidance on whether existing
4 dose limits to the lens of the eye should be changed in the United States. The guidance is based
5 on a detailed evaluation of recent studies on the radiation dose response for the development of
6 cataracts.

7

8 A number of NCRP publications have addressed the issues of risk and dose limitation in
9 radiation protection that have included specific organs and the lens of the eye:

10

- 11 • Report No. 91, Recommendations on Limits for Exposure to Ionizing Radiation
12 (NCRP, 1987);
- 13 • Report No. 98, Guidance on Radiation Received in Space Activities (NCRP,
14 1989a);
- 15 • Report No. 115, Risk Estimates for Radiation Protection (NCRP, 1993a);
- 16 • Report No. 116, Limitation of Exposure to Ionizing Radiation (NCRP 1993b);
- 17 • Commentary No. 12, Radiation Exposure and High-Altitude Flight (NCRP,
18 1995);
- 19 • Report No. 132, Radiation Protection Guidance for Activities in Low-Earth Orbit
20 (NCRP, 2000);
- 21 • Report No. 136, Evaluation of the Linear-Nonthreshold Dose-Response Model for
22 Ionizing Radiation (NCRP, 2001);
- 23 • Report No. 167, Potential Impact of Individual Genetic Susceptibility and
24 Previous Radiation Exposure on Radiation Risk for Astronauts (NCRP, 2010a);
- 25 • Report No. 168, Radiation Dose Management for Fluoroscopically-guided
26 Interventional Medical Procedures (NCRP, 2010b); and,
- 27 • Report No. 174, Preconception and Prenatal Radiation Exposure: Health Effects
28 and Protective Guidance (NCRP, 2013).

29

54

Consultants

Cynthia M. Flannery
U.S. Nuclear Regulatory Commission
Rockville, Maryland

Nobuyuki Hamada
Central Research Institute of Electric
Power Industry
Tokyo, Japan

Lee E. Goldstein
Boston University
Boston, Massachusetts

Phung K. Tran
Electric Power Research Institute
Palo Alto, California

55

56

NCRP Secretariat

57

Michael P. Grissom, Staff Consultant

58

Cindy L. O'Brien, Managing Editor

59

Laura J. Atwell, Office Manager

60

James R. Cassata, Executive Director

61

David A. Smith, Executive Director

62

63

The Council wishes to express its appreciation to the Committee members for the time and effort devoted to the preparation of this Commentary and to the Centers for Disease Control and Prevention and to the U.S. Nuclear Regulatory Commission for financial support.

66

67

68

John D. Boice, Jr.
President

69

70 **Contents**

71

72 Preface ii

73 1. Executive Summary 1

74 2. Introduction 6

75 **2.1** Background 8

76 **2.1.1** Purpose 9

77 **2.1.2** Evaluation Methodologies 10

78 **2.2** Core Questions 10

79 **2.2.1** Should radiation-induced cataracts be characterized as stochastic or

80 deterministic effects? 10

81 **2.2.2** What effects do LET, dose rate, acute and/or protracted dose delivery have on

82 cataract induction and progression? 11

83 **2.2.3** How should detriment be evaluated for cataracts? 11

84 **2.2.4** Based on current evidence should NCRP change the recommended limit for the

85 lens of the eye? 12

86 3. Radiation Protection Principles 13

87 **3.1** Issue of Radiation Risks 14

88 **3.1.1** BEIR V Report 14

89 **3.1.2** UNSCEAR 14

90 **3.2** Foundation of Dose Limits 15

91 **3.3** Previous NCRP Recommendation on the Lens of the Eye 15

92 **3.4** Previous ICRP Recommendations 19

93 **3.5** Other International Reviews 19

94 **3.6** Practical Radiation Protection of the Eye 23

95 **3.6.1** Monitoring Eye Doses 23

96 **3.6.1.1** ICRP External Dose Factors for Lens of the Eye 27

97 **3.6.1.2** EURADOS and ORAMED European Projects 29

98 **3.6.2** Methodologies for Protecting the Eye 30

99 **3.6.3** Health Surveillance Programs 30

100	4. Eye Biology and Lens Effects	32
101	4.1 Eye Biology	32
102	4.1.1 Lens Anatomical Features	34
103	4.1.2 Lens Proliferative Organization	36
104	4.2 Cataracts	36
105	4.2.1 Cataracts and Opacifications	36
106	4.2.2 Cataract Types, Severity and Impact on Vision	38
107	4.2.3 Cataract Causes	40
108	4.2.4 Cataract Mechanisms	41
109	4.2.5 Examination and Quantification of Lens Changes	43
110	4.3 Radiation Effects on the Eye	52
111	4.3.1 Normal Tissue Complications of the Eye.....	52
112	4.3.2 Radiation Cataractogenesis	54
113	4.3.2.1 Absorbed Dose.....	55
114	4.3.2.2 Dose Rate.....	55
115	4.3.2.3 Fractionation	57
116	4.3.2.4 Radiation Quality and RBE	57
117	4.3.2.5 Age.....	58
118	4.3.2.6 Gender.....	59
119	4.3.2.7 Steroid Sex Hormones	60
120	4.3.2.8 Latency	61
121	4.3.3 Mechanisms of Radiation Cataractogenesis.....	65
122	4.3.3.1 Cellular Biology.....	65
123	4.3.3.2 Protein Accumulation	66
124	4.3.3.3 Molecular Biology.....	66
125	4.3.3.4 Oxidative Stress	67
126	4.3.3.5 DNA Damage	68
127	4.3.3.6 Genetic Susceptibility	68
128	4.3.4 Research Gaps	69
129	5. Epidemiological Evidence Related to Ionizing Radiation and Cataracts	72

130	5.1	Introduction	72
131	5.1.1	Recent Reviews of Radiation Cataractogenesis Epidemiological Studies	73
132	5.1.2	Previous Epidemiological Studies	75
133	5.1.2.1	Atomic Bomb	75
134	5.1.2.2	Chernobyl	77
135	5.1.2.3	Medical Patients	77
136	5.1.2.4	Health Care Personnel	78
137	5.1.2.5	Flight Personnel and Astronauts	78
138	5.1.2.6	Other Occupationally Exposed Persons	78
139	5.1.2.6.1	External Exposure	79
140	5.1.2.6.2	Internal Exposure	79
141	5.1.2.6.3	Single Person Results	79
142	5.1.2.7	Population Studies and Residentially Exposed Persons	80
143	5.2	Uncertainties	81
144	5.2.1	Risk and Confounding Factors	81
145	5.3	Evaluating the Epidemiological Evidence	82
146	5.3.1	Variety of Studies	82
147	5.3.2	Epidemiological Quality of Studies	82
148	5.3.3	Odds Ratio Meta-analysis	84
149	5.3.4	Threshold Evaluations	86
150	5.4	Conclusions from Eye Epidemiological Studies	86
151	5.4.1	Results of Eye Epidemiological Evaluation	86
152	5.4.2	Future Work	87
153	6.	Exposed Populations and Implications	89
154	6.1	General – Members of the Public and Occupational Exposures	89
155	6.2	Medical – Occupational and Patients	90
156	6.2.1	Patients	90
157	6.2.2	Workers	92
158	6.3	Nuclear Facilities	95
159	6.3.1	Monitoring	95

160	6.3.2	Protection of the Eye Lens	97
161	6.4	Industrial Radiography	97
162	6.5	Astronauts	98
163	7.	Conclusions and Recommendations	100
164	7.1	Detailed Conclusions and Recommendations	100
165	7.1.1	Should radiation-induced cataracts be characterized as stochastic or deterministic effects?	100
166	7.1.2	What effects do LET, dose rate, acute, and/or protracted dose delivery have on cataract induction and progression?	101
167	7.1.3	How should detriment be evaluated for cataracts?	101
168	7.1.4	Based on current evidence, should NCRP change the recommended limit for the lens of the eye?	102
169	7.2	Additional Recommendations for Evaluation and Research	103
170	7.2.1	Comprehensive Evaluation of Overall Effects of Radiation on the Eye	103
171	7.2.2	Dosimetry Methodology and Dose-sparing Optimization	104
172	7.2.3	Additional High Quality Epidemiologic Studies	104
173	7.2.4	Understanding the Mechanisms of Cataract Development	105
174		Appendix A. Previous Epidemiological Studies Tables	107
175		Appendix B. Evaluating the Epidemiological Evidence Tables	126
176		Glossary	130
177		Symbols, Abbreviations and Acronyms	137
178		References	139
179		Scientific Committee	180
180		The NCRP	#
181		NCRP Commentaries	#
182			
183			
184			
185			
186			

187 **1. Executive Summary**

188

189 The major radiation damage response of the clear crystalline lens of the eye is the loss of
190 lens clarity resulting in clouding or opacification known as a cataract that in an extreme case
191 (usually after high doses > 5 Gy in a single exposure) can cause blindness (e.g., significant visual
192 impairment). However, exposure to low doses of radiation can lead to minor opacifications many
193 years later. The impact of cataract outcomes on vision following either high- or low-doses are
194 highly dependent on the type of radiation, how the exposure of the lens was delivered with
195 respect to dose fraction and time, the genetic susceptibilities of the individual exposed, and also
196 the actual location of the opacity within the lens that may form relative to the visual axis of the
197 individual. The International Commission on Radiological Protection (ICRP) has recently
198 recommended a reduced equivalent dose limit for occupational exposure of the lens of the eye to
199 20 mSv y^{-1} , averaged over 5 y, with no single y > 50 mSv, based on an evaluation of the
200 epidemiological evidence of cataracts in radiation-exposed human populations. Consideration of
201 these recommendations for lower dose limits, and the cost-benefit consequences associated with
202 adopting them, is taking place worldwide by countries including the United States. This NCRP
203 Commentary was requested by the U.S. Nuclear Regulatory Commission to evaluate clinical and
204 experimental evidence for the risk of radiation-induced cataract, to consider cataract types and
205 dose and dose-rate dependence of cataract formation, to provide guidance on whether existing
206 dose limits to the eye should be changed in the United States, and to identify whether any
207 research gaps exist in our understanding of radiation effects on the lens of the eye.

208

209 This Commentary addresses radiation protection principles with respect to the lens of the
210 eye, summarizes the current understanding of eye biology and lens effects (including ionizing
211 radiation effects), reviews and evaluates the current epidemiology related to ionizing radiation
212 and cataracts, assesses exposed populations with the potential for significant radiation exposures
213 to the lens, and makes several conclusions and recommendations.

214

215 Further, this Commentary takes into account the most current information regarding the
216 epidemiologic and mechanistic understanding of the development of cataracts and specifically
217 addresses four core questions:

218
219 Should radiation-induced cataracts be characterized as stochastic or deterministic effects?

220
221 The apparent simplicity of the association between ionizing radiation exposures and the
222 formation of lenticular opacities belies the complex underlying biological factors and
223 mechanisms including: genetic susceptibility; aging; molecular, cellular, and tissue responses
224 dependent on various radiation exposure parameters. The review of mechanistic studies by
225 several authors as summarized in this Commentary suggests that radiation-induced opacities
226 could be stochastic in nature and perhaps not deterministic (i.e., tissue reactions), as long
227 thought. However, the link between the induction of any, even minor, opacities in animal models
228 and the occurrence of clinically-relevant, vision-impairing cataracts (VICs) in humans is still far
229 from clear. Because of the incoherence of the mechanistic and epidemiologic evidence, it is not
230 yet known if radiation cataractogenesis can be classified as strictly stochastic or deterministic in
231 nature. The epidemiological evidence to date indicates a threshold model, and NCRP has
232 determined that this model should continue to be used for radiation protection purposes at this
233 time.

234
235 The value of the threshold for detectable opacities or vision-impairing cataracts is less
236 clear, with the epidemiological evidence currently pointing to a threshold for vision-impairing
237 cataracts for doses in the region of 1 to 2 Gy. However, NCRP has concluded that it is not
238 possible to make a specific quantitative estimate of lens effect thresholds at this time.

239
240 What effects do LET, dose rate, acute and/or protracted dose delivery have on cataract
241 reduction and progression?

242
243 The epidemiological evidence presented in Section 5 of this Commentary demonstrates
244 that, although different studies have looked at many of these factors independently, there is still

245 very little evidence upon which to base an answer to this question. The mechanistic evidence is
246 clearer in some instances (e.g., in terms of a differential effect of increased ionizing radiation
247 qualities enhancing the induction and progression of opacities) but, as noted above, the
248 relationship between the results from animal models and risks of vision-impairing cataracts in
249 humans is still not clear. The ‘normal’ lens loses clarity with attained age due to a number of
250 physiological aging processes. As such, NCRP has determined that further, high-quality
251 epidemiological and mechanistic studies are required before the question of how exposure to
252 ionizing radiation contributes to further loss of lens clarity can be fully answered. Improvements
253 in methods to determine lens doses in the clinic and the workplace, and in technical approaches
254 to score the different types of lens opacifications arising in different anatomical regions of the
255 lens will strengthen the quality of the new dose-dependent cataract data obtained. Advancement
256 of more basic research on the exact biological target for species-specific differences in radiation-
257 induced cataract formation could lead to the development of biochemical countermeasures that
258 may be applied to attenuate or prevent cataract formation.

259

260 How should detriment be measured and/or evaluated for cataracts?

261

262 Vision-impairing cataracts could be considered the endpoint of greatest concern in terms
263 of lens radiation protection. Cataracts certainly may affect individuals’ ability to carry out their
264 occupations or other daily tasks (Hamada et al., 2014). ICRP Publication 118 (2012) noted that
265 acute doses up to about 0.1 Gy produce no functional impairment of tissues, that detectable lens
266 changes can be identified as low as between 0.2 and 0.5 Gy, and concluded that a nominal
267 threshold of 0.5 Gy for acute or protracted exposure for lens tissue effects is an appropriate
268 method for evaluating lens detriment. While NCRP recognizes that the mechanisms underlying
269 the transition of minor lens opacifications to clinically significant vision-impairing cataracts are
270 still not well understood, it is prudent to regard eye exposures and the potential for lens tissue
271 effects in much the same way as whole-body exposures (i.e., ensure exposures are consistent
272 with ALARA principles), as was previously recommended by NCRP Report No. 168 (NCRP,
273 2010b). This includes careful justification and optimization in exposure situations including
274 radiation doses to the lens of the eye.

275

276 Based on current evidence, should NCRP change the recommended limit for the lens of
277 the eye?

278

279 Current epidemiological studies of the effect of radiation on the lens of the eye indicate
280 that there is an association between exposure to ionizing radiation and initiation or development
281 of post-subcapsular cataracts, mixed and/or cortical vision-impairing cataracts in humans for
282 various exposure situations. The systematic review of the current eye epidemiology data has
283 shown that the probable risks for cataracts (i.e., specifically post-subcapsular, mixed, and/or
284 cortical cataracts) are likely increased at an exposure level that is somewhat less than the earlier
285 estimates by ICRP or NCRP. Both ICRP and NCRP had earlier assumed threshold values for
286 vision-impairing cataracts of 2 to 10 Sv for single brief exposures and > 8 Sv for protracted
287 exposures (NCRP, 1989a; ICRP, 2007). ICRP has also noted that ophthalmologically-detectable
288 opacities might result from lower doses of 0.5 to 2 Sv for acute exposures (ICRP, 1991; 2012).

289

290 NCRP acknowledges that most of the available data on lens effects have large associated
291 uncertainties and limitations that do not yet support a quantitative estimate of a specific threshold
292 value for effects from either acute or chronic lens exposures. However, the preponderance of
293 evidence appears to suggest the possibility that effects (e.g., lens opacities and/or cataracts) could
294 occur at lower doses than previously considered when developing occupational lens of the eye
295 dose limit recommendations based on the potential for worker lens doses over time. Therefore,
296 NCRP has determined that it is prudent to reduce the current recommended annual lens of the
297 eye occupational dose limit from 150 mSv (NCRP, 1993b) down to 50 mGy, a value in harmony
298 with the current occupational whole-body effective dose limit of 50 mSv (NCRP, 1993b). No
299 new annual dose limit is recommended for members of the public lens of the eye exposure as
300 NCRP judges the existing annual limit of 15 mSv (NCRP, 1993b) to be adequately protective.

301

302 NCRP no longer recommends the use of equivalent dose for specific tissue exposures,
303 because these quantities were developed for stochastic effects whereas the principal outcomes
304 being addressed are specific tissue reactions (or deterministic effects) in nature. Recommended

305 limits with regard to tissue reactions should be based on absorbed dose, as was the underlying
306 consideration for skin dose limits (NCRP, 1989b; 1993b; 1999). If it is necessary to apply the
307 recommended lens limit to high-LET radiation, NCRP recommends the approach taken in NCRP
308 Report No. 132 (2000) in which the absorbed dose is multiplied by the relative biological
309 effectiveness of the radiation to obtain a weighted gray (or ‘gray equivalent,’ Gy-Eq). This may
310 then be compared to the limit expressed in gray (Gy).

311

312 **NCRP recommends that the annual dose limit for occupational exposures for the**
313 **lens of the eye be reduced to 50 mGy.**

314

315 While the currently available information for the effects of ionizing radiation on the lens
316 has provided input on appropriate guidance with regard to radiation protection, much more work
317 is needed to develop a complete understanding of such detriments. NCRP recommends ongoing
318 evaluation and additional research in the following areas: comprehensive evaluation of the
319 overall effects of ionizing radiation on the eye, dosimetry methodology and dose-sparing
320 optimization techniques, additional high quality epidemiology studies, and a basic understanding
321 of the mechanisms of cataract development.

322

323

324 **2. Introduction**

325

326 The cornea and the crystalline lens of the eye are our windows to the world. The
327 opacification of the lens that we call ‘cataract’ prevents light from reaching the retina at the back
328 of the eye, and is the major cause of blindness worldwide, despite being curable by lens
329 replacement surgery. Cataracts can form in different anatomical locations within the lens,
330 perhaps due to different etiologies. The posterior subcapsular cataract has long been associated
331 with the radiation-induced etiology, although it might be prevalent in patients with diabetes or
332 after steroid treatments.

333

334 Prevention of cataracts is an important goal requiring an understanding of the various and
335 diverse causes of lens opacification. Significant epidemiological differences in cataract
336 prevalence have been reported in different countries depending on genetics, pathologies or
337 environmental exposures. Since early clinical evidence from radiotherapy (Merriam and Focht,
338 1957; Merriam et al., 1972) indicated an apparent dose threshold below which radiation cataracts
339 had not been reported, it was thought that radiation cataract could be prevented by limiting the
340 dose of ionizing radiation to the lens of the eye. However, the radiation etiology is complex
341 because cataracts also can be produced by exposure to a variety of wavelengths throughout the
342 electromagnetic spectrum from x rays to microwaves (Harding and Crabbe, 1984); causation also
343 has been linked to exposures to sunlight, infrared, and ultraviolet light; and, it is now understood
344 that cataracts occurring as a result of exposure to very low doses are likely to have extremely
345 long latency periods. Thus, prevention of cataracts appears to be more complex than by simply
346 limiting exposure of the lens to ionizing radiation.

347

348 Recent epidemiological evidence has suggested that the threshold dose of ionizing
349 radiation for specific tissue reaction effects with late manifestation (including the lens) may be
350 lower than previously thought (EPRI, 2014; ICRP, 2012), and that radiation cataractogenesis
351 may even be a stochastic effect. In April of 2011, ICRP issued a “Statement on Tissue
352 Reactions” (ICRP, 2011) that was followed by ICRP Publication 118 “ICRP Statement on Tissue
353 Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs – Threshold

354 Doses for Tissue Reactions in a Radiation Protection Context” (ICRP, 2012). The key issues
355 addressed in ICRP Publication 118 are the following:

356

357 • ICRP has defined a ‘practical’ threshold dose that is required to cause a particular
358 tissue injury effect in at least 1 % of exposed individuals.

359 • The threshold for lens of eye effects (cataracts and other opacities) is now
360 considered to be 0.5 Gy. Previous dose limits were based on a much higher
361 threshold, in the range of ~ 2 to > 5 Gy (ICRP, 2012).

362 • ICRP recommended a reduced equivalent dose limit for occupational exposure of
363 the lens of the eye to 20 mSv y^{-1} , averaged over 5 y, and no single y > 50 mSv.
364 This is the same value as the ICRP recommended for occupational effective dose
365 limit, which is applicable to the whole body (ICRP, 2012).

366 • The new recommended equivalent dose limit for occupational exposure of the
367 lens of the eye is based on prevention of radiogenic cataracts with an ICRP
368 underlying assumption of a nominal threshold at 0.5 Gy for acute, protracted or
369 chronic exposure. ICRP recognized that there was less evidence for protracted or
370 chronic exposure results and that the available evidence mainly refers to opacities
371 rather than cataracts impairing vision (ICRP, 2012).

372 • ICRP noted that these new recommendations (ICRP, 2012) were consistent with
373 their basic framework of radiological protection: “...to prevent the occurrence of
374 deterministic effects, by keeping doses below the relevant thresholds, and to
375 ensure that all reasonable steps are taken to reduce the induction of stochastic
376 effects...” (ICRP, 1991).

377

378 This represents a significant change from previous recommendations of an annual
379 occupational limit of 150 mSv equivalent dose for protection of the lens of the eye. These
380 changes, and the ramifications of implementing them, are under consideration by several
381 countries, including the United States.

382

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

1. The threshold of x-ray irradiation for the induction of minimally detectable lens opacities for single exposures was 2 Gy, and 5.5 Gy with exposures fractionated over 3 months or longer,
2. The threshold dose to cause a progressive cataract was about 5 Gy,
3. All patients developed cataracts after a single dose of 7.5 Gy or 14 Gy fractionated exposures, and
4. The time between exposure and detection of the cataracts was inversely related to dose.

These observations, together with additional information from other reports involving whole-body human radiation exposures for bone marrow transplantation or cancer treatments (Britten *et al.*, 1966; Henk *et al.*, 1993; Morita and Kawabe, 1979) led to the establishment of acute and protracted ionizing radiation dose limits for the lens of the eye. Another major source of information on radiation-induced cataracts came from the study of the atomic bomb survivors (Choshi *et al.*, 1983, Miller *et al.*, 1967; 1968; Otake and Schull, 1982). Primarily using these cataract data from human exposures, ICRP Publication 14 (1969), ICRP Publication 26 (1977) and ICRP Publication 60 (1991a) have provided previous radiation protection recommendations.

2.1.1 Purpose

The purpose of this Commentary is to make a detailed re-evaluation of the available literature on the radiation dose response for the development of cataracts, to evaluate the quality of the quantitative measurements, to understand the underlying susceptibility of the lens to radiation exposure, and to consider the interaction of confounding factors such as normal aging. Despite advances in technology that have helped to reduce radiation doses in the clinic to patients and staff, occupational radiation exposures of the lens of the eye have increased in certain aspects of medical practice (*e.g.*, interventional radiologists and cardiologists) likely because of the application of interventional techniques to additional pathologies and the

442 consequent increase of workload (Abe et al., 2013; Dauer, 2014; Dauer et al., 2010; Vano et al.,
443 1998).

444

445 **2.1.2** Evaluation Methodologies

446

447 This Commentary was written by multi-disciplinary experts based on a comprehensive
448 review of all prior radiation lens dose limits from national and international regulatory or
449 advisory bodies. The key epidemiological and radiobiological literature upon which the previous
450 guidance on dose limits was based was carefully evaluated with a focus on understanding the
451 statistical significance of each of the study populations, and where possible, the identification of
452 the underlying dose response-dependent variables and mechanisms of action. Low-LET radiation
453 was the predominant radiation source scrutinized. The methodology used in assessing cataracts
454 in the background of the aging lens was carefully noted in each study. Cataract prevention
455 strategies have been evaluated in terms of their potential impact on radiation protection practices
456 and the recommended dose limits. Science gaps and research needs were identified.

457

458

458 **2.2 Core Questions**

459

460 Four core questions were defined as important to address in this Commentary.

461

462 **2.2.1** Should radiation-induced cataracts be characterized as stochastic or deterministic effects?

463

464 Radiation effects are frequently identified as either stochastic or deterministic for
465 radiation protection purposes. Stochastic effects are defined as random events leading to effects
466 whose probability of occurrence in an exposed population (rather than severity in an affected
467 individual) is a direct function of radiation dose. Stochastic effects are commonly regarded as
468 having no threshold. Hereditary effects and some somatic effects, especially cancer, are regarded
469 as being stochastic. Deterministic (tissue reaction) effects may appear early or late after
470 irradiation. These effects occur above a threshold dose, and increase in both incidence and
471 severity with increasing dose. Radiation-induced cataracts have long been assumed to be a
472 deterministic effect due to the reported threshold effect, a dose below which cataracts are not

473 identified. Recent evaluation of cataracts after low doses of radiation has revealed that the lower
474 the dose, the longer the latency before a frank opacity appears (Blakely, 2012). The availability
475 of new technologies to digitally detect cataracts has highlighted the fact that more sensitive
476 methods to detect and score cataracts that impact vision have been improving and contributing to
477 quantitative and qualitative evaluations of cataract grades. However, comparisons with results
478 acquired with older technologies are difficult. ICRP has noted that more recent epidemiology
479 appears to support a nominal low threshold of about 0.5 Gy for opacities and/or cataract
480 induction (ICRP, 2012).

481

482 **2.2.2** What effects do LET, dose rate, acute and/or protracted dose delivery have on cataract
483 induction and progression?
484

485 Merriam and Focht (1957; 1962) were early pioneers in the study of the relationship
486 between radiation dose and human cataract formation. They studied patients exposed to
487 orthovoltage radiation for head and neck cancers with ophthalmologic examinations every 3 y
488 after treatment. They concluded that single doses of 200 rad (2 Gy) or cumulative doses of 550
489 rad (5.5 Gy) were adequate to induce cataracts. Their work also suggested that the amount of
490 radiation delivered in a single exposure might be as important as the total dose. They
491 demonstrated that higher doses were related to earlier onset and more severe cataract formation,
492 but that fractionating the total dose lengthened the latent period and resulted in less severe
493 cataract formation (Gragoudas et al., 1995; Merriam, 1957). Ferrufino-Ponce and Henderson
494 (2006) have pointed out that Henk et al. (1993) and Gragoudas et. al. (1995) described a slightly
495 higher threshold for cataract formation after fractionated radiotherapy (5 Gy) and highlighted the
496 tendency for lower cataract rates with lower dose fraction sizes. This dose threshold was
497 confirmed by Esik (1996) and similar thresholds increased the risk of cataract formation with
498 other radiation modalities (Fife et al., 1994).

499

500 **2.2.3** How should detriment be evaluated for cataracts?
501

502 A cataract is defined as a clouding of the normally transparent crystalline lens that can
503 lead to a decrease in vision depending on the anatomical location of the opacity relative to the

504 visual axis. Vision-impairing cataracts (VICs) could be considered to be the endpoint of greatest
505 concern in terms of lens radiation protection. However, the mechanisms underlying the transition
506 from minor lens opacifications to clinically significant VICs are still not well understood, and
507 this is likely to be an extremely relevant radiation protection issue requiring further investigation.
508 Some have suggested using specific tests to evaluate loss in visual contrast sensitivity (Vano et
509 al., 2013a). If a cataract impairs visual function, lens replacement surgery, although an invasive
510 procedure, is usually highly successful.

511

512 **2.2.4** Based on current evidence should NCRP change the recommended limit for the lens of
513 the eye?
514

515 Many questions remain unanswered regarding the current evidence for a dose threshold
516 for radiation-induced cataract. Despite the high prevalence of cataract formation after elevated
517 doses of radiation, a percentage of patients still do not develop clinically-significant cataracts
518 (Ferrufino-Ponce and Henderson, 2006). The underlying mechanisms of radiation-induced
519 cataract are not yet completely understood. The Commentary addresses the available data and
520 makes specific recommendations on the limit for the lens of the eye.

521

522

523 **3. Radiation Protection Principles**

524

525 NCRP in its 1993 recommendations (NCRP, 1993b) established a framework for
526 radiation protection composed of three main elements:

527

- 528 • **Justification** – the need to justify any activity which involves radiation exposure
529 on the basis that the expected benefits to society exceed the overall societal costs.
- 530 • **ALARA** – the need to ensure that the total societal detriment from such justifiable
531 activities or practices is maintained as low as is reasonably achievable (ALARA),
532 economic and social factors being taken into account.
- 533 • **Limitation** – the need to apply individual dose limits to ensure that the
534 procedures of justification and ALARA do not result in individuals or groups of
535 individuals exceeding levels of acceptable risk.

536

537 It was recognized that the use of the term ALARA was analogous to the term
538 optimization used by ICRP (1989a). However, it should be kept in mind that the expression
539 ALARA is only part of the concept of optimization when dealing with medical exposures of
540 patients, recognizing that the radiation protection framework applies in a different way to
541 occupational and medical exposures. The ICRP concept of optimization implies, more precisely,
542 keeping patient exposure to the minimum necessary to achieve the required medical objective
543 (diagnostic or therapeutic). In diagnostic imaging and x-ray guided interventions, it means the
544 number and quality of images are sufficient to obtain the information needed for diagnosis or
545 intervention. The focus of the effort in NCRP Report No. 116 (NCRP, 1993b) was to relate their
546 recommendations, and any adjustments, to ICRP Publication 60 (1991a) to form guidance for the
547 U.S. Nuclear Regulatory Commission (NRC) for use in the formulation of rulemaking leading to
548 possible changes in the regulatory dose limits for occupational workers. The dose limits
549 previously recommended by NCRP are discussed below (Section 3.3).

550

551

552

553

3.1 Issue of Radiation Risks

554

555

556

557

558

Risk estimates provided by NCRP (1993a) were primarily focused on stochastic risk for two major potential outcomes following ionizing radiation exposures: cancer and genetic (inheritable) effects. However, annual equivalent dose limits to the lens to prevent deterministic effects for occupational workers and the public were recommended.

559

560

3.1.1 BEIR V Report

561

562

563

564

565

566

567

568

569

570

571

572

573

574

The National Research Council of the National Academies updated their findings on the effects of low-levels of ionizing radiation on populations (NA/NRC, 1980) in a new report in 1990 (NA/NRC, 1990), known as the BEIR (Biological Effects of Ionizing Radiation) V report. That report stated: "...it is clear from the foregoing that detectable injury of the lens can result from a dose of as low as 1 Gy, depending on the dose rate and LET of the radiation, the threshold for a vision-impairing cataract under conditions of highly fractionated or protracted exposure is thought to be no less than 8 Sv..." (NA/NRC, 1990). The conclusion from this review was that such doses would exceed the amount received from occupational exposure under normal working conditions and also greatly exceeded the exposures to members of the general population from non-occupational types of exposure. Because the belief at the time was that radiation-induced cataracts were strictly deterministic effects (*i.e.*, there were dose thresholds), no stochastic risk estimate was provided and that was reflected in NCRP (1993a) not providing specific risk factors for radiation-induced cataracts.

575

576

3.1.2 UNSCEAR

577

578

579

580

581

The principal issues of risk referred to by NCRP in establishing the recommendations in 1993 (NCRP, 1993b) besides BEIR V were a set of United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) reports available at the time (UNSCEAR, 1972; 1977; 1986; 1988). All of these reports focused on stochastic effects (*i.e.*, cancer or genetic effects) and the limited amount of information on somatic effects was largely focused on the human embryo

582 and fetus. UNSCEAR (1986) did provide information regarding malformations of the eye during
583 periods of major organogenesis, but not on effects on the adult lens of the eye. Although
584 UNSCEAR (1988) did consider the acute effects of exposures from the Chernobyl nuclear power
585 plant accident, lens of the eye effects were not identified. Hence, the risk factors provided by
586 NCRP (1993a; 1993b) for the lens of the eye were largely based on BEIR V alone.

587

588

589

3.2 Foundation of Dose Limits

590 The goal of radiation protection is to prevent the occurrence of serious radiation-induced
591 conditions (acute and chronic deterministic effects) in exposed persons and to reduce stochastic
592 effects in exposed persons to a degree that is acceptable in relation to the benefits to the
593 individual and to society from the activities that generate such exposures (NCRP, 1993b). As
594 such, the foundations of dose limits are the specific objectives of radiation protection, namely: 1)
595 to prevent the occurrence of clinically significant radiation-induced deterministic effects by
596 adhering to dose limits that are below the apparent threshold levels, and 2) to limit the risk of
597 stochastic effects (*i.e.*, cancer and genetic effects) to a reasonable level in relation to societal
598 needs, values, benefits gained and economic factors (NCRP, 1993b). These objectives can be
599 achieved by ensuring that all exposures are ‘As Low As Reasonably Achievable’ (ALARA) in
600 relation to benefits to be obtained and by applying dose limits for controlling occupational and
601 general public exposures (NCRP, 1993b).

602

603

604

3.3 Previous NCRP Recommendation on the Lens of the Eye

605 NCRP provides scientific guidance and advice regarding radiation protection issues. A
606 number of NCRP reports explicitly address issues relevant to this Commentary’s focus on the
607 lens of the eye. A brief summary of the key points on lens of the eye protection from each of
608 these reports is included in Table 3.1. Additional detailed summaries of each of the relevant
609 NCRP reports have also been collated recently by EPRI (EPRI, 2014).

610

611

612

613

Table 3.1—Previous NCRP guidance on lens of the eye protection.

NCRP Report	Key Points
No. 91 (1987)	<ul style="list-style-type: none"><li data-bbox="672 478 1143 562">• Lens opacification identified as a nonstochastic effect<li data-bbox="672 594 1243 730">• Dose thresholds depend heavily on the biological endpoints considered and their precise definition<li data-bbox="672 762 1271 846">• 150 mSv annual dose equivalent to the lens of the eye occupational limit<li data-bbox="672 877 1292 957">• 50 mSv annual dose equivalent to the lens of the eye public limit
No. 115 (1993a)	<ul style="list-style-type: none"><li data-bbox="672 1010 1292 1209">• Noted a consideration of late and non-cancer somatic effects, including effects of ionizing radiation on inducing cataracts in the lens of the eye
No. 116 (1993b)	<ul style="list-style-type: none"><li data-bbox="672 1262 1243 1346">• Lens of the eye limits expressly based on prevention of deterministic effects<li data-bbox="672 1377 1271 1461">• 150 mSv annual equivalent dose to the lens of the eye occupational limit<li data-bbox="672 1493 1292 1575">• 15 mSv annual equivalent dose to the lens of the eye member of the public limit

614

615

616

Table 3.1–(continued).

NCRP Report	Key Points
No. 132 (2000a)	<ul style="list-style-type: none"><li data-bbox="670 474 1192 674">• Radiation protection limits for occupationally exposed persons were recommended to prevent clinically significant deterministic effects<li data-bbox="670 699 1291 898">• For deterministic effects, organ doses should be multiplied by an appropriate relative biological effectiveness (RBE) to adjust for radiation quality (Gy-Eq)<li data-bbox="670 924 1263 1123">• For activities in low-earth orbit, limits of 4.0, 2.0, and 1.0 Gy-Eq for career, 1 y, and 30 d respectively to prevent deterministic effects on the eyes<li data-bbox="670 1148 1276 1444">• Noted that limiting the scattered dose to the lens of the eye to a range of 1 to 3 Gy prevented major clinical effects on the eye based on work showing thresholds ranging from 2 to 10 Gy acute doses and 4 Gy for fractionated doses

617

618

619

Table 3.1--(continued).

NCRP Report	Key Points
No. 153 (2006a)	<ul style="list-style-type: none">• Definition of a clinically significant cataract is obscured by the unidirectional nature of cataracts• Relatively low doses of space radiation are correlated with an increased incidence and earlier appearance of cataract
No. 167 (2010a)	<ul style="list-style-type: none">• Noted that some recent research suggested that there may not be a definite threshold for radiation effects on the lens of the eye
No. 168 (2010b)	<ul style="list-style-type: none">• Noted that until current dose-limit values are reassessed, it is prudent to regard eye exposures in much the same way as whole-body exposure (<i>i.e.</i>, ensure exposures are consistent with the ALARA principle)

620

621

622

623

624

625

626

627

628

3.4 Previous ICRP Recommendations

629

630

631

632

633

634

635

636

637

638

639

640

3.5 Other International Reviews

641

642

643

644

645

646

647

648

649

650

The predecessor of ICRP was established in 1928 in order to provide scientific guidance on the growing use of ionizing radiation in the medical community. ICRP has expanded its efforts to include many other aspects of radiation protection, including astronauts exposed to space radiation and the wide-spread use of radiation sources in the field of nuclear energy. Recent recommendations by the ICRP (2012) on significantly lowering the lens of the eye dose limits have led to much discussion in the radiation protection community. A brief summary of the key points on lens of the eye protection from each of these reports is included in Table 3.2. Additional detailed summaries of each of the relevant ICRP publications have also been recently collated by EPRI (EPRI, 2014).

UNSCEAR eventually reviewed lens of the eye health effects in several later reports (UNSCEAR, 2008; 2011b; 2013b) typically noting that cataracts are deterministic effects. UNSCEAR (2008) acknowledged that several newer studies suggested that pre-clinical lens opacity lesions may form after dose to the lens < 1 Gy and noted that additional follow-up of the major cohorts was necessary to better characterize the risk to the lens. UNSCEAR (2013b) suggested that childhood exposures result in an approximately two-fold increase in sensitivity compared to adulthood exposures for cataracts, although the levels of evidence were characterized as ‘weak.’

651

652

653

Table 3.2—Previous ICRP recommendations on threshold values for lens injuries and lens dose limits.

ICRP Publication	Key Points
No. 41 (1984)	<ul style="list-style-type: none">• Threshold dose denotes the amount of radiation that is required to cause a particular effect in at least 1 to 5 % of exposed individuals• Threshold dose equivalent of protracted low-level occupational radiation for vision-impairing cataracts is estimated to exceed 8 Sv, although detectable opacities might result from smaller doses• 150 mSv dose equivalent occupational limit each year for 50 y would not cause a vision-impairing cataract (ICRP, 1984)
No. 60 (1991a)	<ul style="list-style-type: none">• Severe effects are not likely in most tissues at annual doses of less than about 0.5 Gy• Lens of the eye shows higher sensitivities• Pathogenesis of lens opacification not well understood

654

655

656

Table 3.2--(continued).

ICRP Publication	Key Points
No. 85 (2000)	<ul style="list-style-type: none"><li data-bbox="672 476 1260 621">• Noted that work suggests a 2 Gy threshold for cataract with 5 Gy being necessary to produce progressive disease<li data-bbox="672 646 1260 791">• There is evidence that lens opacification, without loss of vision, can result from exposure to doses as low as 0.2 Gy<li data-bbox="672 816 1260 898">• 2 Gy acute radiation dose may cause cataract<li data-bbox="672 924 1260 1005">• 4 Gy protracted exposures may cause cataract if received in less than 3 months<li data-bbox="672 1031 1260 1121">• 5 Gy protracted exposures may cause cataract in periods exceeding 3 months
No. 103 (2007)	<ul style="list-style-type: none"><li data-bbox="672 1173 1292 1264">• 150 mSv annual equivalent dose to the lens of the eye occupational limit<li data-bbox="672 1289 1292 1379">• 15 mSv annual equivalent dose to the lens of the eye public limit<li data-bbox="672 1404 1292 1600">• Because of uncertainty concerning lens of the eye risk, there should be particular emphasis on optimization in situations of exposure of the eye<li data-bbox="672 1625 1292 1715">• Noted that cataracts took several years to develop after an absorbed dose of ~ 1.5 Gy<li data-bbox="672 1740 1292 1820">• Recognized uncertainties in the assignment of dose thresholds for cataracts

657

658

659

Table 3.2--(continued).

ICRP Publication	Key Points
No. 118 & Tissue Effects Statement (2011; 2012)	<ul style="list-style-type: none"><li data-bbox="669 478 1292 617">• Underlying assumption of a nominal threshold of 0.5 Gy for acute or protracted exposure<li data-bbox="669 646 1292 730">• Detectable lens changes noted at doses of between 0.2 and 0.5 Gy<li data-bbox="669 760 1292 844">• Acute doses up to ~ 0.1 Gy produce no functional impairment of tissues<li data-bbox="669 873 1292 1012">• Occupational lens of the eye limit of 20 mSv y^{-1}, averaged over defined periods of 5 y, with no single year exceeding 50 mSv<li data-bbox="669 1041 1292 1178">• No new limit recommended for public exposures to the lens of the eye (<i>i.e.</i>, public lens of the eye limit to remain at 15 mSv y^{-1})

660

661

692 for individual monitoring is the personal dose equivalent, $H_p(d)$, which is the dose equivalent in
693 ICRU (soft) tissue at an appropriate depth, d , below a specified point on the human body. The
694 specified point is normally taken to be where the individual dosimeter is worn. For the
695 assessment of effective dose, $H_p(10)$ (i.e., a depth $d = 10$ mm) is chosen, and for the assessment
696 of the dose to the skin and to the hands and feet the personal dose equivalent, $H_p(0.07)$, with a
697 depth $d = 0.07$ mm, is used. A depth of $d = 3$ mm has been proposed for the rare case of
698 monitoring the dose to the lens of the eye. In practice, however, $H_p(3)$ has rarely been monitored
699 and $H_p(0.07)$ can be used for the same monitoring purpose. Operational quantities are
700 measurable, and instruments for radiation monitoring are calibrated in terms of these quantities.
701 In routine monitoring of low-LET radiation types, the values of these operational quantities are
702 typically taken as a sufficiently precise assessment of effective dose and skin dose, respectively,
703 in particular, if their values are below the protection limits.” While this Commentary did not
704 specifically evaluate the accuracy or adequacy of the quantity personal dose equivalent for
705 assessing the radiation exposure of the lens of the eye, Table 3.3 summarizes information related
706 to the issue of measuring the lens of the eye dose equivalent (LDE) with different low-LET
707 radiation types and at different depths in the eye related to the ‘true’ LDE. For non-low LET
708 exposure situations, such as in neutron exposures, $H_p(0.07)$ and $H_p(10)$ are probably not
709 appropriate surrogates for $H_p(3)$ because of buildup of charged secondaries from high-energy
710 neutrons as well as scattering and attenuation of low-energy neutrons. Uncertainties in radiation
711 weighting factors should be viewed as a source of dosimetric uncertainty (i.e., contributing to
712 uncertainty in equivalent dose to the lens) (NCRP, 2011; 2012).

713
714 For medical workers exposed as part of fluoroscopically-guided interventional (FGI)
715 procedures (e.g., those associated with interventional radiology or cardiology), NCRP has
716 provided specific guidance on monitoring lens of the eye exposures in Report No. 168 (NCRP,
717 2010b). In addition, the European Union Basic Safety Standard (EU BSS) recommends adequate
718 individual monitoring for all workers receiving equivalent lens doses > 6 mSv (BSS, 2014).
719 Various types of radiation monitors are available. NCRP (2000a) provides detailed descriptions
720 of several types of dose-monitoring devices. The radiation monitors and monitoring services
721 should comply with the National Voluntary Laboratory Accreditation Program (NIST, 2008).

722

723

724

Table 3.3—How to measure LDE^a for low-LET radiation (adapted from Behrens and Dietze, 2011).

Radiation Field	H _p (0.07) ^b /H _{lens}	H _p (3) ^c /H _{lens}	H _p (10) ^d /H _{lens}
Photons < 30 keV	0.9 – 5	0.6 – 1	0.01 – 0.9
Photons > 30 keV	0.8 – 1.1	1 – 1.2	0.9 – 1.2
Electrons	1 – 500	~ 1	<< 1 – 1.2
Implementation	Adequate for photon radiation	Adequate for photons, necessary for beta	Not appropriate for low E photons or beta

725

^aLDE = lens of the eye dose equivalent.

726

^bMeasurement by an extremity dosimeter.

727

^cMeasurement by a proposed dosimeter dedicated to LDE.

728

^dMeasurement by a whole-body dosimeter.

729

730

731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760

A worker in the FGI procedure environment may wear as many as three personal dosimeters (*i.e.*, on the torso, at the neck, on the hand). However, these devices indicate only the radiation level received by the device. None of these dosimeters directly measure the value of the equivalent dose (E or H_E) received by the worker. The actual values require adjustments for the attenuation of the radiation due to the use of protective equipment by individual workers. Two different methods for positioning personal dosimeters on staff wearing protective aprons are used at present in the United States. These are a single dosimeter worn at the neck outside and above the protective apron; and, dual dosimeters, one worn under the protective apron at the waist or on the chest and the other worn outside and above the apron at the neck (NCRP, 2010b). ICRP (2000a) recommended that staff performing FGI procedures wear two dosimeters, one under the apron and one at collar level above the protective apron.

Equivalent dose to the lens of the eye is usually inferred from a personal dosimeter placed elsewhere on the worker's body. The preferred locations are either at the collar level outside any radiation protection garments or near the eyes. In general, the reading on a collar dosimeter is likely to be somewhat higher than the actual dose to the lens of the eye (Kim *et al.*, 2008). Measurements can be performed to define a correction factor if needed (Farah *et al.*, 2013). The collar dosimeter reading should be directly used in the absence of such a measured correction. Over-table x-ray systems result in more scattered radiation to the upper body of workers performing FGI procedures than do under-table x-ray systems (NCRP, 2010b). Opacities in the lens of the eye have been reported with over-table x-ray systems (Farah *et al.*, 2013; Vano *et al.*, 1998b). When protective eyewear is worn it reduces exposure to the lens of the eye. Useful attenuation depends on the size and shape of the device as well as on the working conditions of the wearer. The actual attenuation is seldom as high as the nominal attenuation of the protective eyewear (Moore *et al.*, 1980; Schueler *et al.*, 2009).

When specific lens of the eye dosimetry has not been used (as has been the case for many professional workers in the medical sector), it may be possible to make an indirect estimation of lens dose. Vano and colleagues (2013b) tested such an approach and noted that: "...the

761 experimental results of such a methodology allow for realistic estimations of the dose to the
762 lenses of the eyes from the workload of the cardiologists and from the level of use of radiation
763 protection tools when personal dosimeters have not been regularly used.”

764

765 Investigations should occur if personal-dosimeter readings for an individual are
766 substantially above or below the expected range for that individual’s duties (NCRP, 2010b). As
767 an example, NCRP Report No. 168 (2010b) noted: “Too low a dosimeter reading should prompt
768 a formal investigation ... collar-dosimeter readings that are < 25 % of the average reading for
769 that worker or worker group should be investigated to determine if the assigned dosimeter is
770 being worn appropriately.”


771

772 **3.6.1.1 ICRP External Dose Factors for Lens of the Eye.** ICRP recently published
773 recommendations on special considerations for assessing absorbed dose in the lens of the eye
774 (ICRP, 2010). ICRP acknowledged strong differences in sensitivity to ionizing radiation
775 exposure with respect to cataract induction among the tissues of the lens of the eye (Charles and
776 Brown, 1975; ICRP, 1955) and suggested that in such cases it is necessary to consider a local
777 volume within the organ in which the dose is highest (ICRP, 2010). Since ICRP referenced
778 computational phantoms that represented the lens of the eye at a relatively low level of
779 resolution, an ICRP Task Group decided to adopt stylized models of the eye and lens for
780 electrons, photons and neutrons for estimating the dose conversion coefficients for irradiations
781 resulting in a steep dose gradient (ICRP, 2010). The eye model of Behrens *et al.* (2009), based on
782 the recommended data given in Charles and Brown (1975), was adopted for photon, electron and
783 neutron radiations. For electron irradiation, the bare eye model was assumed to be exposed
784 (Figure 3.1). For photon and neutron irradiation calculations, the eye model was incorporated
785 into the head of a mathematical model averaged from Adam and Eva (ICRP, 2010) (Figure 3.2).

786

787 Dose conversion coefficients for these more refined lens geometries in the stylized
788 phantoms were calculated for several irradiation conditions and geometries. These are provided
789 in Appendix F, ICRP Publication 116 (ICRP, 2010) and can be utilized for assessing absorbed
790 dose in the lens of the eye.

791



792


793

794

795

796

Fig. 3.1. The detailed stylized eye model by Behrens *et al.* (2009) as it was simulated in ICRP Monte Carlo calculations. All dimensions are given in mm. M denotes the x-position of the centers of the spheres and ϕ denotes the corresponding diameters (ICRP, 2010).



797

798

799

800

801

802

Fig. 3.2. Three-dimensional views of the eye as simulated in ICRP Monte Carlo calculations. Left shows a side view of the eye model implemented in the stylized head phantom shown at the right (ICRP, 2010).

803

804 **3.6.1.2 EURADOS and ORAMED European Projects.** EURADOS is a non-profit organization
805 promoting research and development as well as European cooperation in the field of ionizing
806 radiation dosimetry. In a recent EURADOS report (2014), it was stated that the challenge is to
807 provide reliable, accurate and on-line personal dosimetry information for occupationally exposed
808 workers. This requires monitoring workers in real time for all limiting dose quantities (i.e., whole
809 body, lens of the eye, extremities, etc.) regardless of the protection methods used and to provide
810 input for the optimal application of the ALARA principle. There is still much work to be done
811 regarding lens of the eye dosimetry. For example, standardization of methods to measure lens of
812 the eye dose, development of practical lens of the eye dosimeters, and testing and comparing
813 different lens of the eye dosimeters are needed. There is also a lack of data for lens of the eye
814 doses of workers in different industries. For example, in medical applications, correlations of
815 lens of the eye doses with other dose quantities, determination of reference lens of the eye doses
816 for different procedures, as well as testing and improvement of the efficiency of different
817 protection measures (such as leaded glasses) need to be explored. The development of a
818 dosimetry protocol to assess all of these factors is particularly required.

819

820 The main objective of the European Optimization of Radiation Protection for Medical
821 (ORAMED) staff (Domienik et al., 2011) project was to obtain a set of standardized data on
822 extremity and lens of the eye doses for staff in interventional radiology and cardiology. A
823 coordinated measurement program in different hospitals in Europe was carried out. The highest
824 doses were found for procedures involving implants of pacemakers, renal angioplasties and
825 embolizations. The highest lens of the eye doses were measured during embolizations. It was
826 concluded that it is difficult to find a general correlation between kerma area product and
827 extremity or lens of the eye doses, although other studies have suggested this association (Dauer
828 et al., 2010).

829

830

831 **3.6.2** Methodologies for Protecting the Eye

832

833 The practical problems for protection of the lens depend on the type of radiation, its
834 energy and the operational exposure scenario (i.e., the geometry relative to radiation source and
835 shielding), chiefly concerning the use of appropriate radiation and general eye safety tools (e.g.,
836 screens or goggles) that are compatible with the work to be performed. In FGI procedures, the
837 use of adequate eye protection is clearly a necessity, especially for high-volume practices (Dauer
838 et al., 2010; NCRP, 2010b). Several guidance documents for the medical industry have been
839 developed that suggest means of comprehensive lens protection for occupational exposures (e.g.,
840 Chambers et al., 2011; ICRP, 2000; Miller et al., 2010; NCRP, 2010b; Stecker et al., 2009).
841 Leaded glasses have been shown to reduce lens doses by a factor of about three (or higher),
842 shielded sterile drapes by a factor of about 25, and suspended ceiling shields by a factor > 100
843 (Thornton et al., 2010). Additional optimization suggestions for patient protection are needed
844 [e.g., Prins et al. (2011)]. In the nuclear industry, it is common to utilize respirator face shields,
845 bubble suit masks, and/or goggles in order to reduce beta doses to the lens.

846

847 **3.6.3** Health Surveillance Programs

848

849 Few (if any) detailed protocols on health surveillance programs for lens opacities have
850 been issued. Some of the published papers with results of the IAEA Retrospective Evaluation of
851 Lens Injuries and Dose (RELID) program recommend that (Vano et al., 2013a): Periodically
852 obtain a comprehensive ophthalmologic examination, including a detailed dilated slit lamp
853 examination of the posterior lens region, as part of regular medical evaluations recommended by
854 regional or national regulations.

855

856 The RELID international study was initiated by the IAEA in 2008. RELID had two
857 components, namely, 1) evaluation of dose and 2) evaluation of radiation injury. A number of
858 eye testing examinations were carried out. The evaluation of radiation dose to the eye is not a
859 straightforward issue. The current measurement techniques are not adequately developed and are

860 not available for routine use to inform radiation dose to the lens of the eye. Thus retrospective
861 estimations have become necessary, for instance using RELID forms for retrospective evaluation
862 of doses filled in by the exposed individuals. Each participant was asked to provide information
863 on the number of years of work in interventional laboratories, use of protective screens and eye
864 wear, work load with fluoroscopy time and cine (digital or filmed dynamic records of
865 fluoroscopic examinations) details, as well as other information pertaining to techniques that
866 may have had bearing on the radiation dose to the lens of the eye. Based on this information, the
867 radiation dose was estimated. Availability of personal monitoring badge data assisted in
868 correlation. The location of the individual in relation to the radiation source was also taken into
869 account. An ophthalmologist then tested the participants' eyes and scored the PSC opacities
870 using Merriam-Focht scores (0.5, 1.0, 1.5, etc.) separately for each eye. The quantification of
871 opacity score also contributed to the comparison with the estimated radiation dose and
872 established correlation (IAEA, 2014a; 2014b). Other surveillance programs have been suggested
873 (McCarty et al., 2000).

874

875

876 **4. Eye Biology and Lens Effects**

877

878 A brief description of the anatomy of the eye with an emphasis on the lens is provided
879 here to facilitate identification of each of the ocular structures pertinent to the discussion that
880 follows.

881

882

883


4.1 Eye Biology

884 The size of the normal human eye is remarkably similar among adults. The axial length
885 of the globe along the visual axis averages 24 mm (ranging from 21 to 27 mm), and the vertical
886 diameter averages 23.5 mm. The full size of the eye is attained by age 13. The globe has three
887 major layers, enclosing three transparent structures. The outmost layer is composed of the cornea
888 and sclera. The middle layer is known as the uvea, and consists of the choroid, ciliary body and
889 iris. The choroid is the vascular layer of the eye, containing connective tissue, and lying between
890 the retina and the sclera. The innermost layer is the retina. The three transparent structures within
891 the layers are the aqueous humor, the lens, and the vitreous body. The anterior chamber is the
892 region between the cornea and the iris, and the posterior chamber lies between the iris and the
893 lens. The lens is suspended from the ciliary body by the suspensory ligaments. The vitreous
894 humor is a clear jelly that occupies a greater volume than the aqueous humor present behind the
895 lens. Since the adult lens is avascular, oxygen and nutrients diffuse to the lens through both the
896 aqueous and vitreous humors. The trabecular meshwork is an area of tissue in the eye located
897 around the base of the cornea, near the ciliary body, and is responsible for draining the aqueous
898 humor from the eye via the anterior chamber (the chamber on the front of the eye covered by the
899 cornea). The conjunctiva is the transparent membrane that lines the eyelid and covers the sclera
900 (white part of the eyeball). The macula is a very small oval yellowish area surrounding the fovea
901 at the center of the retina (a thin layer of light-sensitive tissue that lines the back of the eye). The
902 fovea is the region of the retina responsible for fine vision. The macula is the region of greatest
903 visual acuity. Light rays are focused onto the retina, where they are transmitted to the brain and
904 interpreted as the images seen (Figure 4.1).

905

906

907



908

909

910 **Fig. 4.1.** Schematic diagram of the human eye (adapted from Wiki, 2014).

911

912

913

914 **4.1.1 Lens Anatomical Features**


915

916 The adult lens is a transparent organ located behind the cornea and the iris with an
917 average horizontal diameter of 9 to 10 mm, and an anterior-posterior thickness of 4.5 mm. The
918 outer edge of the light-facing side of the lens consists of a single layer of epithelial cells, and a
919 membrane that covers the entire organ (Kuszak et al., 1994). The lens germinal epithelium is
920 located around the circumference of the lens at its most peripheral extent, termed the ‘bow’ of
921 the lens. Here fibroblast growth factor 2 (FGF-2) triggers differentiation of the lens epithelial
922 cells into the second cell type in the lens, the lens fiber cell. As the lens fiber cells migrate
923 inwards, all intracellular organelles including the nucleus, mitochondria, Golgi, etc. disappear
924 (Bassnett and Mataic, 1997). The lens fiber cells remain attached anteriorly within the lens
925 beneath the single layer of lens epithelium, and posteriorly to the posterior capsule, until they
926 detach from the capsule and attach to the fiber cells on the other side and form a suture (Figure
927 4.2). It is at this location that PSC cataracts associated with exposure to ionizing radiation may
928 form. The lens fiber cells can be described as “bags of crystalline proteins” as they approach the
929 nucleus of the lens. Since there is little protein turnover in the lens fiber cells, damage to the lens
930 proteins accumulates throughout life (Roberts, 2011). The oxygen tension in the lens is very low,
931 but is sufficient for photo-oxidation to occur (McLaren et al., 1999). Lens cells have several
932 defense systems against light and radiation damage, including antioxidant enzymes [e.g.,
933 superoxide dismutase (SOD) and catalase], and antioxidants (e.g., vitamin E, vitamin C, lutein,
934 and glutathione) (Roberts, 2001). However, these defense systems become diminished after 40 y
935 of age (Lyle et al., 1999). The lens of the adult eye does not have a vascular supply, and as a
936 consequence all necessary materials must be supplied to the eye by the surrounding ocular fluid
937 (the aqueous humor) and all toxic materials must be removed by normal turnover of the aqueous
938 humor (Beebe, 2008).

939

940

941



942

943

944

945

946

947

948

949

950

951

Fig. 4.2. Anatomy of the human lens, a diagrammatic representation of the lens and formation of secondary fiber ('fibre' in figure) cells is shown. Epithelial cells in the anterior germinative zone proliferate in response to FGF stimulation and migrate to the transitional zone posterior to the equator, where upon exposure to higher concentrations of FGF, they differentiate and elongate to form the secondary fiber cells. The fiber cells are gradually packed into the center of the lens, losing organelles as they mature (Augusteyn, 2008).

952

953 **4.1.2 Lens Proliferative Organization**

954

955 The human lens is reported to grow in a biphasic manner throughout life (first
956 asymptotically from conception until early in a newborn’s life followed by linear growth) and
957 shows no evidence of slowing of growth with age (Augusteyn, 2008). Similar observations have
958 been made for lens growth in African elephants, American minks, hippopotami, Spanish ibexes,
959 and woodchucks, but approximately 126 other species studied (including rodents commonly used
960 for laboratory studies of radiation effects on the lens) demonstrated asymptotic lens growth
961 throughout life (Augusteyn, 2014). Normal lens development and growth are dependent on the
962 precise spatial and temporal regulation of lens cell proliferation and fiber cell differentiation.

963

964 **4.2 Cataracts**

965

966 A number of causative factors have been identified for the formation of opacifications
967 (cataracts) in the lens of the eye. This section of the Commentary focuses on cataract
968 characteristics, evaluation and etiology.

969

970 **4.2.1 Cataracts and Opacifications**

971

972 A cataract is a clouding or opacification that occurs in the normally clear lens of the eye.
973 Some cataracts are clinically unimportant, not impairing vision in any way. Nevertheless,
974 cataracts remain the most common cause of severe visual impairment, with visual loss occurring
975 because the opacification prevents light from passing through and being focused on the retina
976 (Yanoff, 2008).

977

978 Most cataracts are associated with aging, but there are a variety of other etiologic factors
979 including: exposure to ionizing and nonionizing radiation, medications, and trauma (Michael and
980 Bron, 2011). In a review of 4,425 persons aged 55 to 80 y at baseline that were followed for an
981 average of 9.8 y, Chang et al. (2011) reported the following associations: increasing age with
982 increased risk of all types of cataract and cataract surgery; males with increased risk of PSC

983 cataracts and decreased risk of cortical cataracts; non-whites with increased risk of cortical
984 cataract; hyperopia with decreased risk of PSC cataract, nuclear cataract, and cataract surgery;
985 vitamin use with decreased risk of nuclear cataract; diabetes with increased risk of cortical
986 cataract, PSC cataract, and cataract surgery; higher educational level with decreased risk of
987 cortical cataract; and, smoking with increased risk of cortical cataract and cataract surgery.
988 Cataracts can reduce the sharpness of vision and can contribute a colored tint to vision. Most
989 cataracts lead to difficulty in observing contrasts in lighting and colors, driving, and reading due
990 to the scattering of light by the opacifications.

991
992 Cataracts are usually corrected with surgical removal followed by implantation of an
993 intraocular lens of appropriate optical power as an out-patient procedure (Vasarada *et al.*, 2012).
994 While 90 % of patients acquire totally corrected vision, there are some complications that can
995 occur in a low percentage of patients including retinal detachment, edema, formation of
996 secondary cataracts on the replaced lens, and others. Stein (2012) reviewed the available
997 literature on serious adverse events after cataract surgery and noted that the risks varied. PSC
998 rupture occurred in 1.9 to 3.5 % of patients, retinal detachment in 0.4 to 3.6 % of patients,
999 endophthalmitis in 0.05 to 0.3 % (with a collective rate of 0.128 %) of patients, and
1000 suprachoroidal hemorrhage in 0.03 to 0.13 % of patients (Stein, 2012). It should be noted that
1001 while this surgery is routine, it is not available throughout the world in developing nations, and
1002 thus cataract development can have significant consequences in those areas.

1003
1004 There is active research in preventing and potentially reversing lens opacities in
1005 experimental laboratory models of cataract. Two recent reports indicate that specific sterols
1006 administered as eye drops can reverse cataract and improve lens transparency in different animal
1007 models, and also when administered to human *ex vivo* lens in experiments (Makley *et al.*, 2015;
1008 Zhao *et al.*, 2015). Clearly more work needs to be done to determine whether these treatments
1009 reduce all types of cataracts, and whether or not they can be adapted for use in humans.

1010

1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040


4.2.2 Cataract Types, Severity and Impact on Vision

Cataracts are usually classified in a somewhat qualitative manner, based on the location of the opacity. Nuclear sclerosis is the most common type of cataract located in the central nuclear part (or central zone) of the lens. Sclerotic changes indicate a change in hardness, and there is often a deposition of brown pigment within the lens. It is linked to smoking as a major causal factor, possibly due to the related inhibition of antioxidant action (Sulochana et al., 2002). Cortical cataracts result from opacities in the cortex of the lens usually beginning in the peripheral part of the lens and spreading into the center of the lens (Richter-Meuksch et al., 2011). Cortical cataracts are associated with diabetes, and exposure to both ultraviolet (Javadi and Zarei-Ghanavati, 2008) and ionizing (Chylack et al., 2009) radiations. PSC cataracts begin in the back of the lens, adjacent to the capsule in which the lens is situated, and are linked to steroids, diabetes and ionizing radiation as causal sources. Supranuclear cataracts are located above the nuclear region of the lens, and are reported to occur in patients with Alzheimer’s disease and Down syndrome (Goldstein et al., 2003; Hockwin, 1994-1995; Moncaster et al., 2010).

It is also worth noting that aging has been linked to all types of cataracts (Beebe et al., 2008) and that more than one type of cataract can be observed in a single lens. Examples of age-related cataracts are shown in Figure 4.3.

Cataracts are also classified as immature, mature and hyper-mature types depending on the degree of opacity vs transparent protein that is present in the lens. In a mature cataract, all of the lens protein is opaque, while in an immature cataract, some of the lens proteins are transparent. For hyper-mature cataracts, proteins in the lens have become liquid (Chylack et al., 1988; 1989; 1993). Cataracts may also be classified as hard or soft depending on the color of the opacity. Light (white) colored opacities are considered soft and dark colored (yellow or darker) are considered as hard (Chew et al., 2010).

1041



1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

Fig. 4.3. Examples of the common types of age-related cataracts are shown here. The upper row of images shows Scheimpflug camera views of the normal lens and four types of age-related cataracts. The images show (from left to right) the cross-section of the cornea, the dark gap of the aqueous humor and then the area of the lens from anterior to posterior. Note the bright anterior spokes of the cortical cataract, the bright midline nuclear cataract, and the bright PSC cataract in the middle of the visual axis at the extreme posterior position. Frequently lenses have several cataract types, designated mixed cataracts. The lower row of photographs represents retroillumination images of the three common types of age-related cataracts looking down along the visual axis (Beebe, 2008).

1055

1056 Cataracts can also be delineated as either partial or total, based on the extent of the
1057 opacity. For total cataracts, the whole lens has lost transparency, while for partial cataracts, only
1058 certain portions of the lens are opaque. A partial cataract may remain stationary or it may later
1059 extend, becoming progressive. The most common partial cataracts are the anterior and posterior
1060 polar cataracts, both of which are stationary. Anterior and posterior cortical cataracts are
1061 progressive partial cataracts. They may be stationary for years, and/or progress with time after
1062 their initial appearance.

1063

1064 Clinical studies in humans have shown that depending on the radiation dose and duration
1065 of exposure, a radiation-induced opacity could remain stationary in the early stages, develop to
1066 an intermediate stage and remain stationary, or cross a threshold for clinical significance and
1067 progress to a fully mature cataract (Merriam and Focht, 1957). Clearly, VICs could be
1068 considered the endpoint of greatest concern in terms of lens radiation protection. However, the
1069 mechanisms underlying the transition to clinically significant VICs are still not well understood,
1070 and this is likely to be an extremely relevant radiation protection issue requiring further
1071 investigation.

1072

1073 **4.2.3** Cataract Causes

1074

1075 Age is the most common cause of cataract, with small cataracts that do not significantly
1076 impair vision first evident usually at age 40 but not impacting vision significantly until one to
1077 two decades later. With time, environmental factors (such as sunlight exposure, exposure to
1078 chemicals, etc.) will cause proteins in the lens to aggregate and cloud a small portion of the lens.
1079 As the cataract grows larger with age, vision becomes more impaired (Michael and Bron, 2011;
1080 Wiekel et al., 2013).

1081

1082 Blunt trauma to the lens can cause thickening and swelling of the lens fibers; in some
1083 cases, the capsule can be damaged as well. Electrical injuries (such as lightning injury, high- and

1084 low-voltage injury) also have been reported to cause cataracts in a small percentage of patients
1085 (Hashemi et al., 2008; Korn and Kikkawa, 2014).

1086

1087 Patients with metabolic disorders (such as diabetes and galactosemia) and skin disorders
1088 (such as atopic dermatitis and eczema) have a higher incidence of developing cataracts than the
1089 general population. There appears to be a genetic component to the origin that may be important
1090 in these patients as well (Hamada and Fujimichi, 2015). A variety of infections (e.g., leprosy,
1091 varicella, and toxoplasmosis) predispose to the development of cataracts, and rubella in utero can
1092 lead to cataracts in infants (Thompson et al., 2014). Some medications such as corticosteroids
1093 can induce cataracts, particularly PSC cataracts (Dymlacht, 2013).

1094

1095 Epidemiological studies and experiments in animal systems have demonstrated that
1096 exposures to ultraviolet radiation can induce cataracts. Both UV-A and UV-B have been
1097 implicated. While UV-B is associated with shorter wavelengths and has less penetration than
1098 UV-A, it is very damaging and has been heavily implicated in cataract induction. UV-A
1099 penetrates through the inner skin layers of the eyelid and the other protective parts of the eye and
1100 also can damage the lens. Ocular protection reduces the incidence, and increased dose and
1101 exposure time increase the incidence. Individuals who work outdoors or spend much time
1102 exposed to sunlight are more likely to develop opacities, and there is concern with reductions in
1103 the ozone cover around the earth that cataract incidence may increase (Collman et al., 1988).

1104

1105 Of most importance to this Commentary is the association of cataract induction with
1106 exposure to ionizing radiation, which is discussed in Section 4.3.2.

1107

1108 **4.2.4** Cataract Mechanisms

1109

1110 The mechanisms of cataract induction are not fully understood. Opacifications can occur
1111 due to the misfolding of lens crystalline proteins or due to dysregulation of lens cell
1112 morphologies. The underlying cause of these changes is unclear, although some have considered
1113 that oxidative stress may be an initiating factor that leads to lipid peroxidation, DNA and/or

1114 protein damage and thus results in later changes in the lens and onset of cataractogenesis. Most
1115 of the agents associated with cataract development are agents that lead to the production of
1116 reactive oxygen species and oxidative stress in cells. Moreau and King (2012) review the
1117 mechanisms of cataract disease associated with protein aggregation.

1118

1119 Deregulation of normal lens proliferation and differentiation that results in disorderly
1120 arrangement of protein fibers leads to a loss of transparency and cataracts (Benedek, 1971).
1121 Using a transgenic mouse model, Lovicu et al. (2004) demonstrated that during the formation
1122 and growth of transforming growth factor beta (TGF β) induced subcapsular plaques, lens
1123 epithelial cells lose key phenotypic markers including E-cadherin and connexins 43, they
1124 multilayer and subsequently differentiate into myofibroblastic and/or fiber-like cells. They
1125 propose that other growth factors in the eye, namely fibroblast growth factor, may also play a
1126 role in the establishment and regulation of the key cellular processes leading to lens pathology
1127 (Lovicu et al., 2004). Understanding the effects of this cytokine and other molecular aspects and
1128 cellular dynamics of cataract formation and growth is essential to devising strategies for slowing
1129 or preventing cataracts.

1130

1131 Recent studies have also examined a possible role of protein folding functions in
1132 cataractogenesis; much work has shown that mutations in lens connexins, proteins associated
1133 with maintaining lens cell gap junctions and cell chaperone function (which refolds misfolded
1134 proteins) are associated with the development of congenital cataracts in humans. It is thought
1135 that somatic defects in these pathways may also be associated with onset of cataracts from
1136 oxidative damage causes (Berthoud and Beyer, 2009; Beyer et al., 2013). Similarly, genetic
1137 polymorphisms of another chaperone protein, HSP70, also have been found to be associated with
1138 cataract induction (Hamada and Fujimichi, 2015; Zhang et al., 2013).

1139

1140 Many have discussed a possible role for DNA damage in the induction of cataracts,
1141 although not all cells of the lens have DNA. Several reports have noted that damaged nuclei,
1142 mitochondria, and DNA can be found in subcapsular and cortical cataracts, possibly due to the

1143 failure of lens fiber cells in the bow region of the lens to differentiate properly (Pendergrass et
1144 al., 2005; Pendergrass et al., 2010).

1145

1146 It is unclear whether cataracts of different morphologies have different pathologies. The
1147 focus of this commentary is on ionizing radiation-induced cataracts, and by necessity, reference
1148 to studies of cataracts of other causes will be limited.

1149

1150 **4.2.5 Examination and Quantification of Lens Changes**

1151

1152 Although visual acuity and functional impairment tests are modern methods to evaluate
1153 visual decrements, the evaluation of radiation effects on the crystalline lens has primarily been
1154 limited to clinical examination and documentation of physical changes in the anatomy of the
1155 lens. Since different types of cataract are associated with opacities in various different parts of
1156 the lens, it is appropriate to classify cataracts according to their location within the lens.

1157

1158 The development of biomicroscopy instrumentation to noninvasively observe the eye has
1159 progressed from the original ophthalmoscope that Babbage designed in 1846 (Duke-Elder, 1962)
1160 to the use of oblique illumination and microscopic examination with a slit lamp (Berliner, 1966;
1161 Tate and Safir, 1991), and the specular microscope (Bourne and Enoch, 1976). Two approaches
1162 have been used: (1) subjective methods of lens observation based largely on slit lamp
1163 microscopy, and (2) objective methods of determining lens transparency or lens opacity, also
1164 based on slit lamp documentation, but according to the Scheimpflug principle combined with the
1165 retroillumination technique (Hockwin, 1994-1995) (Table 4.1).

1166

1167 Due to age-related changes in the transparency of the lens, early lenticular changes due to
1168 cataract formation cannot be discerned by subjective methods. The densitometric analysis of
1169 Scheimpflug slit images, however, allows the exact measurement of the light scatter in the single
1170 lens layers, and enables the early recognition of disturbances in transparency crucially important

1171

Table 4.1—Comparison of methods used to score lenticular cataracts in vivo.

Method	Provides	Advantages	Disadvantages	Reference
Slit-lamp biomicroscopy exam with photography or video	<ul style="list-style-type: none"> Slit of light is projected onto the lens and detected by a long working distance microscope focused on the lens – first developed by Gullstrand in 1911 	<ul style="list-style-type: none"> Provides visual display 	<ul style="list-style-type: none"> Subjective evaluation 	Duke-Elder, 1962
Scheimpflug slit-lamp exam with camera optics	<ul style="list-style-type: none"> Scheimpflug imaging initially provided photographic images for comparison with standard photographs of different cataract features 	<ul style="list-style-type: none"> Rapid Easy to perform Fast to learn 	<ul style="list-style-type: none"> Geometric optical limitations and imaging through the cornea leads to high-order image distortion Requires pupil dilation Posterior cortex or capsule lesion difficult to score 	Brown, 1974; Cook and Koretz, 1998

Table 4.1—(continued).

Method	Provides	Advantages	Disadvantages	Reference
Scheimpflug rotating photo-slit-lamp camera exam Pentacam image analysis and assays lens density	<ul style="list-style-type: none"> • Cross-sectional lens image from anterior to posterior to evaluate lens density • Image of lens nucleus and PSCs located in the center of the posterior lens aspect • New optical technologies, such as Pentacam acquire 50 images in ~ 2 sec by a rotating Scheimpflug camera measurement and offer built-in Pentacam Nucleus Staging software for objective classification • Camera captures images in different meridians and creates a 3D image of the crystalline lens • Scheimpflug images allow for a continuous measure, whereas the LOCS III which has grading systems in steps, permit the detection of more subtle amounts of progression 	<ul style="list-style-type: none"> • Permits scaling of the lens density from less to more sclerotic by visual inspection or densitometric planimetry • Best imaging of nuclear sclerosis or nuclear cataract • Provides objective measure of lens density compared to LOCS III 	<ul style="list-style-type: none"> • No standardized screening evaluation of cataracts published yet 	<p>Datiles <u>et al.</u>, 1995; Gupta <u>et al.</u>, 2013; Hockwin <u>et al.</u>, 1982; Kirkwood <u>et al.</u>, 2009; Lim <u>et al.</u>, 2014; Sasaki and Nakamura, 1978; Sasaki <u>et al.</u>, 1979</p>

Table 4.1—(continued).

Method	Provides	Advantages	Disadvantages	Reference
“Thrifty” Scheimpflug retro-illuminated slit-lamp exam	<ul style="list-style-type: none"> Retro-imaging the lens with a flash reflected off the retinal surface resulting in an orange color “disc” against which lens opacities appear as areas of darkness 	<ul style="list-style-type: none"> Used in population-based studies Can be used to detect non-central PSC that could be missed or inadequately imaged with the Scheimpflug techniques 	<ul style="list-style-type: none"> More cost effective 	Klein and Klein, 1992
MRI refractive index	<ul style="list-style-type: none"> Non-optical imaging technique that provides novel information on lens shape, including asphericity of lens surface and ciliary body position and anatomy 	<ul style="list-style-type: none"> Does not require information on lens optical properties 	<ul style="list-style-type: none"> Time consuming technique Low resolution 	Jones <u>et al.</u> , 2005; Kasthuriragan <u>et al.</u> , 2011; Strenk <u>et al.</u> , 2004
Scheimpflug 3D-microscopic tomography	<ul style="list-style-type: none"> 3D microscopic imaging of the cataract in a human lens <u>in vivo</u> 		<ul style="list-style-type: none"> Not yet used for large population-based studies No data on radiation-induced cataracts with this method 	Masters, 1998


1179
1180 in cataract epidemiology (Hockwin, 1994-1995; Jain and Grewal, 2009; Wegener and Junga,
1181 2009). Prevalence and/or incidence studies involving a single examination of a cohort have
1182 severe limitations in assessing multifactorial cataract processes which require repeated
1183 examinations for objective classification before visible opacifications appear (Datiles and Ansari,
1184 2006).

1185
1186 Quantification of cataracts has commonly been done using the Merriam-Focht Cataract
1187 Scoring System (Figures 4.4.a-d). The Merriam-Focht system has been described as: "...taking
1188 into account the frequency of observed posterior and anterior opacities, sutural changes, vacuoles
1189 and other lens defects, and the percent opacity as a function of lens anterior and posterior surface
1190 area..." (Merriam and Focht, 1962). Figure 4.5 illustrates the tendency of human radiation-
1191 induced cataracts to develop in the PSC region of the lens.

1192
1193 A Lens Opacities Classification System (LOCS) III also has been developed to facilitate
1194 scoring of the severity of cataracts. This system includes slit-lamp images for grading nuclear
1195 color and nuclear opalescence as well as retroillumination images for grading cortical cataracts
1196 and PSC cataracts. Severity is graded on a decimal scale (Figure 4.6) (Chylack et al., 1993).

1197
1198 Several standardized clinical grading and photographic systems comparing a patient's
1199 cataract with standard photographs have been developed. These include: (1) LOCS I, II and III
1200 (Chylack et al., 1988; 1989; 1993), (2) the Wisconsin Clinical and Photographic Cataract
1201 Grading System (Klein et al., 1990), (3) the Wilmer Clinical and Photographic Grading System
1202 (Taylor and West, 1989), (4) the Oxford Clinical Cataract Grading System (Sparrow et al.,
1203 1986), (5) the AREDS (Age-Related Eye Disease Study) (Braccio et al., 1998; Kaffoff et al.,
1204 2001), (6) the NEI Clinical Cataract Grading System (Vivino et al., 1993), (7) the Japanese
1205 CCRG Cataract Grading System (Sasaki et al., 1990), (8) the WHO (World Health Organization)
1206 Cataract Grading System (Thyleflors et al., 2002), and (9) the systems for quantifying posterior
1207 capsule opacification in subjects who have had cataract surgery (Bender et al., 2004; Tetz et al.,
1208 1997).


1209



1210

1211 **Fig. 4.4.a.** Illustrations of the Merriam-Focht Cataract Scoring System (+1, +2, +3, and
1212 +4) are shown in Figures 4.4.a-d, in this figure two characteristic 1+ cataracts showing the early
1213 central postcapsular vacuoles and dots with widening of the suture lines and an increase in the
1214 light reflex (Merriam and Focht, 1962).

1215



1216


1217

1218 **Fig. 4.4.b.** A 2+ cataract showing the increase in the posterior cortical opacity, left, and
1219 the beginning of the central anterior subcapsular opacity, right (Merriam and Focht, 1962).

1220

1221

1222




1223

1224

Fig. 4.4.c. This shows a stage 3+ opacity with extension of the changes in both the anterior and posterior cortex. The anterior cortical changes are on the left and the posterior cortical opacities are on the right (Merriam and Focht, 1962).

1226

1227



1228

1229

1230


Fig. 4.4.d. A stage 4+ cataract in which the lens is completely opaque (Merriam and Focht, 1962).

1231

1232

1233

1234



1235

1236

1237

1238

1239

1240

1241

1242


1243

1244

1245

Fig. 4.5. Radiation-induced cataracts tend to develop in the posterior lens as shown in Panels a-d. Panel (a) shows early changes typically present in the central axis of the lens. Panel (b) shows that the central opacity may become denser, note the cross-sectional drawing in the center demonstrating on the left a dense posterior opacity. Panel (c) shows that the lenticular opacity may extend out to the periphery. Panel (d) shows that more advanced cataracts may also develop anterior changes. Note the wedge-shaped changes in the bottom left-hand corner representing opacification of the lenticular cortex. Also, note cross-sectional drawing demonstrating, from left to right, posterior, cortical, and anterior changes (Gordon *et al.*, 1995).

1246



1247

1248


1249

1250

1251

Fig. 4.6. A depiction of the LOCS III Cataract Scoring System (Chylack *et al.*, 1993).


1283



1284

1285 **Fig. 4.7.a.** The eye with i) cortical cataract and ii) PSC and uneven retroillumination due
1286 to polarizing effect of the camera, the original digital photo. Picture from the Nidek EAS-1000
1287 (Nidek, Japan) (Gershenson and Robman, 1999).

1288



1289

1290

1291 **Fig. 4.7.b.** The software analysis result is shown in this image with the threshold cutting
1292 off both the dark areas of cataract and the poorly illuminated pupil periphery (areas iii and iv)
1293 thus producing a 24 % error in measurement of cortical cataract (i) (Gershenson and Robman,
1294 1999).

1295

1296 The conjunctiva, cornea, uvea, and retina are somewhat intermediate in radiosensitivity. Many
1297 clinical investigators have confirmed these observations in numerous subsequent studies that are
1298 nicely summarized in several books and clinical reviews (Cox and Ang, 2010; Fajardo et al.,
1299 2001; Finger, 2009; Swetha et al., 2011).

1300

1301 Acute or late complications of the eye (e.g., those occurring within 3 months, or several
1302 months to years after exposure or completion of treatment, in regard to their first appearance,
1303 respectively) are dictated by several intrinsic and extrinsic factors, including the composition of
1304 the tissue of the irradiated eye structure, the capacity of the tissue to withstand the injury, the
1305 vascular integrity of irradiated volume, patient age, dose, dose rate, co-morbidities and dietary
1306 supplements or medications that the individual may have ingested before, during or after
1307 irradiation (Brady and Yaeger, 2001; Finger, 2009). In general, acute effects refer to damage
1308 sustained by rapidly proliferating cells, and many can be resolved by timely and appropriate
1309 medical management. Late effects usually result from vascular damage and subsequent ischemia,
1310 and are chronic in nature. Acute effects resulting in residual lesions may result in the appearance
1311 of ‘consequential’ late effects.

1312

1313 Several studies note possible effects with doses in the tens of Gy or greater to the sclera
1314 (Cox and Ang, 2010; Finger, 2009), cornea (Cox and Ang, 2010; Finger, 2009; Jeganathan et al.,
1315 2011), conjunctiva (Barabino et al., 2005), retina (Dhir et al., 1982; Jiang et al., 1994; Krema et
1316 al., 2011; Mewis et al., 1982; Parsons et al., 1994a; Viebahn et al., 1991), optic nerve (Jiang et
1317 al., 1994; Nakissa et al., 1983; Parsons et al., 1994b), lacrimal system and Meibomian glands
1318 (Brady, 1996; Durkin et al., 2007; Horwath-Winter et al., 2013; Jeganathan et al., 2011; Karp et
1319 al., 1979; Kennerdell et al., 1992; Parsons et al., 1994b), and the uvea (Sagerman and Alberti,
1320 2003).

1321

1322 **4.3.2** Radiation Cataractogenesis

1323

1324 It is well established that exposure to ionizing radiation leads to development of lens
1325 opacities. The latency and the severity of lesions are known to be dependent on a number of

1326 factors, including age and gender, as well as exposure characteristics including dose, dose rate
1327 and fractionation. Evidence that these factors are inter-related further complicates efforts to
1328 elucidate dose-response relationships. The available data are discussed, with respect to a number
1329 of different confounding factors, in this section.

1330

1331 **4.3.2.1 Absorbed Dose.** Until recently, it was accepted that the induction of cataracts was
1332 considered to be a deterministic effect of radiation and that the threshold was ~ 2 Gy for
1333 opacities to develop (for acute exposures) for low-LET radiations such as gamma or x rays
1334 (Abdelkawi, 2012; Bendel *et al.*, 1978; Merriam and Focht, 1962; Wolf *et al.*, 2008).

1335

1336 A deterministic model is supported by the vast majority of the epidemiological evidence
1337 (Section 5). However, there is some evidence that lens opacities may follow an approximately
1338 linear non-threshold (LNT) theory with increasing dose for either low- or high-LET radiation
1339 exposures and across a range of doses. For instance, Hall *et al.* (2015) recently demonstrated a
1340 quadratic relationship between dose and the 5 y development of cataracts for patients receiving
1341 total body irradiation (TBI; Figure 4.8). Di Paola *et al.* (1978) showed an LNT relationship for
1342 numbers of lenticular opacities and doses of 0 to 3 Gy of x rays and 0 to 0.38 Gy of 14 MeV fast
1343 neutrons. Furthermore, the mechanistic evidence presented in Sections 4.3.3.5 and 4.3.3.6,
1344 particularly the genetic and DNA damage work, could be interpreted to suggest a stochastic
1345 mechanism of radiation cataractogenesis (Hamada and Fujimichi, 2015).


1346

1347 **4.3.2.2 Dose Rate.** The lack of concrete epidemiological evidence regarding dose rate
1348 dependence led ICRP to conclude that there is no dose rate effect for lens effects (ICRP, 2012;
1349 Section 5) and most recent studies confirm this observation [(e.g., the Hall *et al.* (2015) recent
1350 meta-analysis of patients undergoing radiotherapy following hematopoietic stem cell
1351 transplantation].

1352

1353

1354



1355

1356

Fig. 4.8. The 5 y cataract incidence after hematopoietic stem cell transplantation as a function of dose. Solid curve indicates the model predicted probability standardized for an adult population and regular ophthalmologic surveillance. Dashed curves indicate the 95 % confidence interval (CI). Patient series included in the meta-regression were plotted as discrete points with area scaled according to the number of patients (Hall *et al.*, 2015).

1361

1362

1363

1364 **4.3.2.3 Fractionation.** The role and contribution of dose fractionation to radiation cataract
1365 development has been examined in great detail in the animal eye (ICRP, 2012). Some studies
1366 have reported dose-rate effects at relatively high doses, for instance, in a study of radiotherapy
1367 patients carried out by Deng et al. (1984), 80 % of patients receiving single-dose 10 Gy ⁶⁰Co
1368 gamma-ray irradiation developed cataracts, compared to only 18 % of patients receiving
1369 fractionated TBI. Although the evidence for fractionated and protracted exposures in humans has
1370 been strengthened by a number of recent high quality studies considering medical workers and
1371 patients, overall, the data are still fairly sparse and somewhat conflicting (Hall et al., 2015).
1372 Furthermore, although studies in this category are sometimes lacking in statistical power, they do
1373 tend to have high quality dosimetry at low doses, which means that they are very important for
1374 assessing whether the prevailing risk model also applies to the low dose region. In summary,
1375 there is evidence of a modifying effect of dose fractionation.

1376

1377 **4.3.2.4 Radiation Quality and RBE.** The vast majority of epidemiological studies looking at
1378 radiation-induced cataract have focused on acute or chronic exposure to low-LET radiation
1379 (Minamoto et al., 2004; Nakashima et al., 2006). Those studies that do consider alternative
1380 exposure have generally not considered the influence of RBE; however, it is notable that the
1381 highest relative risks (RR) have been observed for astronauts who are exposed to a wider range
1382 of radiation types including a mixture of high-energy protons and heavy ions as well as
1383 secondary particles (Cucinotta et al., 2001) and pilots who have increased ionizing radiation
1384 exposure from solar particle events and galactic cosmic radiation (Jones et al., 2007; Rafnsson et
1385 al., 2005). There has been concern that individuals working in preparation of
1386 radiopharmaceuticals for nuclear medicine procedures may have relatively high lens exposures,
1387 but measurements suggest this is not the case (Kopeck et al., 2011).

1388

1389 The RBE effect is well documented in animal studies, which have often focused on the
1390 need to elucidate the mechanistic response to high-LET (Di Paola et al., 1980) with the aim of
1391 investigating the implications for astronauts (Hall et al., 2005). A relationship between RBE and
1392 size of opacity has also been proposed for space radiations (Chylack et al., 2009). Inadequate

1393 dose response data exist for photons or high-LET radiation sources to precisely calculate the
1394 RBE for cataracts induced in human populations. However, RBE data have been reported from
1395 animal studies investigating high-LET-induced radiation cataract. Based on these data, the
1396 estimated cataract grade-dependent RBE values for the ATM^{+/-} haploinsufficient mouse were
1397 somewhat higher than those for the wild type mice, ranging from 5 to 24 (Hall et al., 2006). For
1398 the wild-type animals, the estimated RBE values of the iron-ions are in the range of 5 to 15.
1399 These RBE values, for 0.325 Gy of 148 keV/ μ m iron ions, are consistent with earlier
1400 measurements for heavy-ion induced cataractogenesis in wild-type animals, by doses including
1401 0.025 and 0.5 Gy of 88 keV/ μ m argon ions, and 190 keV/ μ m iron ions (Brenner et al., 1993). In
1402 these earlier studies, only confidence bands for the RBE could be estimated, and the upper and
1403 lower 90 % confidence limits of the RBEs for the wild-type animals, 35 weeks after exposure,
1404 ranged from 8 to 30 at 0.25 Gy, and from 4 to 12 at 0.5 Gy. The RBE estimates for the wild-type
1405 animals are consistent with earlier results in other animal models. Riley et al. (1991) reported
1406 irradiation of Sprague-Dawley rats with 0.6 GeV/amu iron ion doses from 0.1 to 2 Gy, with
1407 estimated RBEs of about 7.4 for doses from 0.1 to 0.5 Gy. Similarly, Lett et al. (1985) reported
1408 an RBE of 4 to 6 for stationary cataract induction in rabbits with 0.5 to 5 Gy of 0.46 GeV/amu
1409 iron ions.

1410

1411 While this Commentary will not go into detail about high-LET exposures, studies have
1412 shown that neutrons are extremely effective at inducing cataracts at low doses, such as showing a
1413 50 fold increase in cataract induction at low doses compared to low-LET x rays (Di Paola et al.,
1414 1978). Other studies are being done with astronauts exposed in space to high-LET high-Z
1415 particles (HZE) radiation (Cucinotta et al., 2001).

1416

1417 **4.3.2.5 Age.** The age dependence of radiation cataractogenesis has long been understood
1418 (Choshi et al., 1983; Dynlacht, 2013; Klein et al., 1998; 2000; Wang et al., 2014). In humans,
1419 several studies have shown that the young developing lens is especially sensitive to ionizing
1420 radiation exposure (Day et al., 1995; Hall et al., 1999; Wilde and Sjostrand, 1997). Radiation-
1421 induced cataracts usually originate in the PSC region (Dynlacht, 2013; Worgul et al., 1976).
1422 However, there is also evidence from human and animal studies that exposure to ionizing

1423 radiation leads to early manifestation of cataracts that would otherwise be seen in old age
1424 (Dynlacht, 2013; Kleiman et al., 2007; Rafnsson et al., 2005; Smilenov et al., 2008; Worgul et
1425 al., 2002). This issue is discussed further below (Section 4.3.3).

1426
1427 The importance of age at exposure is evident in much of the epidemiological literature
1428 examining radiation cataract risk. It is clear from human studies of astronauts (Cucinotta et al.,
1429 2001) that ocular cataracts are appearing at younger ages as a consequence of exposure to a
1430 whole range of damaging agents, including ionizing radiation. It is equally clear that high-LET
1431 particles are much more effective than low-LET x rays, and that this may account for the
1432 reported cataracts in astronauts. Relevant examples of age at risk, from the atomic-bomb
1433 survivors' cohorts, suggest that relative risks for exposure to radiation decreased to a statistically
1434 significant extent with increasing age at examination (Minamoto et al., 2004; Nakashima et al.,
1435 2006; Neriishi et al., 2012). A great deal of published evidence suggests (Section 4.3.2.6) that the
1436 steroid sex hormones account for age- and gender-based differences in the progression and
1437 prevalence of cataract that normally occur spontaneously in humans and in animal models
1438 (Dynlacht, 2013). Medical workers developed radiation cataracts at earlier ages than expected
1439 (Milacic, 2009) and lens injuries were observed as a result of cumulative doses after several
1440 years of work (Jacob et al., 2013; Vano et al., 2013). Commercial airline pilots have been shown
1441 to develop cataracts at a younger age than non-pilots (Raffnsson et al., 2005), and age was found
1442 to be a highly statistically significant factor for development of radiation induced cataracts for
1443 NASA astronauts (Cucinotta et al., 2001). Both the airline pilot and astronaut cataract studies
1444 described the age at which the cataract was scored. The observed acceleration is known to be
1445 dose dependent (Dynlacht, 2013; UNSCEAR, 2013b). Furthermore, the epidemiological
1446 observations are supported by evidence in rodent models (Cogan and Donaldson, 1951; Dynlacht
1447 et al., 2012; 2013; Hudson et al., 2011; Merriam and Szechter, 1975).

1448
1449 **4.3.2.6 Gender.** Relatively few studies have specifically investigated the influence of gender in
1450 development of radiation-induced cataracts. It is known that females have a slightly higher
1451 incidence of spontaneously occurring (age-related) cataracts (Klein et al., 1998; Varvas et al.,
1452 2002). However, although the baseline difference means that most epidemiological studies adjust

1453 for gender, few have considered the influence of gender on dose dependent risk, with the
1454 evidence to date being far from conclusive (Kawamoto et al., 1962; Minamoto et al., 2004;
1455 Neriishi et al., 2007; Worgul et al., 2002). In contrast, animal studies have generally indicated a
1456 relatively strong association between gender and radiation-induced cataract incidence with males
1457 being more sensitive than females, but not due to estrogen levels (Henderson et al., 2009), and
1458 rate of progression (Henderson et al., 2010). There is also evidence that both the age and gender
1459 effects may be dependent on species and radiation type, as discussed below (Section 4.3.3).

1460

1461 The issue of gender differences in cataractogenesis is complicated. Despite numerous
1462 confounding issues, the majority of experimental, clinical and epidemiological studies indicate
1463 that age and gender appear to be determinants for radiation cataractogenesis induced by high-
1464 and low-LET irradiation (Dynlacht, 2013). However, the type of radiation is an important factor
1465 in determining the age response of the lens. The latent period, rate of progression, and cataract
1466 severity after exposure to low-LET radiation depend on the age at irradiation. While species-
1467 related differences preclude the idea that the same patterns of cataractogenesis would be
1468 observed universally in both irradiated animals and humans, the published evidence
1469 demonstrates that male rats have a higher incidence compared to females exposed to low-LET
1470 radiation, and that older rats develop opacities that appear earlier, and progress faster than those
1471 in younger animals exposed to high-LET radiation. On the female side, the prevalence of
1472 spontaneously occurring cataracts increases with age, and is slightly higher for women compared
1473 to men (Vavvas et al., 2002). Administration of estrogen to postmenopausal women, however,
1474 results in a decrease in cataract formation, compared to age-matched postmenopausal women not
1475 receiving hormone replacement therapy (Benitez del Castillo et al., 1997; Cumming et al., 1997).
1476 Thus the data indicate that estrogen may promote or protect against cataractogenesis induced by
1477 ionizing radiation, depending on when it is administered relative to the time of the irradiation
1478 (Dynlacht, 2013).

1479

1480 **4.3.2.7 Steroid Sex Hormones.** A large amount of data suggest that steroid sex hormones (SSH)
1481 are involved in gender as well as age differences in radiation cataract incidence and progression
1482 (Benitez del Castillo et al., 1997; Cumming and Mitchell, 1997; Freeman et al., 2001; 2004;

1483 Henderson et al., 2010; Klein et al., 1994). Dynlacht et al. (2013) comprehensively reviewed the
1484 data in this field and found that estrogen may promote or protect against cataractogenesis
1485 induced by ionizing radiation, depending on when it is administered relative to the time of
1486 irradiation (Bigsby et al., 2009; Dynlacht et al., 2006; 2008).

1487

1488 **4.3.2.8 Latency.** Latency is the time elapsed between radiation exposure and the detection of
1489 opacities. It varies roughly inversely with dose (Kleiman et al., 2008; 2012; Merriam and Focht,
1490 1962; Smilenov et al., 2008). Figure 4.9 illustrates this relationship. Latency is also codependent
1491 on a number of influential factors, including the dose, the ionization density of the radiation, and
1492 the charged particle radiation species (Dynlacht, 2013).

1493


1494 The role and contribution of dose fractionation to radiation cataract development has
1495 been examined in great detail in the animal eye (ICRP, 2012). The data are also somewhat
1496 conflicting; however, when exposure to low-LET ionizing radiation is fractionated or
1497 administered over a protracted period, the latent period is usually increased and progression is
1498 slower (Dynlacht, 2013).

1499

1500 Very few valid, comprehensive studies have been performed to allow the determination
1501 of the relationship between age, gender, dose fractionation, and latency period for radiation-
1502 induced cataracts. Work done by Merriam and Focht (1962) is illustrated in Figures 4.10.a-d.
1503 Six-month old female rats (White Sherman strain) were used. One eye of each animal was
1504 irradiated and the contralateral eye was used as a control. The animals were anesthetized and
1505 immobilized. A small cone was used to limit the x-ray beam to one eye only with a lead shield
1506 covering the rest of the body. The dose to the eye was measured under experimental conditions
1507 with a phantom rat, using a small Baldwin-Farmer condenser ionization chamber. In all of the
1508 experiments the following factors were used: 200 kVp x rays, tube window half-value layer
1509 equivalent of 1.0 mm Cu, and tissue-to-source distance of 20 cm. Single doses of 500 R (~ 5
1510 Gy), 1,000 R (~ 10 Gy), 1,500 R (~ 15 Gy), and 2,000 R (~ 20 Gy) were given to each group
1511 which consisted of approximately 20 to 30 rats. The dose rate was 180 R (~ 1.8 Gy) per minute.

1512

1513



1514


1515

1516 **Fig. 4.9.** Plot of doses to the lens of cancer radiotherapy patients in single acute
1517 exposures (see left side of the plot), for a treatment time of three weeks to three months, or a
1518 treatment time extended for more than three months (plotted on the right side). The different
1519 symbols indicate that there was no cataract at that dose, a stationary or progressive cataract, or it
1520 was not determined if there was a cataract. These data are the origin of the 200 R (~ 2 Gy) dose
1521 threshold for a single acute exposure to result in a cataract (Merriam and Focht, 1962).

1522

1523


1524



1525

1526 **Fig. 4.10.a.** Plots of average cataract for given radiation exposures against time elapsed
1527 after treatment as figure (a) curves for 2,000 R (~ 20 Gy) single and divided groups (Merriam
1528 and Focht, 1962).

1529



1530


1531

1532 **Fig. 4.10.b.** Figure (b) curves for 1,500 R (~ 15 Gy) single and divided groups with the
1533 curve for the single treatment as the average of two experiments shown by the solid and open
1534 triangles (Merriam and Focht, 1962).

1535

1536


1537



1538

1539 **Fig. 4.10.c.** Figure (c) curves for 1,000 R (~ 10 Gy) single and divided groups (Merriam
1540 and Focht, 1962).

1541



1542

1543

1544 **Fig. 4.10.d.** Figure (d) curves for 500 R (~ 5 Gy) single and divided groups in which
1545 neither group had been followed sufficiently long to determine the final shape of each curve;
1546 however, a difference between them is apparent (Merriam and Focht, 1962).

1547

1548

1549

1550 Each animal was numbered individually by a coded ear punch, and the treated eye could
1551 be either the right or the left. Similar divided doses were delivered to one eye of each animal, in
1552 comparable groups, in a total of six days, given on the first, third and sixth days. This time
1553 interval was chosen since, as a fraction of their life span, it approximates the duration of
1554 treatment most commonly employed clinically for human radiotherapy with a treatment time of
1555 three weeks to three months. Each of the approximately 250 animals was examined with the slit-
1556 lamp (corneal microscope) before treatment, and weekly, or every few weeks, thereafter. The
1557 examiner had no knowledge as to which eye had been treated, or, in most cases, which dosage
1558 group was being examined. At random times a whole group was re-examined on the same day
1559 without the knowledge of the examiner. The two results so obtained showed no significant
1560 difference. The method chosen to score the cataracts was to estimate the average lens opacity at a
1561 given time of observation after exposure. The cataracts were graded 1+ to 4+ at each
1562 examination. In classifying the cataracts as 1+, 2+, 3+, or 4+ the Merriam-Focht criteria were
1563 used as depicted in Figures 4.4.a-d. Overall, the outcome of the study indicated dose sparing
1564 effects with fewer cataracts appearing with divided doses, and longer latencies with decreasing
1565 total doses.

1566

1567 **4.3.3** Mechanisms of Radiation Cataractogenesis

1568

1569 Radiation-induced damage may deregulate normal lens cell functions leading to the
1570 formation of opacities in the lens. Several potential targets and pathways are discussed below.

1571

1572 **4.3.3.1** Cellular Biology. During the course of normal lens fiber differentiation, the lens fiber
1573 cell nucleus disintegrates along with other cytoplasmic organelles in a rapid and highly
1574 coordinated manner and DNA is cleaved (Bassnett, 2002; Bassnett and Mataic, 1997). While on
1575 the surface the degradation of organelles and DNA that occurs in lens cells bears a striking
1576 resemblance to apoptosis, this process, which is critical for establishing lens clarity, is a
1577 completely separate process involving, at least in part, several different mechanisms (Nishimoto

1578 et al., 2003). Pendergrass et al. (2010) have proposed that the failure to degrade nuclei and DNA
1579 may contribute to cataract development in young adult mice.

1580
1581 Differentiated lens epithelial cells do not contain nuclei or mitochondria, and are
1582 dependent on the overlying epithelial cell layer for nutrient transport and energy production.
1583 Thus damage leading to the formation of cataracts is generally assumed to occur in the
1584 germinative zones, where proliferation of lens cell fibers begins. Damage to the genome,
1585 resulting in mutation or misrepair is likely to be the dominant mechanism at low doses (rather
1586 than cell killing).

1587
1588 **4.3.3.2 Protein Accumulation.** It has been shown that lens fibers have a very high protein
1589 content to enable transparency and refractivity (Beebe et al., 2011). Lens protein accumulation
1590 and crystalline interactions are discussed in detail in Moreau and King (2012). Lens protein
1591 accumulation is thought to play a major role in radiation-induced cataract development, with
1592 abnormal accumulation of alpha-, beta- and gamma-crystallines (possibly due to post-
1593 translational modifications related to structure) leading to light scattering rather than light
1594 transmission, which results in the observable opacities (Hamada et al., 2014). Protein changes in
1595 gamma irradiation induced cataracts were reported to be similar to changes observed in age-
1596 related cataracts (Muranov et al., 2010). Misregulation of lens crystallines may be related to
1597 aging as well as radiation-induced opacity following, for example, fractionated low doses
1598 (Abdelkawi, 2012).

1599
1600 **4.3.3.3 Molecular Biology.** Abnormal cell proliferation, which is usually kept in check by p53
1601 dependent pathways, may have a role in radiation cataractogenesis and also has mechanistic
1602 similarities to tumorigenesis (Wiley et al., 2011). Tumor related factors potentially associated
1603 with cataractogenesis have recently been reviewed, and human studies have demonstrated
1604 involvement of mutations in oncogenes, tumor suppressor genes and other tumor related genes
1605 (Hamada and Fujimichi, 2015). Abnormal functioning of cell cytokines, differentiation and cell
1606 adhesion molecules in irradiated cultured human lens cells is also implicated in cataractogenesis
1607 (Chang et al., 2000; 2005; 2007; McNamara et al., 2001).

1608

1609 It is postulated that aberrantly dividing and/or differentiating cells in the pre-equatorial
1610 region of the lens epithelium migrate predominately to the lens posterior pole, where they
1611 become lens fibers which lead to clinical cataracts (ICRP, 2012). Recent evidence has
1612 demonstrated that ionizing radiation can indeed induce unexpected proliferation in human
1613 epithelial lens cells (Fujimichi and Hamada, 2015) and that low dose irradiation may be
1614 particularly effective in this, although this requires much further investigation (Markiewicz *et al.*,
1615 2014).

1616

1617 **4.3.3.4 Oxidative Stress.** Oxidative stress is thought to be a contributor to radiation-induced
1618 damage leading to cataracts. The important role of antioxidants in the lens is reviewed in a recent
1619 paper by Hamada *et al.* (2014). As an example, in humans, antioxidant activity has been shown
1620 to decrease in patients > 70 y, leading to more severe nuclear and cortical cataracts (Hasanova *et*
1621 *al.*, 2009). In animal studies with mice exposed to 11 Gy of x rays to the head, cataracts matured
1622 within a very short time scale (*i.e.*, on the order of 30 days), but after a relatively long latent
1623 period (5 to 11 months). Descendants of the damaged and superficially repaired lens epithelial
1624 cells were found to differentiate and migrate abnormally. It was postulated that this resulted in
1625 critical uptake of environmental oxygen to the lens that overwhelmed the resident antioxidant
1626 protection machinery, resulting in coagulation of lens proteins and thus cataract formation (Wolf,
1627 2008). Cataract formation in 11 Gy irradiated (head only) mice showed accelerated loss of
1628 epithelial cells and other damage (such as lens fibers with nuclei, nuclear fragments, reactive
1629 oxygen species, and oxidized DNA bases) that is also observed in age-related cataractogenesis
1630 (Pendergrass *et al.*, 2010). Mechanistically, these data support the supposition that radiation leads
1631 to acceleration of cataract formation. Indeed, aging has been linked to the breakdown of
1632 antioxidant mechanisms leading to accumulation of oxidized components. Oxidation has thus
1633 been described as the hallmark of age-related nuclear cataract.

1634

1635 The key factor in preventing oxidation has been postulated to be the presence of the
1636 antioxidant glutathione (Truscott, 2005); however, intraperitoneally injected antioxidants (such

1637 as melatonin) have been shown to augment antioxidant capacity in the lens and reduce oxidative
1638 stress (Taysi et al., 2005).

1639

1640 **4.3.3.5 DNA Damage.** While there are still a number of unanswered questions regarding the
1641 role of radiation-induced DNA damage in the induction or progression of cataracts, it has been
1642 proposed that the accumulation of, or failure to repair DNA lesions in lens epithelial cells may be
1643 a precursor to radiation cataractogenesis (Jose, 1978; Kleiman and Spector, 1993; Worgul et al.,
1644 1991). The consequences of DNA damage may not be known until the affected lens epithelial
1645 cells differentiate and migrate to the posterior cortex. A role for oxidative damage in the
1646 opacification process has been proposed (Avunduk et al., 2000). The free radicals produced in
1647 response to ionizing radiation can interact with DNA to form single strand breaks (SSBs), double
1648 strand breaks (DSBs), and base damage, such as the adduct 8-hydroxyguanosine (8-OHG).
1649 While radiation-induced SSBs are rapidly repaired (Aufderheide et al., 1987), mouse lenses may
1650 retain 8-OHG well after SSB repair is complete.

1651

1652 It is well known that unrepaired DSBs can lead to chromosomal aberrations; the
1653 presence or persistence of asymmetrical exchange-type aberrations correlates well with cell
1654 killing (Hall et al., 2005). Repair of DSBs in most cell lines irradiated with x rays is biphasic
1655 (Baumstark-Khan et al., 1999), but the slow component is much longer in lens epithelial cells.
1656 This could imply that unrestored DSBs remain long after irradiation (Aufderheide et al., 1987).
1657 The lens tolerates higher doses when the radiation dose is fractionated (*i.e.*, the onset of
1658 opacification is delayed and incidence of cataracts is reduced), implying that DSB repair occurs
1659 between doses (Merriam and Focht, 1957; 1962). However, low dose rate studies suggest that the
1660 lens is slow at repairing DSBs (Brenner et al., 1996).

1661

1662 **4.3.3.6 Genetic Susceptibility.** Many of the more recent mechanistic studies have focused on
1663 the genetic basis of cataract development (Hamada and Fujimichi, 2015). The ATM, Rad9 and
1664 Brca1 genes are known to be critical to pathways controlling DNA damage response signaling,
1665 repair or apoptosis.

1666

1667 Opacities in ATM-deficient mice were observed earliest in ATM homozygotes, but
1668 cataracts also developed earlier in heterozygotes compared to wild-type mice for all doses
1669 (Worgul et al., 2002). The severity and latent period were directly related to the number of
1670 genomically damaged cells attempting differentiation. Because ATM is involved in cell cycle
1671 control and pathways to apoptosis, this would indicate that cataracts may be due to defective
1672 control of these pathways in response to DNA damage.

1673
1674 PSC opacities were found to develop earlier in x-ray irradiated double heterozygotes
1675 ($ATM^{+/-}/Rad9^{+/-}$) than in either of the single heterozygotes, which again developed earlier than in
1676 wild-type mice (Kleiman et al., 2007). Smilenov et al. (2001) investigated individual genetic
1677 susceptibility of cataracts in mice heterozygous for the ATM, Brca1 and Rad9 genes. Exposure
1678 to 0.5 Gy of 250 kVp x rays led to elevated cataract development in double-heterozygote
1679 combinations, and cataracts appeared earlier in double heterozygotes. Heterozygosity of the
1680 ATM and Brca1 genes resulted in increased resistance to apoptosis and heterozygosity of the
1681 ATM and Rad9 genes led to increased resistance to apoptosis and sensitivity to radiation.
1682 Worgul et al. (2002) showed that ATM heterozygous mice are also more sensitive to heavy-ion
1683 exposure. ATM gene polymorphism has also been indicated as a risk factor for cataract surgery
1684 among atomic-bomb survivors (Neriishi et al., 2009).

1685
1686 **4.3.4** Research Gaps
1687

1688 More data are required in most of the areas discussed in this section, but in particular to
1689 elucidate the molecular responses to radiation in the lens, to provide a clearer link between the
1690 initial damage response and formation of lens opacities.

1691
1692 In terms of cataracts, it is important to first fully define the target cells for radiation
1693 cataractogenesis, in particular for PSC opacities. There is a lot of evidence to suggest that it is
1694 the germinative zone at the edges of the lens epithelium which are relevant for PSC development
1695 (Eshagian and Streetan et al., 1980; Von Sallman et al., 1955; Worgul et al., 1975), however it is
1696 not impossible that effects, for instance those linked to antioxidant action, may occur as a result

1697 of exposure to the general lens microenvironment. The next question is how radiation incident on
1698 the target (cells or otherwise) triggers lens opacification. Many questions remain regarding the
1699 role of oxidation and DNA damage; the mechanisms of radiation response and the effect of
1700 radiation on genetic and molecular biological control of lens fiber formation; and finally, lens
1701 fiber migration and accumulation, as outlined above. In particular, it would be useful to answer
1702 specific mechanistic questions regarding: what are the oxidation effects that occur in the lens
1703 response to ionizing radiation, including the exact antioxidant response that follows; how the
1704 lens responds in terms of the role of accumulation of damage in proteins versus the role of post-
1705 translational modifications (Hamada et al., 2014); and, how/which genes play a part in the
1706 development of radiation-induced PSC.

1707

1708 Furthermore, intracellular communication in the lens has been the subject of a number of
1709 recent studies. For instance, structural changes in the murine lens, which are linked to pre-
1710 cataractous changes, have been identified as being due to a lack of the connexin43 gap junction
1711 protein (Gao and Spray, 1998). It recently has been suggested that a change in charge of amino
1712 acid 23 in connexin50 is linked to cataract formation (Thomas et al., 2008). Further, a single
1713 point mutation in the gamma D-crystalline gene has been shown to lead to reduced protein
1714 solubility and to the formation of intra-nuclear aggregates (Wang et al., 2007). The magnitude
1715 and relevance of these effects for radiation cataractogenesis require further elucidation.

1716

1717 Numerous in vitro and in vivo studies indicate that, in addition to targeted effects of
1718 damage induced directly in cells by radiation, a variety of non-targeted effects may contribute to
1719 determining the overall outcome after radiation exposure. Effects including genomic instability
1720 and bystander effect have been observed both in vitro and in vivo across many mammalian
1721 systems and cell types, including human tissues (Morgan, 2003a; 2003b).

1722

1723 There is active research in preventing and potentially reversing lens opacities in animal
1724 models of cataract. Clearly, more work needs to be done to determine whether these treatments
1725 will be adapted for use in humans (Makley et al., 2015; Zhao et al., 2015).

1726

1727 It is generally understood that apoptosis in the lens is a rare event. It is possible that
1728 accumulation of small scale lens epithelial cells (LECs) losses due to apoptosis may induce
1729 alterations leading to reduced transparency (Charakidas et al., 2005). Indeed exposure to UVB
1730 has been demonstrated to lead to apoptosis in LECs in a time- and dose-dependent manner (Ji et
1731 al., 2015). However, the implications for ionizing radiation exposure remain unclear.

1732
1733 Telomere damage is an area of current interest, and such damage can result from
1734 genotoxic and oxidative stress (Hewitt et al., 2012). Recently, shorter telomere lengths were
1735 observed in Chernobyl accident recovery workers diagnosed with cataract 23 y after recorded
1736 doses up to 300 mSv, however there was no significant association between telomere length and
1737 dose (Reste et al., 2014). Recent reviews of the association between oxidative stress and cataract
1738 have also indicated a potential role of premature senescence. Indeed, it has been suggested that
1739 such biomarkers of oxidative stress can be considered as general biomarkers for life expectancy
1740 in veterinary circles and cataract treatments focusing on prevention of loss of functional telomere
1741 length are already in development (Babizhayev and Yegorov, 2015).

1742
1743 For radiation protection purposes, it is also important to consider the role of RBE, dose
1744 protraction and fractionation, and to address what lies behind the inverse relationship between
1745 latency period and dose. In conclusion, studies involving more than one type of radiation and
1746 more than one type of exposure scenario would be highly useful in addressing the remaining
1747 research questions, including those discussed above.

1748
1749

1750 **5. Epidemiological Evidence Related to Ionizing Radiation and Cataracts**

1751

1752

5.1 Introduction

1753

1754

1755

1756

1757

1758

1759

1760

1761

1762

1763

1764

1765

1766

1767

1768

1769

1770

1771

1772

1773

1774

1775

1776

1777

1778

1779

Epidemiology is the study of the distribution of disease and its determinants or risk indicators in particular populations. Thus study of a given disease relies upon specification of the target population as well as an accurate description of the disease or phenotype. While a primary task of epidemiology is to find consistencies across populations and results so that one can make scientific generalizations when possible, for radiation-induced cataract there are also two important questions we face with regard to differences among cohorts: (1) What are the characteristics of the populations of interest: is it the general US population or special exposure cohorts, and, if the latter, what are the specifics of each cohort that may differ from other exposed cohorts and do they alter the estimates of risk related to exposure to ionizing radiation; and, (2) How is the phenotype defined; is it accurate and uniform across studies?

The response to the first question as outlined in this section is that there are very limited data concerning exposure to ionizing radiation in the general U.S. population. Estimates of such exposure from medical records often rely on self-report of diagnostic or therapeutic medical exposure and even then actual dose or doses are often inaccurate and the specific source of exposure may be inaccurate. Thus, the exposure data we consider in this Commentary are only those related to special cohorts where exposure is likely to be higher than that of the general U.S. population. Note that several of these studies have been performed in other populations that may or may not be directly relevant to general U.S. populations. There is additional limited reference to information from animal models. This is, in part, because the biology of lens opacities in animals may differ in important ways from those in humans, and laboratory breeding and housing may further the disparity between laboratory animals and humans. The intriguing observations regarding genetic effects on sensitivity to lens opacities in laboratory models (and limited data in humans) needs to be further evaluated in humans to understand the possibility of inherent susceptibility to (or protection from) the lens effects of ionizing radiation (Kleiman et al., 2007), reviewed in detail in Section 4.

1780

1781 Question two is perhaps a more important issue as the diagnostic criteria for labeling a
1782 cataract has not only varied from publication to publication but has also changed over time. As
1783 detailed in Section 4, there are a number of different types of cataract: those related to radiation
1784 and those related to other factors, including age, as well as the many different ways in which
1785 cataracts can be classified (e.g., those which are visually impairing or not). This is important
1786 because the different types of opacity may have a different profile of risk factors or risk
1787 indicators. Unfortunately, detailed data regarding all the possible modifying factors and
1788 confounders are rarely available and this must be kept in mind when evaluating the evidence of
1789 radiation-induced or related cataract. While estimates of dosages and sources of exposure have
1790 been made (NCRP, 1989a), we do not yet understand what types of lens damage from ionizing
1791 radiation must occur for opacifications to form, or whether a deterministic or stochastic model is
1792 appropriate.

1793

1794 This section contains detailed reviews of the available literature and further analysis
1795 based on categorization of the studies according to how well the risk factors have been
1796 characterized.

1797

1798 **5.1.1 Recent Reviews of Radiation Cataractogenesis Epidemiological Studies**

1799

1800 In spite of the well-documented history of radiation-induced cataracts, there is still
1801 considerable uncertainty surrounding the relationship between dose and radiation cataract
1802 development, which is of concern to the risk assessment community (ICRP, 2012). In recent
1803 years, a number of new studies have suggested an elevated risk of cataract development in
1804 populations exposed to low doses of ionizing radiation. Consequently, several reviews of these
1805 radiation cataractogenesis epidemiology studies have recently been published in the literature
1806 (Ainsbury et al., 2009; Blakely, 2012; Blakely et al., 2010; Bouffler et al., 2012; Cooper, 2009;
1807 Hamada and Fujimichi, 2014; Hamada et al., 2014; Hammer et al., 2013; ICRP, 2012; Little,
1808 2013; Martin, 2011; Shore et al., 2010; Thorne, 2012). In general, these reviews have concluded
1809 that there is a strong likelihood of an association between exposure to ionizing radiation and

1810 initiation or development of various cataracts and that, while there is uncertainty, a lower
1811 threshold or nonthreshold (i.e., a stochastic response) may be an appropriate model for radiation
1812 cataractogenesis risk (EPRI, 2014).

1813
1814 An earlier review of the epidemiologic literature indicated that some findings are
1815 consistent with the absence of a dose threshold (Shore and Worgul, 1999). More recent reviews,
1816 such as Cooper (2009) highlighted the possibility that cataracts may develop at absorbed doses
1817 below the threshold of ~ 1.5 Gy previously given by ICRP. Ainsbury et al. (2009) noted that
1818 "...much of the science is contradictory, and it is therefore very difficult to reach a firm
1819 conclusion between a threshold and a no-threshold dose response for cataract formation, which is
1820 likely to be a multifactorial process..." and judged that a threshold in the region of 0.5 Gy of
1821 low-LET radiation, or even the possibility of a non-threshold response with a doubling dose that
1822 may be of the order of ~ 2 Gy could exist. Blakely et al. (2010) summarized thirteen
1823 presentations on updated reviews of epidemiological and biological research on radiation
1824 cataractogenesis and emphasized that the most important recent epidemiological finding was that
1825 there was stronger evidence that low-LET radiation causes opacities at exposures lower than
1826 previously expected (i.e., a dose-effect threshold as high as 5 Gy for vision-impairing cataracts).
1827 Shore et al. (2010) not only suggested that radiation-associated opacities occur at much lower
1828 doses, but that the findings from various studies indicated that radiation risk estimates are
1829 probably not due to confounding by other cataract risk factors, and that risk is observed after
1830 both childhood and adult exposures. Thome (2012) suggested that the accumulating
1831 radiobiological and epidemiological evidence makes it more appropriate to treat cataract
1832 induction as a stochastic rather than a deterministic effect. Hammer et al. (2013) noted that
1833 substantial uncertainty about the level and the existence of a threshold subsists and that current
1834 studies are heterogeneous and inconclusive regarding the dose-response relationship. Little
1835 (2013) noted that radiation doses of 1 Gy or more are associated with increased risk of PSC and
1836 accumulating evidence suggests that cortical cataracts may also be associated with ionizing
1837 radiation. He further suggests that the dose-response appears to be linear, although a modest
1838 threshold of no more than ~ 0.6 Gy cannot be ruled out.

1839

1840 **5.1.2 Previous Epidemiological Studies**

1841

1842 In general, the very early radiation cataract studies were limited in that they failed to take
1843 into account increasing latency periods as doses decrease, did not have sufficient sensitivity to
1844 detect early lens changes, and only had a relatively few subjects with doses below a few Gy.
1845 Recently, EPRI completed a detailed review and evaluation of radiation cataractogenesis
1846 epidemiology studies (EPRI, 2014) in which they identified and selected 59 publications in the
1847 formal literature that report results on about 44 study populations. This is a larger number of
1848 studies than has been evaluated in previous reviews. See Appendix A, Tables A.1 through A.7
1849 for a detailed summary of the specific study information including: reference, area of study, type
1850 of study, study period, study population (characteristics, study size), type of radiation exposure,
1851 reconstructed dose, exposure assessment, outcome assessment, results or risk estimates for
1852 cataract [at the 95 % confidence interval (CI)], and if adjustments were made to confounders in
1853 the main model. The identified studies report addressed various exposure conditions including
1854 acute exposures, mixed exposure situations, as well as protracted exposure to low doses of
1855 ionizing radiation and the development of a cataract or opacification. The types of studies are
1856 grouped and discussed below generally according to exposure conditions.

1857

1858 **5.1.2.1 Atomic Bomb.** Appendix A, Table A.1, summarizes information from cataract studies of
1859 atomic bomb survivors. These studies show increased risk of cataracts for acute exposures of
1860 ionizing radiation, perhaps 1 Gy or lower.

1861

1862 The earliest studies (Cogan et al., 1949; 1950) were initially performed within 5 y after
1863 the exposures and studied generally younger subjects (i.e., 2 to 16 y) and showed a prevalence of
1864 lens abnormalities using an ophthalmoscope in those individuals within 1 km of the atomic
1865 bomb's hypocenter. Larger studies (Nefzger et al., 1969; Otake and Schull, 1982; Otake et al.,
1866 1990; 1996) began to explore cataract dose responses, showing axial opacities with increases in
1867 the higher dose (i.e., > 2 Gy) group of exposed individuals. A major study in 1978 to 1980
1868 compared the prevalence of lens opacities in participants of the Adult Health Study (AHS, a
1869 biennial clinical examination collective of both Hiroshima and Nagasaki survivors) to a 'non-

1870 exposed' group (Choshi et al., 1983). Doses in the exposed group ranged from 0 to 6 Sv (based
1871 on the earlier T65DR dose estimates) and an increasing prevalence of PSC with increasing dose
1872 and with decreasing age at examination was observed, but no trends were estimated. However,
1873 no standardized lens opacity system was utilized. Yamada et al. (2004) who later updated non-
1874 cancer outcomes in the AHS cohort followed up for the longer period 1958 to 1998 and using the
1875 DS86 dosimetry noted an increased relative risk for opacities at 1 Sv, as well as a suggested
1876 linear dose-response effect for cataracts. However, again no standardized lens opacity system
1877 was utilized.

1878

1879 Minamoto et al. (2004) re-examined AHS and atomic bomb survivors who had
1880 previously participated in ophthalmological examinations. This study utilized the standardized
1881 LOCS II quantitative grading system (Section 4) and showed significant radiation effects for
1882 PSC and cortical cataracts, but not nuclear cataracts. Nakashima et al. (2006) updated the results
1883 by applying the new DS02 dosimetry finding similar results. Nakashima et al. (2006) also
1884 specifically addressed the question of dose threshold, finding 0.6 Sv for cortical cataract and 0.7
1885 Sv for PSC, with 90 % CI including 0 Sv, suggesting that the thresholds were not significantly
1886 greater than 0 Sv. However, questions have been raised of the data quality used in the atomic
1887 bomb survivor studies and the data are currently being reviewed (RERF, 2013a; 2013b; 2014a;
1888 2014b) (Section 5.3).

1889

1890 One important study evaluated cataract surgeries in AHS and related cohorts (Nakashima
1891 et al., 2013; Neriishi et al., 2007; 2012). The results agree with the earlier opacity evaluations
1892 and have shown an increased risk at about 1 Sv and possible thresholds below about 0.8 Sv.
1893 While there is a potential uncertainty introduced when using cataract extraction as an end point
1894 rather than lens opacification (*i.e.*, quantifiable cataract scoring), since lensectomy is performed
1895 when visual impairment is strong, it is a subjective, individual decision (Hammer et al., 2013). It
1896 should be emphasized that in a cohort study, such surgery is likely an appropriate surrogate for
1897 VICs, the endpoint of greatest concern in terms of lens of the eye radiation protection.

1898

1899 **5.1.2.2 Chernobyl.** Appendix A, Table A.2, summarizes information on the cataract studies
1900 including Chernobyl liquidators and cleanup workers. In general, the two reported studies show
1901 increased risk of cataracts for acute (and possibly chronic) exposures to ionizing radiation,
1902 perhaps 1 Gy or lower.

1903
1904 A small cohort study was performed over the period of 1986 to 2000 in the Ukraine
1905 (Nadejina et al., 2002) that included people with acute radiation syndrome (ARS, N = 11) as well
1906 as Chernobyl recovery workers (N = 30). It was estimated that the ARS group had a mean dose
1907 of 3.2 Gy and the recovery workers had a mean dose of 0.2 Gy. Almost half of ARS cases had
1908 ‘radiation cataracts’ and none of the recovery workers developed ‘radiation cataracts.’ In
1909 addition to the small size of the study, a major uncertainty is introduced because the grading
1910 system was not reported.

1911
1912 A much more comprehensive study of 8,607 Chernobyl cleanup workers exposed
1913 between April 26, 1986 and December 31, 1987 was performed by examinations using the
1914 Merriam-Focht Cataract Scoring System about 12 to 14 y after exposure (Worgul et al., 2007)
1915 and attempted to address several important confounders. Lens doses for this cohort ranged from
1916 0 to > 1 Gy with a median of 123 mGy. Significant increased risk was noted for PSC, cortical
1917 and mixed cataracts. In addition, the investigators selected a maximum likelihood central
1918 estimate of the dose threshold for stage 1 cataract and stage 1 PSC of less than 0.5 Sv. Some
1919 uncertainty is introduced by the dosimetric assessment methods for different groups of exposed
1920 persons.

1921
1922 **5.1.2.3 Medical Patients.** Appendix A, Table A.3, summarizes information from cataract studies
1923 of medical patient exposures. These exposures should be considered acute, clinical case
1924 exposures. Eleven case reports and/or cohort studies of clinical exposures of medical patients
1925 from radium, x rays, helium ions, or internal alpha emitters were evaluated. There are large
1926 uncertainties in many of the medical patient study results due to the varying outcome assessment
1927 methodologies employed, lens dosimetry estimation techniques, and unclear confounder
1928 adjustments. In general, studies of patients who received estimated lens doses > 2 Gy (and

1929 especially higher doses) showed increased risk of cataracts. However, most of the medical
1930 patient studies had very few patients with < 2 Gy and had limited follow-up times. A few studies
1931 appear to suggest increased risk of cataract at doses < 2 Gy. Both the studies by Wilde and
1932 Sjostrand (1997) and Hall et al. (1999) appear to show that opacity grade increases with lens
1933 dose.

1934

1935 **5.1.2.4 Health Care Personnel.** Appendix A, Table A.4, summarizes information from cataract
1936 studies of health care personnel exposures. There were nine studies on chronic (i.e., protracted)
1937 exposures among health care personnel, mostly x-ray technologists and/or interventional
1938 radiology and cardiology personnel. While these studies suffer from various individual study
1939 quality limitations (e.g., dosimetry uncertainties, inconsistent cataract scoring, lack of
1940 confounder adjustments, and possible selection/reporting bias), in general they suggest the
1941 prevalence for cataracts in the chronically exposed groups and especially for those who did not
1942 employ protective eyewear or shielding. Most of the reported opacities were in the PSC region.

1943

1944 **5.1.2.5 Flight Personnel and Astronauts.** Appendix A, Table A.5, summarizes information from
1945 cataract studies of flight personnel and astronaut exposures. Several studies by NASA and others
1946 have investigated the exposure of flight personnel and astronauts to cosmic radiation and
1947 subsequent development of cataracts (Chylack et al., 2009; 2012; Cucinotta et al., 2001; Jones et
1948 al., 2007; Rafnsson et al., 2005; Rastegar et al., 2002). Although there are individual study
1949 limitations (based on small population sizes, potential for bias, questionable control groups, or
1950 handling of confounder effects) most of the results suggest that exposures to high-LET ionizing
1951 radiation could have different effects on the lens than does low-LET ionizing radiation (Blakely,
1952 2012).

1953

1954 **5.1.2.6 Other Occupationally Exposed Persons.** Appendix A, Table A.6, summarizes information
1955 from cataract studies of other occupationally exposed persons. Persons with other occupational
1956 exposures were included in eight, mostly smaller-sized population, studies. Generally, protracted
1957 exposures below occupational limits did not appear to increase risk of cataracts, while higher

1958 doses and especially high doses received acutely, may increase risk of cataract. However, these
1959 studies suffer from large uncertainties and limitations, making generalizations suspect.

1960

1961 **5.1.2.6.1 External Exposure.** The earliest of the studies evaluated 847 nuclear power workers at
1962 the National Reactor Testing Station with doses ranging from 1 to 253 mSv (based on dosimetry
1963 badge results) noting no lens changes related to occupational radiation exposure (Voelz, 1967).
1964 Okladnikova et al. (2007) assessed chronic external gamma radiation for nuclear workers at
1965 Mayak over 50 y and noted that such doses did not cause radiation-induced effects when they do
1966 not exceed the limit of the yearly dose for personnel (basically, ICRP limits at the time) and that
1967 cataracts could be considered a radiation effect at doses > 4 Gy when received acutely. In a
1968 separate study of occupational nuclear power workers with acute radiation syndrome (ARS, N =
1969 37) or chronic radiation syndrome (ChRS, N = 1,828) Okladnikova et al. (1994) had earlier noted
1970 radiation cataract only for > 3 Gy in one case of ARS personnel and no cases of radiation
1971 cataract in ChRS personnel. Both studies were limited by unspecified cataract scoring
1972 methodology. Shang and Fu (2007) reported on a study of radiation workers and noted an
1973 increase in more advanced opacities with longer radiation working time. However, this study
1974 was limited by a lack of dosimetry and unspecified cataract scoring methodology.

1975

1976 **5.1.2.6.2 Internal Exposure.** Persons with occupational internal exposures were included in two
1977 small population studies. In each study, lens doses were not estimated and no standard cataract
1978 scoring methodology was utilized. In a cohort study based on medical records of radium dial
1979 painters, increased rates of cataract incidence were observed in persons having ingested 50 μCi
1980 or more of ^{226}Ra and ^{228}Ra compared to others, with increasing rates with time since exposure
1981 (Adams et al., 1983). In a report on 97 retired actinide-exposed radiation workers with a range of
1982 lifetime effective doses of about 0 to 600 mSv, a significant PSC incidence was observed
1983 (Jacobson, 2005).

1984

1985 **5.1.2.6.3 Single Person Results.** Two studies reported on a single case outcome. Hayes and
1986 Fisher (1976) noted some posterior light scattering upon examination of extracted lenses of a
1987 worker exposed periodically from about 1935 to 1950 to external gamma radiation from radium.

1988 Griffith et al. (1985) noted premature (47 y old) PSC opacities in a worker who had experienced
1989 both internal and external exposures.

1990

1991 **5.1.2.7 Population Studies and Residentially Exposed Persons.** Appendix A, Table A.7,
1992 summarizes information from cataract studies of populations or residentially exposed persons.

1993

1994 Three large population cohort (i.e., cross sectional) studies evaluated cataracts, including
1995 the Beaver Dam Eye Study in the United States (Klein et al., 1993; 2000) and the Blue
1996 Mountains Eye Study in Australia (Hourihan et al., 1999). These studies investigated possible
1997 associations between medical imaging by computed tomography (CT) scans to the head and
1998 cataract development. The studies are limited by self-reporting of cataract endpoints and
1999 radiation exposures from CT and other medical imaging. The Beaver Dam Eye Study reported an
2000 OR for PSC of persons with a history of CT scans of 1.45 (95 % CI, 1.08 to 1.95), while in the
2001 Blue Mountains Eye Study it was 1.0 (95 % CI, 0.4 to 2.7).

2002

2003 Studies assessing cataracts in residents exposed to radioactive contamination have been
2004 performed in the Ukraine (Day et al., 1995) and Taiwan (Chen et al., 2001; Hsieh et al., 2010).
2005 The Ukrainian study evaluated school children living in two towns with ¹³⁷Cs deposits leading to
2006 a cumulative effective dose of about 30 mSv compared to children living in a non-exposed city.
2007 There was a small excess of subclinical PSC in exposed versus non-exposed children. However,
2008 significant limitations of this study are that ophthalmologists were aware of the children's
2009 exposure status and that not all controls were randomly selected (Hammer et al., 2013). In the
2010 Taiwan study, persons were exposed for up to 15 y from ⁶⁰Co contaminated steel used in the
2011 construction of their houses with cumulative whole-body doses ranging from 1 to 1.204 mSv. A
2012 radiation effect based on minor subclinical lenticular changes was observed in the subgroup of
2013 persons below age 20 at the time of examination, but not in others (Chen et al., 2001; Hsieh et
2014 al., 2010). The dosimetry estimates for the study were based on the reliance on self-reported
2015 information regarding the time spent in each room of the contaminated buildings.

2016

2017
2018 **5.2 Uncertainties**
2019

2020 As discussed in the literature reviews and elsewhere, the epidemiological studies
2021 informing radiation cataract risk differ in terms of many factors, including but not limited to:
2022 source of radiation, radiation quality, study design, study population, study size, time since
2023 exposure, range of lens doses, method of lens dosimetry/dose reconstruction, scoring of
2024 magnitude/severity of lens opacities, and the assessment of further risk factors and potential
2025 confounders.

2026
2027 **5.2.1 Risk and Confounding Factors**
2028

2029 There are a large number of known or suspected confounding factors for development of
2030 radiation cataracts and the epidemiological studies investigating these phenomena vary widely in
2031 the potential confounders considered. Most studies consider location, age at exposure (and/or age
2032 at examination) and gender. For example, in the right eyes 0.9 % of women 43 to 54 y of age in
2033 the Beaver Dam Eye Study had cataract while 57.5 % of women 75 years of age or older had
2034 cataract at the baseline visit (Klein et al., 1992). For men, the prevalence was about 5 % less than
2035 in women but the age trend was similar. The age effect was true for NSC, PSC and CC. Aside
2036 from age and gender (Graw et al., 2011), other factors related to cataract were smoking (Harding
2037 and Van Heyningen, 1989; Klein et al., 1993b; Leske et al., 1991; West et al., 1989), steroid use
2038 (Spencer and Andelman, 1965), diabetes (Klein et al., 1995), ultra-violet light exposure
2039 (Cruickshanks et al., 1992; Taylor et al., 1988), heavy drinking (Ritter et al., 1993), hypertension
2040 (Hiller et al., 1986; Klein and Klein, 1982; Klein et al., 1995b), and statin or other prescription
2041 medications (Leuschen et al., 2013; Robman and Taylor, 2005). The strength of the association
2042 of these factors differs by type of cataract.

2043
2044 The impact of potential confounders has been included in many of the epidemiologic
2045 studies of radiation effects on the lens of the eye. Appendix A provides a list of specific
2046 confounder adjustments in each study (Tables A.1 to A.7). Findings from various studies indicate

2047 that radiation risk estimates are probably not due to confounding by other cataract risk factors
2048 and that risk is seen after both childhood and adult exposures (Shore et al., 2010). Also of
2049 interest is the potential increased sensitivity of the lens at young ages (ICRP, 2012; Nakashima et
2050 al., 2006; UNSCEAR, 2013b).

2051

2052 **5.3 Evaluating the Epidemiological Evidence**

2053

2054 **5.3.1 Variety of Studies**

2055

2056 Only a few of the epidemiological studies have investigated the association of low doses
2057 of ionizing radiation and the development of cataract (EPRI, 2014; Hammer et al., 2013).

2058 Overall, the studies differ in several important aspects, including the source of radiation, type of
2059 exposure scenario, study design, study size, range of lens doses, the method (if any) of dose
2060 estimation, the choice of lens detriment endpoint studied, the method (and possible scoring) of
2061 endpoints, and the adjustment (or assessment) of other risk factors and/or potential confounders.
2062 In addition, several of the studies suffer from significant methodological weaknesses.

2063

2064 **5.3.2 Epidemiological Quality of Studies**

2065

2066 Recently EPRI (EPRI, 2014) systematically assessed the available epidemiological
2067 literature to evaluate and conduct a meta-analysis of the results. All potentially relevant studies
2068 underwent a formal evaluation and were assigned a quality score according to their
2069 methodological strengths and weaknesses. The general approach involved awarding each study a
2070 zero for generally expected good study design (0), a point (+ 1) for each methodological
2071 strength, and penalizing with a negative score (- 1) for each evident shortcoming. Such a
2072 methodology is typically used when evaluating available epidemiologic evidence for outcomes
2073 due to exposures (e.g., U.S. EPA evaluations such as Wartenberg et al., 2000).

2074

2075 The evaluation quality scoring developed by EPRI was conducted according to the
2076 following criteria.

2077

- 2078 1. Study Design: proportionate incidence ratio studies or prevalence only studies = -
2079 1; cohort or case-control studies = 0.
- 2080 2. Dosimetry: no dosimetric assessment = -1; dose reconstruction = 0; individually
2081 measured and/or verified doses = +1.
- 2082 3. Age Adjustment: no = -1; yes = 0.
- 2083 4. Confounding by Other Cataract Causes: likely but not addressed = -1; possible
2084 but not clearly evident = 0; unlikely or addressed = +1 (e.g., studies that
2085 accounted for other known cataract risk factors).
- 2086 5. Numerical Risk Assessment: not included = -1; yes (e.g., HR, RR, OR) = 0.
- 2087 6. Exposure-response Analysis: no = 0; yes = +1.
- 2088 7. Account for Latency: if < 5 y since exposure = -1; ≥ 5 y since exposure = 0.
- 2089 8. Reporting Bias: likely = -1; possible but not clearly evident = 0; unlikely/adjusted
2090 = +1 (e.g., case-control studies using recorded occupational histories).
- 2091 9. Selection Bias: likely = -1 (e.g., due to a reliance on referral of cases to a clinic);
2092 possible but not clearly evident = 0 (e.g., in clinical-based case-control studies);
2093 unlikely/addressed = +1 (e.g., in cohort studies or population-based case-control
2094 studies).
- 2095 10. Pathology Method: not specified = -1 (e.g., ‘ophthalmological exam,’ or surrogate
2096 measure such as ‘cataract surgery’); slit-lamp evaluation by physician = 0;
2097 physician examination and slit-lamp evaluation documented with photos = +1.
- 2098 11. Blinded Pathology or Scoring: not blinded = -1; blinded = 0.
- 2099 12. Cataract Scoring: not specified or only by presence of opacities or ‘increased
2100 luminescence’ = -1; LOCS I or II or III or Merriam-Focht or other definitions = 0.

2101

2102 EPRI used the scoring as a formal approach to classify studies into three tiers. Tier III
2103 included studies that had an overall negative score (i.e., < 0) and were considered unreliable for
2104 the meta-analysis. Those studies that had scores of zero or above were divided into two groups.
2105 Studies with the higher (> 1) total score were included in Tier I and considered most informative.
2106 Tier II included the remaining studies that received a total score of 0 to 1 but were considered
2107 less useful due to methodological shortcomings.

2108

2109 EPRI quality scoring results are listed in Appendix A, Table A.8 (EPRI, 2014). Of 58
2110 studies specifically reporting various cataract type results, 9 of the studies were categorized as
2111 Tier 1 (quality score > 1) and were considered the most informative. Fifteen of the studies were
2112 categorized as Tier 2 (quality score 0 to 1) and were considered important, but less useful due to
2113 methodological shortcomings. Thirty-four of the studies were categorized as Tier 3 (quality score
2114 < 1) and were considered unreliable from an epidemiologic study view, but were mentioned for
2115 completeness of the literature review process.

2116

2117 **5.3.3** Odds Ratio Meta-analysis

2118

2119 Among the cataract epidemiology studies, there are several that provided either odds
2120 ratios or risk ratios for exposed versus unexposed persons for a given dose, usually at 1 Gy.
2121 These studies have been extracted from information in all the studies that are listed in Appendix
2122 B, Table B.1 (EPRI, 2014). The individual studies estimated the risk ratios at 1 Gy by using a
2123 linear no threshold dose-response function. The Tier 1 and 2 studies consisted of the Chernobyl
2124 clean-up workers by Worgul et al. (2007), several papers of the atomic-bomb survivors cohort, a
2125 clinical study of exposed infants by Hall et al. (1999), and a study of radiation technologists by
2126 Chodick et al. (2008). These studies are a combination of acute and chronic exposures as well as
2127 child versus adult exposures. It is of interest to see what a simple meta-analysis of this
2128 information would show.

2129

2130 It is important to note that there are some limitations associated with each of these
2131 studies. For example, the atomic-bomb survivor studies on cataracts did not utilize a standard
2132 photographic method, several of the photographs were not in sharp focus (making them difficult
2133 to judge), and a retro-illumination camera was not used for examination of cortical and PSC
2134 cataracts (RERF, 2013b). The study of radiological technicians is a low dose (i.e., < 60 mGy)
2135 questionnaire study with a relatively high estimated relative risk (RR) at 1 Gy, which was not
2136 statistically significant (Chodick et al., 2008). The Hall et al. (1999) study, which considered the
2137 effects of medical exposures to infants and combined the estimated effects with studies of

2138 individuals exposed as adolescents and adults may present difficulties of interpretation. This may
2139 be illustrated by the study of atomic-bomb survivors by Nakashima et al. (2006), which included
2140 mostly adolescents as well as some adults, and which found PSC to have a strong age at time of
2141 exposure effect. Finally, in the Chernobyl study, the individual dose uncertainties were
2142 substantial.

2143
2144 Recognizing these study limitations, a meta-analysis estimate using the Tier 1 and 2 data
2145 given in Table B.1 was carried out. The updated Nakashima et al. (2006) data, with the newer
2146 dosimetry, was used in place of the earlier Minamoto et al. (2004) data. Appendix B, Table B.2,
2147 summarizes the results. The meta-analysis estimate for PSC gives a significant odds ratio of 1.45
2148 Gy⁻¹ when the Nakashima study was included. The meta-analysis estimate for cortical cataracts
2149 gives an odds ratio of 1.36 Gy⁻¹ while excluding the Nakashima study raised the odds ratio
2150 slightly (1.50 Gy⁻¹). The meta-analysis estimate for mixed cataracts gives a value of an odds ratio
2151 of 1.75 Gy⁻¹ while the meta-analysis estimate for nuclear cataracts gave a non-significant odds
2152 ratio of 1.07 Gy⁻¹.

2153
2154 The results of this evaluation show that data available from the four Tier 1 and 2 studies
2155 suggest that there is a likelihood of an association between exposure to ionizing radiation at 1 Gy
2156 and initiation or development of PSC, mixed, and/or cortical cataracts in humans for various
2157 exposure situations, but not for nuclear cataracts or opacities. It should be remembered that the
2158 degree of risk estimated at 1 Gy in a particular study does not mean that there is actually an
2159 increased risk at 1 Gy in that study, although in the ideal situation the model chosen would show
2160 a good fit to the observed data. It is simply that a dose-response function (typically a linear
2161 nonthreshold function) is fit to the observed data and an estimate of effect at a convenient
2162 exposure level (such as 1 Gy) is made. This then allows for a comparison of the magnitude of
2163 risk reported among the studies of interest.

2164

2165

2166 **5.3.4 Threshold Evaluations**

2167

2168 Fewer studies attempted to estimate a specific threshold, namely the atomic-bomb
2169 survivor studies (Nakashima et al., 2006) and the Chernobyl study (Worgul et al., 2007). These
2170 values of the estimated cataract thresholds are given in Appendix B (Table B.3). There is
2171 considerable uncertainty in these estimates, which depend heavily upon the dose response
2172 function used and the uncertainties in the dose estimates.

2173

2174 While it is not yet possible to quantitatively estimate a specific threshold value for either
2175 acute or chronic lens exposures at this time, the data from Worgul et al. (2007) appear to suggest
2176 that if a chronic lens dose threshold for cataracts exists, it may be perhaps around 1 or 2 Gy.
2177 However, the data from Nakashima et al. (2006) indicate that there is statistically no difference
2178 in the choice of a threshold estimate for PSC between 0 and 2.5 Gy. Based on these two studies,
2179 it is concluded that there is currently not enough available information to make any new specific
2180 conclusions with regard to chronic or acute exposure thresholds for cataracts.

2181

2182 **5.4 Conclusions from Eye Epidemiological Studies**

2183

2184 **5.4.1 Results of Eye Epidemiological Evaluation**

2185

2186 With the very limited data (much of which is either uncertain or under question), it is not
2187 yet possible to quantitatively estimate a specific threshold value for either acute or chronic lens
2188 exposures. It is therefore also not possible to determine whether the effect is stochastic or
2189 deterministic. However, the systematic review of the current eye epidemiology data has shown
2190 that the probable risks for cataracts (i.e., specifically PSC, mixed, and/or cortical cataracts) are
2191 likely increased at an exposure level that is somewhat less than the earlier estimates of the ICRP
2192 or NCRP. Both ICRP and NCRP had earlier assumed threshold values for vision-impairing
2193 cataracts of 2 to 10 Sv for single brief exposures and > 8 Sv for protracted exposures (NCRP,
2194 1989a; ICRP, 2007). ICRP has noted that ophthalmologically-detectable opacities might result
2195 from lower dose ranges of 0.5 to 2 Sv (50 to 200 rem) for acute exposures (ICRP, 1991; 2012).

2196 Therefore, there is the possibility that effects (e.g., lens opacities and/or cataracts) could occur at
2197 lower doses than previously considered when developing occupational lens dose limits based on
2198 the potential for worker lens doses over time.

2199

2200 **5.4.2** Future Work

2201

2202 It is suggested in ICRP Publication 118 (2012) that continued follow-up of study
2203 populations including atomic-bomb survivors (RERF, 2014a; 2014b), Chernobyl victims, and
2204 various occupationally exposed individuals may lead to a more precise estimate of any threshold.
2205 Hammer et al. (2013) recommended evaluation of German interventional cardiologists since they
2206 would have protracted exposures. Internationally, continued follow-up of uranium miners,
2207 individuals exposed at Chernobyl, as well as the Techa River and Mayak plant workers may also
2208 be of further interest. Ainsbury et al. (2014) recommended implementation of a systematic
2209 screening program for people exposed occupationally to ionizing radiation. Studies of aircrew
2210 and pilots have been identified as useful. Cohorts exposed to protracted doses and studies
2211 focused on childhood exposure are also particularly interesting, due to the lack of current data in
2212 these areas and the evidence that the developing lens may be more radiosensitive (Dymlacht,
2213 2013; Hall et al., 1999; Nakashima et al., 2006; UNSCEAR, 2013b).

2214

2215 In terms of study design, accurate, individual cumulative/retrospective lens dosimetry and
2216 information regarding the exposure scenario (e.g., whole or partial body/gradient exposure, dose
2217 rate, and fractionation) are needed. Longitudinal studies should consider which endpoints are
2218 most suitable (i.e., ideally looking at progression in addition to prevalence). This is perhaps
2219 particularly relevant to dose protraction. Prospective as well as retrospective studies should also
2220 be undertaken. In addition, future work may be able to elucidate the role of radiation quality
2221 (e.g., RBE, LET, etc.) on lens effects. Objective, comprehensive, measurement of cataracts and
2222 quantification of lens changes are also very important to provide properly quantified information
2223 concerning incidence and progressive severity of opacities. Studies should also determine the
2224 degree of visual deficit associated with opacities and/or cataracts. Furthermore, sufficiently long
2225 follow-up periods have been identified as crucial factors for accurate assessment of the

2226 relationship between dose and radiation-induced cataracts. Consideration of the large number of
2227 potential confounders is also necessary. Finally, large populations are key to ensure statistical
2228 power, particularly at the lowest doses.
2229
2230

2231 **6. Exposed Populations and Implications**

2232

2233 A number of persons likely would be affected by ICRP's recommendations (2012). This
2234 section gives a brief summary of these groups of individuals and discusses the potential
2235 implications of the recommendations. The implications would apply chiefly to radiation workers.

2236

2237 **6.1 General - Members of the Public and Occupational Exposures**

2238

2239 Firstly, in terms of exposures to the general public, ICRP Publication 118 (2012) states:
2240 "No new limit has been recommended for public exposures to the lens of the eye, as the
2241 Commission judged that the existing limit was adequately protective, and therefore reduction of
2242 the limit could impose unnecessary restrictions. It seems highly improbable that any member of
2243 the public would receive a dose to the lens of the eye over a lifetime in excess of the nominal
2244 threshold of 0.5 Gy in a planned exposure situation considering: application of the effective dose
2245 limit of 1 mSv/year; the low likelihood of the lens of the eye being preferentially exposed for any
2246 significant period; and optimization of protection below the equivalent dose limit for the lens of
2247 the eye" (ICRP, 2012).

2248

2249 For practical radiation protection purposes, the European Union Basic Safety Standards
2250 (EU BSS) provides an example legal framework. The revised EU BSS was published in January
2251 2014 after an extensive period of consultation regarding the ICRP's recommendations (it must be
2252 implemented by European Union member countries by February 6, 2018). The standard states
2253 that the current effective dose limits for public exposure should be maintained. However, it also
2254 states that there should be no further need for averaging over five years for public exposure
2255 (except in special circumstances specified in national legislation). In the EU BSS, the public
2256 exposure limit is therefore set to an effective dose of 1 mSv per year, with a limit on the
2257 equivalent dose for the lens of the eye at 15 mSv per year (BSS, 2014).

2258

2259 For occupational exposures, the EU BSS is in accordance with the ICRP
2260 recommendations, with the effective dose limit set at 20 mSv y^{-1} and the following statement

2261 regarding lens doses: "...the limit on the equivalent dose for the lens of the eye shall be 20 mSv
2262 in a single year or 100 mSv in any five consecutive years subject to a maximum dose of 50 mSv
2263 in a single year, as specified in national legislation." Apprentices and students have an additional
2264 equivalent lens dose limit of 15 mSv in a year, and workers are required to be classified as
2265 'Category A' (i.e., subject to individual monitoring and medical surveillance) if equivalent lens
2266 doses greater than 15 mSv in a year might be expected (BSS, 2014).

2267
2268 IAEA TECDOC No. 1731 (2013) discusses specific implications for relevant
2269 occupational exposure scenarios. Medical, nuclear and industrial radiography settings have all
2270 been identified as important; these are discussed individually in the following sections. Notably
2271 in the EU BSS, medical exposures are exempt provided they are adequately justified, the patient
2272 is made fully aware of the risks and doses are monitored and recorded. For air and space crews,
2273 the EU BSS states the following: "The exposure of air crew to cosmic radiation should be
2274 managed as a planned exposure situation. The operation of spacecraft should come under the
2275 scope of this Directive and, if dose limits are exceeded, be managed as a specially authorised
2276 exposure..." (BSS, 2014).

2277
2278 It is worth noting that the EU BSS is applicable to human activities which involve the
2279 presence of natural radiation sources that lead to a significant increase in the exposure of workers
2280 or members of the public, with air and space crew and processing of materials with naturally-
2281 occurring radionuclides given as examples. It is not applicable to natural levels of radiation
2282 including cosmic radiation above ground exposure to radionuclides present in the undisturbed
2283 earth's crust which cannot easily be controlled (BSS, 2014).

2284

2285 **6.2 Medical – Occupational and Patients**

2286

2287 **6.2.1 Patients**

2288

2289 The early reports by Merriam (1956) and Merriam and Focht (1962) on the time-dose
2290 relationship for cataract production in animal models and radiotherapy patients served as the

2291 basis for the frequently-cited threshold doses for cataracts, of ~ 2 Sv and ~ 5.5 Sv for single and
2292 fractionated exposures, respectively. While there is still some debate as to the minimum
2293 cataractogenic dose for fractionated/protracted exposures, epidemiological data for astronauts or
2294 individuals inadvertently exposed for long durations support much lower thresholds than
2295 originally proposed. Data from radiotherapy patients, though somewhat scant, may shed light on
2296 this issue.

2297
2298 Head and neck cancer patients that received fractionated doses to the lens of the eye of
2299 4.5 to 30 Gy of ⁶⁰Co gamma rays or 5 MeV x rays delivered in 10 to 20 fractions began to
2300 develop opacities between 3 to 9 y post-irradiation and severity was dose-dependent (Henk et al.,
2301 1993). Doses and dose rates to the lens of the eye from eye plaque ¹²⁵I brachytherapy can vary
2302 widely (such as 0.4 to 1 Gy/h prescribed to the tumor over 3 to 7 days; dose to lens equal to 12 to
2303 36 Gy). However, the median time to observe cataract was 2.5 y (range 0.5 to 5 y) after
2304 treatment, and at least half of the eyes developed cataracts within 5 y post-treatment, with latent
2305 periods significantly shorter for lenses exposed to ≥ 24 Gy (ABS, 2014; COMSG, 2014). Data
2306 from patients receiving total body irradiation (TBI) usually suffer from bias, since most will
2307 receive some form of chemotherapy (Belkacémi et al., 1996). There was a significant sparing
2308 effect with use of a fractionated protocol (Deeg et al., 1984). Cataracts due to fractionated doses
2309 to the human lens coincidental to radiotherapy for uveal melanoma have revealed that the
2310 fraction of the germinal epithelium irradiated correlates with the risk of cataract (Meecham et al.,
2311 1994).

2312
2313 Radiology imaging patients may also receive radiation doses to the lens of the eye. While
2314 optimization to reduce lens of the eye doses (e.g., use of gantry tilt in certain CT examinations)
2315 may be possible in some cases, completely avoiding lens exposure may be difficult even with
2316 state-of-the-art equipment.

2317
2318 Eye lens doses for CTs may range from 0.11 mGy for sinonasal digital tomosynthesis to
2319 380 mGy for some interventional neuroradiology procedures (e.g., embolization) (IAEA, 2014c).
2320 It has also been reported that cumulative lens doses can be > 100 mGy in children exposed to

2321 repeated CT scans (Michel et al., 2012). Lens doses to patients during perfusion CT of the brain
2322 have been reported by Ringelstein et al. (2014). Values were from 10.7 to 80.9 mGy. Sandborg
2323 et al. (2010) measured lens doses to patients during interventional neuroradiology procedures
2324 and obtained average and maximum doses to the left eye of 51 and 515 mSv (coiling) and 71 and
2325 289 mSv (embolization). The dose to the adult lens from a dental cone beam CT has been
2326 measured to be about 0.14 mGy (Prims et al., 2011).

2327

2328 **6.2.2** Workers

2329

2330 Medical practitioners performing fluoroscopically-guided interventional (FGI)
2331 procedures can receive relatively high ocular doses, especially when protection tools are not used
2332 (Dauer et al., 2010; Kim et al., 2008; 2012; NCRP, 2010b; Vano et al., 2006; 2008).
2333 Interventional radiologists and cardiologists are frequently positioned in close proximity to
2334 patients during procedures in which exposure to scattered radiation to the lens can be very high
2335 (e.g., during fluoroscopic examinations or image-guided interventional procedures). Kim et al.
2336 (2012) found that the mean dose per case measured over personal protective devices to operators
2337 performing FGI procedures ranged from 19 to 800 (median 113) μSv at eye level. Kim et al.
2338 (2008) found that the mean dose per case measured over personal protective devices to operators
2339 performing cardiac catheterization protocols ranged from 0.4 to 1,100 μSv at eye level. In a
2340 single high-volume imaging cancer center, the hospital average measured lens dose equivalent
2341 (LDE) was 2.1 mSv for all monitored medical staff, with inpatient nurses receiving the lowest
2342 average LDE at 0.4 mSv y^{-1} and FGI physicians receiving the maximum doses to the unprotected
2343 lens, with an average of 11.1 mSv y^{-1} and a 75th percentile of 19.3 mSv y^{-1} (Dauer, 2014). The
2344 European ORAMED project has recently also provided detailed results on eye exposure for
2345 many procedures in interventional cardiology and radiology (Domienk et al., 2011; Farah et al.,
2346 2013). Large variations in operator lens of the eye doses suggest that optimizing procedure
2347 protocols and proper use of protective devices and shields could reduce occupational radiation
2348 dose to the lens substantially (Kim et al., 2012; NCRP, 2010b).

2349

2350 In an international study, the mean annual effective dose for interventional cardiologists
2351 was 0.7 mSv [ranging from 0.5 to 10 mSv h⁻¹, with procedures lasting anywhere from < 0.5 min
2352 to 90 min (such as during the treatment for an aortic aneurysm)]. However, there is some concern
2353 that these represent underestimated values (Le Heron et al., 2010); often the dose to the lens will
2354 be underestimated unless a dosimeter is worn at the collar. In another report, Picano et al. (2012)
2355 has reported that for interventional cardiologists effective doses per procedure range from 0.02 to
2356 38 µSv for diagnostic catheterization, 0.2 to 31.2 µSv for percutaneous coronary intervention,
2357 0.2 to 9.6 µSv for ablation, 0.3 to 17.4 µSv for pacemaker or intracardiac defibrillation
2358 implantations, and 50 to 200 µSv for procedures involving occlusions and valve/aneurysm
2359 repairs. Measurements received over personal protective devices in the examination room range
2360 from 0.4 µSv to 1.1 mSv at the eye level for each of perhaps hundreds or thousands of
2361 procedures each year. A cardiologist's head would receive approximately 100 µSv per single
2362 ablation procedure with perhaps more than 20 to 30 mSv y⁻¹ if a ceiling-suspended screen is not
2363 used, resulting in an estimated eye dose of approximately 0.5 mGy/procedure, without eye
2364 protection (IAEA, 2014a). For a single coronary angiography session, an operator's eyes would
2365 receive a dose of 165 µSv or 37 µSv, without or with protection, respectively (Picano et al.,
2366 2012). Through the use of protective eyewear and proper placement of the viewing monitor, this
2367 population of workers can reduce the dose to the eyes by 90 % (Le Heron et al., 2010).

2368
2369 Since many fluoroscopic procedures are conducted outside radiology departments, one
2370 may assume that there are a multitude of doctors and nurses who may not have received
2371 sufficient training in radiation dosimetry and protection to achieve that level of protection in their
2372 examination rooms. A recent study by Sanchez et al. (2014) obtained individual measurements
2373 of lens of the eye doses during 33 clinical procedures carried out in catheterization cardiac
2374 laboratories with OSL and electronic dosimeters located on the cardiologists' goggles (left side).
2375 In most procedures, although not always, the ceiling suspended screen was used. The authors
2376 noted that the average value decreased to 40 µSv per procedure if the two highest values are
2377 removed from the sample. Radiologists performing neuroembolization procedures may receive a
2378 lens dose of 1.4 to 5.6 mSv per procedure, depending on distance from the patient and whether a
2379 movable shield or leaded glasses are utilized (Vano et al., 2008). Not surprisingly, in a study of

2380 116 interventional cardiologists, Vano et al. (2010) found that 38 % had cataracts, compared to
2381 12 % in matched controls. In a later follow-up study, Vano et al. (2013a) found that 50 % of
2382 interventional cardiologists and 41 % of nurses and technicians showed evidence of PSC
2383 opacifications after receiving eye doses ranging from 0.1 to 18.9 Sv over several years.

2384

2385 Lens of the eye doses in interventional fluoroscopy may be very different depending on
2386 the use of protection tools (e.g., screens and/or goggles). Individual dose measurements of lens
2387 of the eye doses were performed during cardiac clinical procedures with dosimeters located on
2388 cardiologists' goggles (left side). The average $H_p(0.07)$ per procedure measured with
2389 thermoluminescent dosimeters (TLD) or optically stimulated luminescent (OSL) dosimeters was
2390 80 μSv , with a maximum value of 697 μSv in a single procedure (Sanchez et al., 2014). Scatter
2391 doses at the C-arm during cardiac catheterization procedures have been measured in about 2,000
2392 procedures to range from 0.5 to 2.5 mSv/procedure, depending on the complexity of the
2393 procedures. The ratio between the scatter dose at the C-arm and the kerma area product resulted
2394 in about 10 $\mu\text{Sv}/\text{Gy}\cdot\text{cm}^2$ of patient dose. These values may be a conservative estimation of the
2395 range of doses to the lens of the eye for the operators if radiation protection tools are not used
2396 (Vano et al., 2013b).

2397

2398 During PET/CT guided interventions, the median effective dose was 0.02 (range 0 to
2399 0.13) mSv for the primary operator, 0.01 (range 0 to 0.05) mSv for the nurse anesthetist, and
2400 0.02 (range 0 to 0.05) mSv for the radiological technologist. The median extremity dose
2401 equivalent for the operator was 0.05 (range 0 to 0.62) mSv. The median operator effective dose
2402 for the procedure was 0.015 mSv when conventional biopsy mode CT was used, compared to
2403 0.06 mSv for in-room image guidance, although this did not achieve statistical significance due
2404 to the small sample size ($p = 0.06$). The operator dose from PET/CT-guided procedures is not
2405 significantly different than typical doses from fluoroscopically guided procedures. The major
2406 determinant of radiation exposure to the operator from PET/CT-guided interventional procedures
2407 is time spent in close proximity to the patient (Quinn et al., 2012; Ryan et al., 2013).

2408

2409 It has been suggested that anesthesiologists involved in lengthy neurointerventional
2410 radiology procedures may receive ocular radiation exposures similar to or exceeding those of
2411 radiologists. Anastasian et al. (2011) reported that the average radiation exposure to an
2412 anesthesiologist’s face was 6.5 μSv per interventional procedure. Some anesthesia personnel
2413 involved with cardiac catheterization accumulate the equivalent of 1.3 to 1.8 mSv per month
2414 (Henderson et al., 1994).

2415

2416 In a recent survey of occupational doses worldwide, it was found that “...80 % of general
2417 and CT radiographers did not receive measurable doses...” (Le Heron et al., 2010).
2418 Kesavachandran et al. (2012) reported an annual radiation dose for the eyes of orthopedic
2419 specialists as varying between 0.06 to 23 mSv. Burns et al. (2013) reported that leaded
2420 eyeglasses reduce radiation exposure of orthopedic surgeons’ eyes tenfold (i.e., a 90 % reduction
2421 in dose) during acquisition of typical fluoroscopic views of the hip and pelvis.

2422

2423

2424

6.3 Nuclear Facilities

2425 The majority of the occupational dose to the lens of the eye in nuclear facilities is the
2426 result of time spent in uniformly distributed radiation fields. The NRC in NUREG 0713 Volume
2427 33 (NRC, 2011b) provides industry lens of the eye doses for 2011 that indicates that a very small
2428 fraction of workers exceeded 25 % of the current regulatory limit of 150 mSv y^{-1} (NRC, 2008).
2429 Of the over 65,000 monitored individuals, 18 individuals (inclusive of all uranium fuel cycle
2430 industries) had reported doses greater than 30.75 mSv with the maximum individual lens of eye
2431 dose equivalent (LDE) of 49 mSv. These data are inclusive of workers who are exposed under
2432 uniform and non-uniform radiation field conditions that also include fields with lower
2433 penetrating sources, such as low-energy gamma and higher-energy beta ionizing radiation.

2434

2435 **6.3.1** Monitoring

2436

2437 Monitoring of eye dose as well as assessing field conditions with existing instrumentation
2438 will be impacted by any reduction in the lens of the eye dose limit. Currently, monitoring is

2439 required when lens doses are likely to exceed 10 % of the regulatory limit (NRC, 2008).
2440 Procedure guidance for making lens of the eye monitoring decisions, in particular for workers
2441 exposed to non-uniform radiation fields in the course of their work, relies on adequate
2442 assessment of area dose rates and personnel monitors' energy responses. Existing federal limits
2443 for whole-body exposures allow for adequate and conservative dosimetry utilizing algorithms or
2444 stay-time assessments that are normally based on tissue depths and associated correction factors
2445 for the skin and deep tissue, not specifically for the 3 mm eye lens tissue depth. Most nuclear
2446 facilities do not currently estimate lens dose prior to entry to perform work since present limits
2447 for skin and whole-body exposures will assure doses well below existing limits. A lower limit
2448 would increase the importance of ensuring that lens dose assessments are not only accurate, but
2449 also not overly conservative.

2450

2451 Dosimetry algorithm reviews will be necessary and changes likely based on radiation
2452 exposure situations and radiation quality. At a minimum, new energy specific studies would be
2453 necessary to provide revised dosimetry correction factors. It is noteworthy that there are
2454 presently no peer reviewed standard dosimetry quantities or conversion factors for lens dose
2455 equivalent, although ICRP recently addressed considerations for assessing absorbed dose in the
2456 lens of the eye in ICRP Publication 116, Appendix F (ICRP, 2010).

2457

2458 Additional review with regard to the monitoring of external dose equivalent from external
2459 sources (EDEX) approaches may be required. The term EDEX describes the calculation of
2460 effective dose equivalent (EDE) as described in ICRP Publication 26 (1977), with respect to
2461 external radiation exposure. The nuclear power industry accomplishes this via U.S. NRC
2462 Regulatory Guide 8.40 (NRC, 2010). For doses that are primarily from above the head where the
2463 head is more highly exposed than the trunk, there are implications for the use of this weighting
2464 method in light of a reduced LDE limit. In certain situations, particularly those with a dose
2465 gradient above the head, the lens dose could be limiting where under present limits this is not a
2466 concern. The EDEX technique provides the practitioner the benefit of a more accurate dose
2467 record for doses to the body and can allow for longer effective stay times, which can be valuable
2468 in minimizing the need to switch out workers during certain activities. Overall task efficiency is

2469 typically improved under such scenarios thereby reducing collective worker exposures. It is
2470 possible that a lowering of the eye dose limit would reduce or negate the ability to apply EDEX
2471 for effective dose assessment as facilities may subsequently require monitoring of the head as an
2472 indicator of eye dose and just assign this dose as the effective dose. While a special case, such
2473 aspects emphasize the possible implications of eye dose limits that are close to or below whole-
2474 body dose limits. Such a reduction would certainly drive reassessment of dose gradients as
2475 discussed above, which would raise awareness on the part of radiation protection professionals
2476 for those cases where head exposures may cause the lens of eye dose to become limiting.

2477

2478 **6.3.2** Protection of the Eye Lens

2479

2480 Protection for the lens of the eye needs reassessment. Lower limits and a resulting need
2481 for more accurate assessments will likely drive a case for use of protection factors under certain
2482 exposure situations. It will be useful to have information available on reasonable protection
2483 factors that can be applied considering beta radiation thresholds for various type/thicknesses of
2484 protective materials. In this area, as with monitoring, dosimetry quantities and measurements
2485 will need additional technical information provided for implementation. Protection factor data
2486 for commonly used materials (e.g., respirator face shields, bubble suit masks, and goggles) with
2487 companion energy information may be necessary.

2488

2489 **6.4 Industrial Radiography**

2490

2491 Another group of workers for whom change in the limits on exposure of the lens of the
2492 eye might be significant is industrial radiographers. In 2009, IAEA established the Information
2493 System on Occupational Exposure in Medicine, Industry and Research (ISEMIR). ISEMIR was a
2494 project aiming to improve occupational radiation protection in those areas of radiation use in
2495 medicine, industry and research where non-trivial occupational exposures occur. As part of
2496 ISEMIR, a Working Group on Industrial Radiography (WGIR) was established to analyze
2497 information on individual and collective occupational radiation dose as well as on existing dose
2498 reduction techniques, both in normal operations and in accident situations in industrial areas.

2499 Three questionnaires were developed by WGIR to gain insight into occupational radiation
2500 protection in industrial radiography around the world. These questionnaires were distributed to
2501 individual industrial radiographers (*i.e.*, the operators), non-destructive testing companies, and
2502 national or state radiation protection regulatory bodies. Reported individual monitoring data for
2503 2009 from the radiographer questionnaire (234 radiographers) and the regulatory body
2504 questionnaire (18,000 radiographers) gave average annual effective dose estimates for industrial
2505 radiographers of 3.4 and 2.9 mSv, respectively. Approximately 2 % of industrial radiographers
2506 received an annual effective dose in 2009 that exceeded 20 mSv (IAEA, 2014e). WGIR did not
2507 collect information on dose to the lens of the eye because industrial radiographers do not
2508 typically conduct separate monitoring of the dose to the lens of the eye since they work in a
2509 relatively homogeneous radiation field.

2510

2511 WGIR reviewed the Strahlenschutzkommission (German Commission on Radiological
2512 Protection) report entitled “Monitoring the eye lens dose” (Strahlenschutzkommission, 2010) and
2513 believed that for exposures in normal operations, the effective dose is a good estimate for dose to
2514 the lens of the eye for photons of energy > 200 keV, and that additional monitoring for the lens
2515 of the eye is not necessary since the exposures during industrial radiography are uniform. The
2516 consensus of WGIR is that there is no need for additional protective measures and the lens of the
2517 eye dose would benefit from dose constraints (*i.e.*, action levels) put on effective dose. These
2518 conclusions would not apply to situations of accidental exposures, which occur frequently in
2519 industrial radiography. For accidental exposures, effective dose would not be a good estimate of
2520 the dose to the lens of the eye because the radiation field at the radiographer’s position might not
2521 be uniform as the distances between source and body are shorter (Van Sonsbeek *et al.*, 2012).

2522

2523

2524

6.5 Astronauts

2525 Astronauts are exposed to a mixed field of electromagnetic and particulate radiation
2526 species derived predominately from galactic cosmic radiation (GCR) and solar particle events
2527 (SPE). The annual dose range measured within the habitable volume of the International Space
2528 Station (ISS) is 44 to 105 mGy (NASA, 2014). It has been estimated that for a 12-month

2529 roundtrip to Mars with current propulsion systems, the dose equivalent for crew members from
2530 the GCR component alone would be 0.66 Sv (a potentially significant upward adjustment to the
2531 dose equivalent would be necessary if one were to include time spent on the surface of Mars)
2532 (Zeitlin et al., 2013). Astronauts are exposed to a number of stressors in addition to SPE and
2533 GCR that may impact health risks including high gravitational forces at launch and microgravity
2534 during the mission. The risk of radiation-induced cataract has been one of the first health
2535 detriments from space flight reported for the astronaut corps, but it is not a primary concern for
2536 NASA during space missions, even though lens opacities could compromise crew performance
2537 during missions and could impact the quality of life upon return to Earth.

2538

2539

2540 **7. Conclusions and Recommendations**

2541
2542 Cataracts of the lens of the eye induced by ionizing radiation are a visible change long
2543 recognized as a detriment to clear vision. However, the apparent simplicity of the association
2544 between radiation exposures and the formation of lenticular opacities belies the complex
2545 underlying biological factors and mechanisms including genetic susceptibility, aging, molecular,
2546 cellular, and tissue responses dependent on various radiation exposure parameters. These issues
2547 have challenged the preparation of guidance on radiation dose limits for the lens of the eye.

2548
2549 This Section summarizes the conclusions drawn by the Committee on the four key
2550 questions, and discusses several pertinent recommendations.

2551

2552 **7.1 Detailed Conclusions and Recommendations**

2553

2554 **7.1.1 Should radiation-induced cataracts be characterized as stochastic or deterministic effects?**

2555
2556 The apparent simplicity of the association between ionizing radiation exposures and the
2557 formation of lenticular opacities belies the complex underlying biological factors and
2558 mechanisms including: genetic susceptibility; aging; molecular, cellular, and tissue responses
2559 dependent on various radiation exposure parameters. The review of mechanistic studies by
2560 several authors summarized in this Commentary indicates that radiation-induced opacities may
2561 be stochastic in nature and not deterministic as long thought. However, the link between the
2562 induction of any, even minor, opacities in animal models and the occurrence of clinically-
2563 relevant, visually-impairing cataracts in humans is still far from clear. Because of the
2564 incoherence of the mechanistic and epidemiologic evidence, it is not yet known if radiation
2565 cataractogenesis is strictly stochastic or deterministic in nature. The epidemiological evidence to
2566 date indicates a threshold model, and the Committee has determined that this model should
2567 continue to be used for radiation protection purposes at this time.

2568

2569 The value of the threshold for detectable opacity or vision-impairing cataracts is less
2570 clear, with the epidemiological evidence currently pointing to a threshold for vision-impairing
2571 cataracts in the region of 1 to 2 Gy. However, NCRP has concluded that it is not possible to
2572 make specific quantitative estimates of lens effects thresholds at this time.

2573

2574 **7.1.2** What effects do LET, dose rate, acute, and/or protracted dose delivery have on cataract
2575 induction and progression?
2576

2577 The epidemiological evidence presented in Section 5 of this Commentary demonstrates
2578 that, although different studies have looked at many of these factors independently, there is still
2579 very little evidence upon which to base an answer to this question. The mechanistic evidence is
2580 clearer in some instances (e.g., in terms of a differential effect of increased radiation ionization
2581 qualities enhancing the induction and progression of opacities) but, as noted above, the
2582 relationship between the results from animal models and risks of vision-impairing cataracts in
2583 humans is still not clear. The ‘normal’ lens loses clarity with attained age due to a number of
2584 physiological aging processes. As such, the Committee has determined that further, high-quality
2585 epidemiological and mechanistic studies are required before the question of how exposure to
2586 ionizing radiation contributes to further loss of lens clarity can be fully answered. Improvements
2587 in methods to determine lens doses in the clinic and the workplace, and in technical approaches
2588 to score the different types of lens opacifications arising in different anatomical regions of the
2589 lens will strengthen the quality of the new dose-dependent cataract data obtained. Advancement
2590 of more basic research on the exact biological target for species-specific differences in radiation-
2591 induced cataract formation could lead to the development of biochemical countermeasures that
2592 may be applied to attenuate or prevent cataract formation.

2593

2594 **7.1.3** How should detriment be evaluated for cataracts?
2595

2596 Vision-impairing cataracts (VICs) could be considered the endpoint of greatest concern
2597 in terms of lens radiation protection. Cataracts certainly may affect individuals’ ability to carry
2598 out their occupations or other daily tasks (Hamada *et al.*, 2014). ICRP Publication 118 (2012)
2599 noted that acute doses up to about 0.1 Gy produce no functional impairment of tissues, that

2600 detectable lens changes can be identified as low as between 0.2 and 0.5 Gy, and concluded that a
2601 nominal threshold of 0.5 Gy for acute or protracted exposure for lens tissue effects is an
2602 appropriate method for evaluating lens detriment. While NCRP recognizes that the mechanisms
2603 underlying the transition of minor lens opacifications to clinically significant VICs are still not
2604 well understood, it is prudent to regard eye exposures and the potential for lens tissue effects in
2605 much the same way as whole-body exposures (i.e., ensure exposures are consistent with ALARA
2606 principles), as was previously recommended by NCRP Report No. 168 (NCRP, 2010b). This
2607 includes careful justification and optimization in exposure situations including radiation doses to
2608 the lens of the eye.

2609

2610 **7.1.4** Based on current evidence, should NCRP change the recommended limit for the lens of
2611 the eye?
2612

2613 Current epidemiological studies of the effect of radiation on the lens of the eye indicate
2614 that there is an association between exposure to ionizing radiation and initiation or development
2615 of PSC, mixed and/or cortical visually-impairing cataracts in humans for various exposure
2616 situations. The systematic review of the current eye epidemiology data has shown that the
2617 probable risks for cataracts (i.e., specifically PSC, mixed, and/or cortical cataracts) are likely
2618 increased at an exposure level that is somewhat less than the earlier estimates of ICRP or NCRP.
2619 Both ICRP and NCRP had earlier assumed threshold values for visually-impairing cataracts of 2
2620 to 10 Sv for single brief exposures and > 8 Sv for protracted exposures (ICRP, 2007; NCRP,
2621 1989a). ICRP has also noted that ophthalmologically-detectable opacities might result from
2622 lower dose ranges of 0.5 to 2 Sv (50 to 200 rem) for acute exposures (ICRP, 1991; 2012).

2623

2624 NCRP acknowledges that most of the available data on lens effects have large associated
2625 uncertainties and limitations that do not yet support a quantitative estimate of a specific threshold
2626 value for effects from either acute or chronic lens exposures. However, the preponderance of
2627 evidence appears to suggest the possibility that effects (e.g., lens opacities and/or cataracts) could
2628 occur at lower doses than previously considered when developing occupational lens dose limits
2629 based on the potential for worker lens doses over time. Therefore, NCRP has determined that it is

2630 prudent to reduce the current recommended annual lens of the eye occupational dose limit from
2631 150 mSv (NCRP, 1993b) down to 50 mGy, a value in harmony with the current occupational
2632 whole-body effective dose limit of 50 mSv (NCRP, 1993b). No new limit is recommended for
2633 public exposures to the lens of the eye, as NCRP judges that the existing annual limit of 15 mSv
2634 (NCRP, 1993b) is adequately protective.

2635

2636 It should be noted that NCRP no longer recommends the use of equivalent dose for
2637 specific tissue exposures, because these quantities were developed for stochastic effects whereas
2638 the principal outcomes being addressed are specific tissue reactions (or deterministic effects) in
2639 nature. Recommended limits with regard to tissue reactions should be based on absorbed dose, as
2640 was the underlying consideration for skin dose limits (NCRP, 1989b; 1993b; 1999). If it is
2641 necessary to apply the recommended lens limit to high-LET radiation, NCRP recommends the
2642 approach taken in NCRP Report No. 132 (2000) in which the absorbed dose is multiplied by the
2643 relative biological effectiveness of the radiation to obtain a weighted gray (or ‘gray equivalent’).
2644 This may then be compared to the limit expressed in gray.

2645

2646 **7.2 Additional Recommendations for Evaluation and Research**

2647

2648 While the currently available information for the effects of ionizing radiation on the lens
2649 has provided input on appropriate guidance with regard to radiation protection, much more work
2650 is needed to develop a complete understanding of such detriments. NCRP recommends ongoing
2651 evaluation and additional research in the following areas: comprehensive evaluation of the
2652 overall effects of radiation on the eye, dosimetry methodology and dose-sparing optimization,
2653 additional high quality epidemiology studies, and a basic understanding of the mechanisms of
2654 cataract development.

2655

2656 **7.2.1 Comprehensive Evaluation of Overall Effects of Radiation on the Eye**

2657

2658 NCRP should consider developing a comprehensive evaluation of the overall effects of
2659 radiation on the eye [e.g., similar to NCRP Report No. 159 (2008) on risk to the thyroid from

2660 ionizing radiation]. A comprehensive evaluation of the eye doses accumulated by the eye over
2661 time by susceptible populations and radiation workers is warranted.

2662

2663 **7.2.2 Dosimetry Methodology and Dose-sparing Optimization**

2664

2665 ICRP Publication 116 (2010) in Appendix F provided revised dose conversion
2666 coefficients for the lens from a significantly refined eye stylized phantom set. Dose conversion
2667 coefficients are now available for several external irradiation conditions and geometries. These
2668 can be utilized for assessing absorbed dose in the lens of the eye. NCRP emphasizes that there is
2669 a continued need for more accurate lens of the eye dosimetry and monitoring, as well as an on-
2670 going opportunity for dose-sparing optimization and the need for more education for all workers.
2671 Additional lens of the eye dose-sparing optimization and more accurate dose assessment for
2672 patient populations with the potential for significant eye exposures are also necessary.

2673

2674 **7.2.3 Additional High Quality Epidemiologic Studies**

2675

2676 Several gaps in knowledge cloud our understanding about the existence of dose
2677 thresholds and the determinants of radiation cataractogenesis. Significant fundamental questions
2678 still remain unanswered. What doses of ionizing radiation are required to trigger lenticular
2679 opacifications that do not result in impairment of vision, and what doses will result in opacities
2680 that impair vision? Some of these gaps in knowledge may be addressed by reanalysis of existing
2681 data sets or through new prospective studies, from which reliable data can be obtained over
2682 prolonged periods.

2683

2684 An evaluation of lens of the eye doses received during routine procedures performed by
2685 interventionalists and the dose received by patients during selected radiotherapy regimens, as
2686 well as high-dose diagnostic or interventional procedures could prove important. The same
2687 populations can be followed to determine the time-dose relationship for progression of radiation-
2688 induced lens opacities from non-vision impairing to vision impairing, and to determine the

2689 mechanisms underlying the dependence of dose rate, age or gender as determinants in radiation
2690 cataractogenesis.

2691

2692 Longitudinal studies should be carried out on radiotherapy patients and radiation workers,
2693 where baseline lens clarity and the dose to the lens of the eye are well documented, to determine
2694 whether low doses of ionizing radiation induce cataracts that will continue to progress and
2695 become vision-impairing, or remain static. Ideally, these studies would involve the use of
2696 biomarker technologies that would allow non-invasive measurement of changes at the cellular
2697 and molecular level that precede actual opacification of the lens.

2698

2699 As highlighted by UNSCEAR (2013b), children exposed to ionizing radiation may be
2700 twice as sensitive to cataract development compared to adults, although the evidence currently
2701 cited may be characterized as ‘weak.’ Data obtained from adults and children exposed to
2702 ionizing radiation as a result of radiotherapy may help determine whether the difference in
2703 radiosensitivity between adults and children is substantial, but care must be taken to analyze data
2704 from individuals without confounding factors.

2705

2706 Having information on age at exposure, as well as all the other relevant factors for a
2707 population exposed to a range of relatively low-dose exposures (e.g., radiation workers) and then
2708 following that population for a significant time after exposure would greatly contribute to
2709 reducing the uncertainty of whether a dose threshold exists. Concurrently, there is also a need to
2710 develop lens-specific dosimetry or methods to accurately assess doses to the lens of the eye.

2711

2712 **7.2.4 Understanding the Mechanisms of Cataract Development**

2713

2714 In terms of mechanisms of cataract development, there is a need to provide a clearer link
2715 between the initial damage response and the formation of lens opacities. There is strong evidence
2716 that the modifying factors discussed in Section 4 (e.g., age, gender, dose rate, and dose
2717 fractionation) all affect cataract risk, and this should be taken into account in future studies.

2718 There is a need to fully define the target cells for radiation cataractogenesis as well as the genetic

2719 makeup and molecular-biological mechanisms of action that lead to protein accumulation
2720 (including the role of protein damage accumulation and post-translational modifications). A
2721 science-informed model for abnormal lens fiber migration and accumulation with the potential
2722 progression to visually impairing cataracts is still required. The role of radiation on the latency
2723 period is not yet well understood.

2724

2725 Systematic studies are required to identify the specific dose-dependent targeted and non-
2726 targeted molecular mechanisms contributing to radiation-induced cataracts in relevant
2727 experimental model systems. In addition, investigations aimed at determining the best ways to
2728 administer agents that will result in high levels of antioxidants like glutathione in the lens of the
2729 eye could provide future nonsurgical methods for cataract prevention.

2730

2731 For radiation protection purposes, it is also important to consider the role of radiation
2732 quality, LET, RBE, dose protraction and fractionation, and to address what lies behind the
2733 inverse relationship between latency period and dose. Studies involving more than one type of
2734 radiation and more than one type of exposure scenario would be highly useful in identifying the
2735 complex issues triggering progressive lens opacification after exposure to ionizing radiation, and
2736 identifying what would be required to maintain normal lens transparency.

2737

2738

2739 **Appendix A**

2740

2741 **Previous Epidemiological Studies Tables**

2742

2743 Tables A.1 to A.7 support the discussion in Section 5.1.2 of this Commentary and have
2744 the following legend:

2745

2746 • AHS = adult health study

2747 • DS = dosimetry system

2748 • LOCS = lens opacification classification system

2749 • N = number in study

2750 • 95 % CI = 95 % confidence interval

2751 • OR = odds ratio

2752 • PSC = posterior subcapsular cataract

2753 • TLD = thermoluminescent dosimeter

2754 • T65DR = tentative 1965 dose estimates revised (Kerr and Solomon, 1976)

2755

2756 Table A.8 supports the discussion in Section 5.2.3 where the scoring criteria used may be
2757 found.

2758

2759

Table A.1—Exposure to doses of ionizing radiation: Acute exposures in atomic bomb survivors and development of cataract.

Reference: First author (year)	Area of Study	Type of Study	Study Period (follow-up time)	Study population characteristics and study size	Type of ionizing radiation exposed	Estimated Dose	Exposure assessment	Outcome assessment	Results or Risk estimates for cataract (95% CI)	Confounder adjustments
Choshi <i>et al.</i> (1983)	Japan	Cohort Study	1978-1980 (33-35 y)	Atomic bomb survivors; Ages from prenatal to >50 y; 62% female; N = 7,227 persons from Atomic Health Study (AHS)	External: Gamma, Neutron	Lens dose range: 0-600 rad	T65DR	Own grading system	300+ rem PSC-RR = 5.28 for < 50 y; 3.99 for 50-59 y and 2.34 for 60+ y. No dose-related differences were seen for cortical or nuclear.	City, Age, Sex
Cogan <i>et al.</i> (1949); Cogan <i>et al.</i> (1950)	Japan	Cohort Study	1949 (4 y)	Atomic bomb survivors; Age mostly 2-16y; N = 1,000 persons within 2,000 m of hypocenter	External: Gamma, Neutron	-	-	Ophthalmoscope; Some slit-lamp	81 lens abnormalities noted in 231 individuals within 1,000 m	Other ocular findings noted
Minamoto <i>et al.</i> (2004); Nakashima <i>et al.</i> (2006)	Japan	Cohort Study	2000-2002 (55-57 y)	Atomic bomb survivors; All ages (mean 8.8 y) N = 873 (M) N = 701 (N) both from AHS	External: Gamma, Neutron	Eye dose range: <0.005-2 Sv (M) Eye dose range: 0-4.90 Sv (N)	DS86 (M) DS02 (N)	LOCS II	(M) OR at 1 Sv for PSC = 1.41 (1.21-1.64); Cortical = 1.29 (1.12-1.49); Nuclear = 1.12 (0.94-1.30). (N) OR at 1 Sv for PSC = 1.44 (1.19-1.73); Cortical = 1.30 (1.10-1.53). OR at 1 Gy = 1.33 (1.28-1.38).	City, Age, Sex, Smoking
Nakashima <i>et al.</i> (2013)	Japan	Cohort Study	1986-2005 (41-60 y)	Atomic bomb survivors; N = 685 cases out of 3,055 participants	External: Gamma, Neutron	Lens dose range: 0-5.14 Gy	DS02	Reported cataract surgery confirmed by ophthalmoscopic exam	76 axial opacities with increases in high-dose group	Not discussed
Nefzger <i>et al.</i> (1969); Otake and Schull (1982); Otake <i>et al.</i> (1990); Otake <i>et al.</i> (1996)	Japan	Cohort Study	1963-1983 (18y+)	Atomic bomb survivors; All ages plus in utero; N = up to 2,468; 1,627 in Hiroshima, 841 in Nagasaki	External: Gamma, Neutron	High >200 rad Low <200 rad	Estimates. Later publications DS86	Ophthalmoscope; Some slit-lamp	76 axial opacities with increases in high-dose group	Age
Neriishi <i>et al.</i> (2007)	Japan	Cohort Study	2000-2002 (55-57 y)	Atomic bomb survivors; N = 3,761 from AHS	External: Gamma, Neutron	Eye dose range: <0.005 – 4.90 Sv	DS02	Lens extraction documented by eye examination	OR at 1 Sv = 1.39 (1.24-1.55) Threshold dose best estimate of 0.1 Gy (<0-0.8).	City, Age, Sex, Diabetes
Neriishi <i>et al.</i> (2012)	Japan	Cohort Study	1986-2005 (41-60 y)	Atomic bomb survivors; N = 6,066	External: Gamma, Neutron	Lens dose mean: 0.54 Gy range: 0-5.14 Gy	DS02	Reported cataract surgery confirmed by ophthalmoscopic exam	1,028/6,066 underwent cataract surgery. Dose response nearly linear.	Age, Sex, and several medical and social
Yamada <i>et al.</i> (2004)	Japan	Cohort Study	1958-1998 (14-54 y)	Atomic bomb survivors; N = 10,339 from AHS	External: Gamma, Neutron	Mean weighted shielded Kerma 0.92 +/- 1.06 Sv	DS86	No grading of opacities	RR at 1 Sv = 1.11 (1.03-1.19)	City, Age, Smoking, Alcohol

Table A.2—Exposure to doses of ionizing radiation: Exposures in Chernobyl liquidators and cleanup workers and development of cataract.

Reference: First author (year)	Area of Study	Type of Study	Study Period (follow-up time)	Study population characteristics and study size	Type of ionizing radiation exposed	Estimated Dose	Exposure assessment	Outcome assessment	Results or Risk estimates for cataract (95% CI)	Confounder adjustments
Nadejina <i>et al.</i> (2002)	Ukraine	Cohort Study	1986-2000 (14 y)	N = 11 people with ARS; N = 30 Chernobyl recovery workers	External: Gamma, Beta	ARS minimum 2.6 Gy, mean 3.2 Gy. Recovery Mean 0.2 Gy	Not reported	Ophthalmologic examinations; cataracts grading system not reported	5 of 11 ARS cases had 'radiation cataracts'. No 'radiation cataracts' but 3 'senile cataracts' in the recovery workers	Not reported
Worgul <i>et al.</i> (2007); Chumak <i>et al.</i> (2007)	Ukraine	Cohort Study	1986-1987 (12-14 y)	Chernobyl liquidators and cleanup workers; N = 8,607	External: Gamma, Beta	Lens dose range: 0-1+ Gy, median: 123 mGy, 44% between 100-199 mGy, 4% received >0.5 Gy	TLD; analytical dose estimated; group dosimetry where possible; doses assessed using teeth where available	Merriam-Focht method	OR at 1 Gy for PSC = 1.42 (1.01-2), Superficial cortical stage 1 = 1.51 (1.1-2.1), Non-nuclear stages 1-5 = 1.65 (1.2-2.3), Nuclear stages 1-5 = 1.07 (0.5-2.0), Threshold estimate for stage 1 PSC = 0.34 Gy (0.18-0.51); stage 1 PSC opacity = 0.35 (0.19-0.66)	Age, sex, smoking, diabetes, steroids, occupations with exposure to chemicals, radiation, UV radiation, infrared, examiner scoring variations, and others

Table A.3—Exposure to doses of ionizing radiation: Acute exposures in medical patients and development of cataract.

Reference: First author (year)	Area of Study	Type of Study	Study Period (follow-up time)	Study population characteristics and study size	Type of ionizing radiation exposed	Estimated Dose	Exposure assessment	Outcome assessment	Results or Risk estimates for cataract (95% CI)	Confounder Adjustment
Albert <i>et al.</i> (1968)	USA	Cohort Study	1940-1959 (10 y)	Medical treatment with x-ray epilation for <u>Tinea capitis</u> ; screening of subsample; N = 234 exposed; N = 232 unexposed	X-ray	Eye dose ~0.5 Gy	Eye dose estimated by calculation model	Slit-lamp examination; abnormal luminescence and early PSC opacities	No difference in unexposed versus exposed for abnormal luminescence or non-PSC opacities. PSC opacities: 13 irradiated and 2 controls OR = 5.9 (1.4-24)	Age, sex, race
Chmelevsky <i>et al.</i> (1988)	Germany	Cohort Study	1945-1952 (30+ y)	Medical treatment with injected radium-224; N = 831 in Spiess Group, N = 58 with cataract	Internal: Alpha; Gamma	Not reported	Injected activity used as dose surrogate	Not reported	Strong correlation between frequency of cataracts and the injected activity with a linear dependence beyond a threshold of 0.5 MBq kg ⁻¹ .	Age
Cogan and Dreisler (1953)	USA	Case reports	Not reported (1.3-14 y)	Medical patients with reported x-rays near eyes; N = 40	100-200 kV x-ray; one case 1200kV	23-2,400 rad	Phantom Measurement	Ophthalmoscope or slit-lamp; lens changes 'characteristic of irradiation'	5 'radiation' cataracts noted, none of which were among the 33 persons with <500 rad	Not Reported
Cogan <i>et al.</i> (1952)	Japan, USA	Case reports	Not reported (not reported)	Mixed population of medical, cyclotron, and Atomic bomb; N = 20	Varied per individual	Not reported	Not reported	Ophthalmoscope or slit-lamp; lens changes 'characteristic of irradiation'	'Radiation' cataracts noted, mostly located at the posterior pole of the lens	Not reported
Hall <i>et al.</i> (1999)	Sweden	Cohort Study	1920-1959 (~36-54 y)	Medical therapy from radium-226 or contact x-ray (<=60 kVp) as child; N = 448 exposed; N = 89 non-exposed	External: Gamma or x-ray	Mean 0.4 Gy (0-8.4 Gy)	Based on mean dose rate to lenses of 0.13 Gy/h (0.05-3.0)	LOCS system; score >=1 considered positive; cortical and PSC opacities	Cortical + PSC prevalence by dose in mGy; 0 = 9/178 (5%) 1-499 = 89/747 (12%) 500-999 = 20/115 (18%) >=1,000 = 20/89 (22%); Cortical RR = 1.50 (1.15-1.95) PSC RR = 1.49 (1.07-2.08)	Diabetes, Steroids, Family history, Other eye disorder, Other radiotherapy
Meecham <i>et al.</i> (1994)	USA	Cohort Study	<May 1991 (3-159 months)	Medical therapy with helium ion irradiation of the eyes for uveal melanomas; N = 336 chart reviews; N = 292 in study	Helium ions	Tumor doses range 48-80 Gy	Radiation therapy treatment planning algorithm; RBE of 1.3	Radiation induced cataract defined as an asymmetric unilateral grade 3+ or 4+ cortical or PSC lesion	129 patients with radiation induced cataract. Risk of cataract peaked at 3 y. Percentage of lens included in the treatment port was predictive correlate with time to development. RR 2.97 for a 25% increase in lens percent in the treatment. If more than 1/2 lens was in the beam, the risk exceeded 90% within 7 y. 10 Gy RR 1.20 (0.98-1.47).	Age, Preexisting opacities, Tumor height, Ciliary body and tumor dose

Table A.3—(continued).

Reference: First author (year)	Area of Study	Type of Study	Study Period (follow-up time)	Study population characteristics and study size	Type of ionizing radiation exposed	Estimated Dose	Exposure assessment	Outcome assessment	Results or Risk estimates for cataract (95% CI)	Confounder Adjustment
Kal <i>et al.</i> (2009)	Various	Review Meta- analysis	<2009 (not reported)	Medical therapy with total body irradiation (TBI); $N = 302$ identified patients in 17 articles	External: High energy x-ray	Estimated lens biologically equivalent dose	Dose estimation model	Not reported	Severe cataracts seen above a threshold of BED=40 Gy. High- dose rate TBI was more effective in cataract induction than low- dose rate TBI.	Fractions, Dose rate, Steroids, Heparin
Merriam and Focht (1957); Merriam <i>et al.</i> (1972)	USA	Case reports	Not reported (mean 4.8 y if cataract; mean 9.3 y if no cataract)	Medical radiation therapy patients; $N = 173$	100-140 kV; or 200-250 kV; or radium plaque/ seed	25-6,900 rad	Phantom Measurement	Ophthalmoscope or slit-lamp; any clinically recognizable opacity having characteristic of a 'radiation' cataract	73 had head irradiation with no cataracts. 200 rad for any opacity, ~500 rad for 'progressive' cataracts. 750-950 rad delivered to the lens in 3-13 weeks had 60 % probability that cataract will develop and 50 % chance that it will be progressive, with corresponding vision loss. 4 cases of cataract with doses ≥ 690 rad	Age, Informally other factors such as hemorrhage, glaucoma, or uveitis
Qvist and Zachau- Christiansen (1959)	Denmark	Cohort Sample	1913-1933 (~20-40 y)	Medical fractionated radium therapy in childhood; $N = 855$ in cohort with treatments to the head. $N = 112$ who received lens dose > 100 rad selected; $N = 56$ examined	Radium applicator External: Gamma	>100 rad selected	Lens dose estimated by calculation model	Ophthalmological examination; methods unspecified		Not reported
Whelan <i>et al.</i> (2010)	USA	Cohort Recall Study	1970-1986 (5-25 y)	Medical radiation therapy in childhood or adolescence; $N = 8,507$ treated; $N = 3,901$ sibling controls	External: High energy x-ray	Eye dose range 0-4,000 cGy	Calculated from water phantom measurement (corrected for eye blocking if utilized)	Recall questionnaire about cataracts; self- reported outcomes, including cataracts	Increased risk of cataracts 5+ years following diagnosis RR = 10.8 (6.2-18.9); If > 200 cGy to the eye RR = 3.2 (2-5.2); median time to onset of cataracts 4.7, range 0-24.1 y	Age, Sex, Steroids
Wilde and Sjostrand (1997)	Sweden	Cohort Study	1930-1964 (30-46 y)	Medical therapy with radium-226 for hemangioma of the eyelid in early childhood (2-13 months); $N = 20$	External: Gamma	Eye dose range 1-11 Gy to treated side; 0.02-0.12 Gy to untreated side	Treatment planning models	Slit-lamp biomicroscopy and retroillumination photography; 'radiation cataract'	All treated eyes had opacities. Opacity grade increased with lens dose. 13 of 20 contralateral lenses had very minor opacities. Punctate opacities at 100 mGy.	Not reported

Table A.4—Exposure to doses of ionizing radiation: Chronic exposures in health care personnel and development of cataract.

Reference: First author (year)	Area of Study	Type of Study	Study Period (follow-up time)	Study population characteristics and study size	Type of ionizing radiation exposed	Estimated Dose	Exposure assessment	Outcome assessment	Results or Risk estimates for cataract (95% CI)	Confounder Adjustment
Chodick <i>et al.</i> (2008)	USA	Cohort Study	1983-2004 (median 19.2 y)	Occupational – Radiological Technologists; <u>N</u> = 35,705	External: Primarily Scattered X-ray	Median lens dose: 21.8 mGy	Film badge readings; occupational history	Self-reported	Hazard of cataract for workers in highest dose group (mean 60 mGy) versus lowest dose group (mean 5 mGy): HR = 1.18 (0.99-1.40). ERR/Gy = 1.98 (-0.69-4.65)	Age, Sex, BMI, Smoking, Diabetes, Diagnostic X-ray and several other
Junk <i>et al.</i> (2004) Haskal and Worgul (2004)	USA	Cohort Sample Screen	2004 (5-36 y)	Occupational – Interventional Radiology; <u>N</u> = 59	External: Scattered X-ray	Not reported	Not reported	Scheimpflug examination after pupil dilation; Precataract changes and PSC cataracts	22 showed 'small paracentral dot-like opacities' in PSC region, and PSC cataracts found in 9 eyes of 5 persons. Concluded that the frequency and severity of PSC opacities increased with age and number of years in the field	Not reported
Kleiman <i>et al.</i> (2009)	Various	Cohort Sample Screen	2008 (1-40 y)	Occupational – Interventional Cardiologists (IC) and other staff; <u>N</u> = 78 volunteers	External: Scattered X-ray	Not reported	Years of service noted	Slit-lamp examination after pupil dilation	18/42 IC doctors had PSC changes consistent with radiation exposure. 3/34 IC nurses or technicians had mild PSC changes.	Not reported
Milacic (2009)	Serbia	Case-Control	1992-2002 (1-10 y)	Occupational – Medical Workers; <u>N</u> = 1,560 exposed <u>N</u> = 1,680 unexposed	External: X-ray	TLD (mean): 1.59 ± 1.30 mSv/y for cataract cases within ionizing zone; 1.63 ± 1.45 mSv/y for those without cataracts	TLD measurement	Visual acuity examination performed, but no grading reported	Prevalence of cataract 7.3% of workers in ionizing zone, compared to 1.5% outside. Radiological technicians had highest prevalence of cataracts (63.5%).	Age, Years worked, Sex, Blood sugar, Blood pressure, Heart disease, Alcohol, Smoking, others
Vano <i>et al.</i> (1998)	Spain	Case Study	1997 (~1-8 y)	Occupational - Interventional Radiology; <u>N</u> = 2 radiologists with lens injuries; <u>N</u> = 2 nurses with lens injuries	External: Scattered X-ray	As high as 450-900 mSv/y. About 1-2 mSv per procedure	Measurement on the equipment	Ophthalmological examination; dot-like paracentral and discrete PSC	Cataracts seen for doses likely above 150 mSv/y; Left eye of interventional radiologist had higher number of opacities	Not reported

Table A.4—(continued).

Reference: First author (year)	Area of Study	Type of Study	Study Period (follow-up time)	Study population characteristics and study size	Type of ionizing radiation exposed	Estimated Dose	Exposure assessment	Outcome assessment	Results or Risk estimates for cataract (95% CI)	Confounder Adjustment
Ciraj-Bjelac <i>et al.</i> (2010)	International	Cohort Sample Screen	Conference April 17-19 2009 (~9 y IC, ~6 y others)	Occupational – Interventional Cardiologists; $N = 58$ exposed; $N = 22$ control	External: Scattered X-rays	Estimated cumulative ocular dose range 0.02-43 Gy; median 1.1 Gy for IC, 0.64 Gy for nurses	Estimated from workload information as self reported, technical equipment and dosimetry reports	Merriam-Focht method; Grade 0.5 or higher in posterior subcapsular region	PSC in 51% of exposed group compared to 9% in controls; PSC in exposed group OR = 10.3 (2.2-48) RR = 5.6 (1.4-21)	Left/right, Sex
Jacob <i>et al.</i> (2010) Jacob <i>et al.</i> (2013)	France	Cohort Sample Screen	2009-2011 (10+ y)	Occupational – Interventional Cardiologists; $N = 106$ exposed; $N = 99$ unexposed	External: Scattered X-rays	Not reported	Not reported	LOCS III; No opacity through stage 5 (severe); opacities localized as cortical, nuclear, posterior subcapsular	No significant difference for either nuclear or cortical lens opacities; PSC lens opacities significantly more frequent among IC (17% vs. 5%, $p=0.006$) for an OR = 3.9 (1.3-11.4). Risk appeared lower for regular users of protective lead glasses OR = 2.2 (0.4-12.8)	Age, Sex, BMI, Smoking, Diabetes, Myopia, Eyeglasses, Steroids
Mrena <i>et al.</i> (2011)	Finland	Cohort Sample Screen	Not reported (> 15 y)	Occupational – Radiologists; $N = 59$	External: Scattered X-rays	Whole body; 10-30 mSv group; 30-204 mSv group	Whole body radiation dose measured by film dosimeters worn above lead apron	LOCS II and Scheimpflug imaging (Nidek EAS-1000); opacities	Excess odds ratio for any lens opacity per 10 mSv: 0.13 (-0.02-0.28). Mean dose for those with PSC was 10 mSv.	Age, Sex, Smoking
Vano <i>et al.</i> (2010)	Columbia, Uruguay	Cohort Sample Screen	09/2008 and 04/2009 (1-40 y)	Occupational – Interventional Cardiologists; Associated personnel; $N = 58$; $N = 52$; $N = 93$ unexposed	External: Scattered X-rays	Lens doses of 0.5 mSv per procedure; median 6.0 mSv IC, 1.5 mSv others	Estimated from workload and typical doses per procedure	Modified Merriam-Focht method; eye opacities and early lens changes	IC compared to unexposed RR = 3.2 (1.7-6.1) ($p<0.005$) for PSC	Not reported

Table A.5—Exposure to doses of ionizing radiation: Exposures in flight personnel or astronauts and development of cataract.

Reference: First author (year)	Area of Study	Type of Study	Study Period (follow-up time)	Study population characteristics and study size	Type of ionizing radiation exposed	Estimated Dose	Exposure assessment	Outcome assessment	Results or Risk estimates for cataract (95% CI)	Confounder Adjustment
Chylack <i>et al.</i> (2009); Chylack <i>et al.</i> (2012)	USA	Cohort Sample Study	2004-2006 (5+ y)	Occupational – Astronauts; N = 171 who flew at least 1 mission in space; Comparison group of N = 53 astronauts who had not flown in space; N = 95 military aircrew personnel; N = 99 non-aircrew ground-based	Cosmic radiation; high-energy protons and heavy ions and secondary particles	Lens dose Overall median 12.9 mSv	TLD measurement	LOCS III	PSC opacity risk for astronauts exposed to higher space radiation dose; OR = 2.33 (1.16-4.26); Per year of age OR = 1.04 (1.01-1.08); Space radiation may be associated with increased PSC area and size. No association with nuclear cataracts.	Age, Sun exposure, occupation, nutritional intake, others
Cucinotta <i>et al.</i> (2001)	USA	Cohort	1977-1988, and more since 1989 (various)	Occupational – astronauts; N = 295 as part of Longitudinal Study of Astronaut Health	Cosmic radiation; high-energy protons and heavy ions and secondary particles	TLD range 0.1-43.2 mGy; Lens dose Range 0.2-91.0 mSv	TLD measurement and reconstructed lens dose from diagnostic x-ray exams	Slit-lamp biomicroscopy under pupil dilation; subjective lens opacification grading system	48 cases of lens opacifications. For lens dose from space radiation only. HR = 2.35 (1.01-5.51) at age 60 y and HR = 2.44 (1.20-4.98) at age 65 y	Diabetes, Renal failure, Steroids, Eye disorders
Jones <i>et al.</i> (2007)	USA	Cohort	1953-2000 (various)	Occupational – Flight personnel (USAF and USN pilots and NASA astronauts); person-years = 13,560,303	Cosmic radiation	Not reported	Employment record	Subjective lens opacification grading system	Hazard ratio (USAF/NASA) HR = 2.6 (1.5-4.8); Hazard ratio USN/NASA) HR = 4.1 (2.1-8.0)	Age
Rafnsson <i>et al.</i> (2005)	Iceland	Case-Control	1996-2001 (Not reported)	Occupational – Airline pilots; N = 274 pilots; N = 374 population-based controls	Cosmic radiation	Range 1-48 mSv	Estimated by employment records, flight profiles, aircraft type	Slit-lamp microscopy and WHO simplified grading system; Nuclear, cortical, central optical zone involvement, or PSC	Nuclear cataract risk if ever been a pilot.	Age, Smoking, Sunbathing habits
Rastegar <i>et al.</i> (2002)	International	Cohort Sample Study Pilot	Conference November 13-17, 2000	Occupational – former astronauts and cosmonauts; N = 21 exposed; N = 395 comparison (307 retired German Air Force pilots with few flights and ground personnel, 88 eye patients)	Cosmic radiation; high-energy protons and heavy ions and secondary particles	Not reported	Self reported time spent in space	Calibration units of a Schiempflug camera system	Descriptive analysis. Most opacity values for lens posterior capsule and posterior cortex region are above the average values in comparison group.	Not reported

Table A.6—Exposure to doses of ionizing radiation: Exposures in other occupationally exposed persons and development of cataract.

Reference: First author (year)	Area of Study	Type of Study	Study Period (follow-up time)	Study population characteristics and study size	Type of ionizing radiation exposed	Estimated Dose	Exposure assessment	Outcome assessment	Results or Risk estimates for cataract (95% CI)	Confounder Adjustment
Adams <i>et al.</i> (1983)	USA	Cohort	First exposure prior to 1930 (not reported)	Occupational – Female radium dial workers; N = 813	Internal: Ra Alpha	Two dose groups: 0-50 and ≥ 50 -5,467 μCi (more than $\frac{1}{4}$ in low dose group)	Extrapolated estimate of radium-226 and radium-228 in blood	Medical records, grading not reported; Cataracts	Prevalence in low-dose group: 14.1%, in high-dose group: 17.1%	Age, Duration of employment
Griffith <i>et al.</i> (1985)	UK	Case Study	1950-1974 (23-47 y)	Occupational – Radiation Worker; N = 1	Internal: Pu ingestion; External: Beta, Gamma, Neutron	External: 70-87 rem Internal: ~ 2 nCi Pu burden	Dosimeters for external dose; internal unknown	Not reported	Premature (47 y old) subcapsular opacities more marked in the region of the posterior pole	Not reported
Hayes and Fisher (1979)	UK	Case Study	1935-1950 (26 y)	Occupational – Radiation Worker; N = 1	External: Gamma from radium-226	Not reported	Employment history	Examination of extracted lenses with slit-lamp photography, thin-section light microscopy, and electron microscopy	Some posterior light scattering noted.	Not reported
Jacobson (2005)	USA	Cohort	Not reported (Not reported)	Occupational – retired DOE actinide exposed workers; N = 97 (with lifetime dosimetric records)	Internal: Actinides External: Gamma	Range 0-600 mSv	Routine monitoring, generally by external dosimeters; worker records	Medical records, grading not reported; Cataracts	Incidence (%) reported, OR = 0.0034+/-0.0016 per mSv (~ 1.40 at 100 mSv)	Age
Okladnikova <i>et al.</i> (1994)	USSR	Case Study	Not reported (35 y)	Occupational – Nuclear Power Workers; N = 37 with Acute Radiation Syndrome (ARS); N = 1828 Chronic Radiation Syndrome (ChRS)	External: Gamma, Neutron	1 ARS case with 3+ Gy; ChRS Range 0.5 – 8 Gy (2-3 Gy/y)	Not reported	Not reported	One case of occupationally associated radiation cataract (dose $> 3\text{Gy}$) reported among 37 ARS cases; No case of radiation cataract in ChRS cases	Not reported
Voelz (1967)	USA	Cohort	1952-1966 (~ 13 y)	Occupational – Nuclear Power Workers; N = 847 (from long-term eye examination program at National Reactor Testing Station)	External: Gamma, Neutron	Range 0.1-25.3 rem;	Dosimetry badge results	Ophthalmoscope and/or slit-lamp; subjective lens opacification grading system	No lens changes related to occupational radiation exposure were identified.	Not reported

Table A.6—(continued).

Reference: First author (year)	Area of Study	Type of Study	Study Period (follow-up time)	Study population characteristics and study size	Type of ionizing radiation exposed	Estimated Dose	Exposure assessment	Outcome assessment	Results or Risk estimates for cataract (95% CI)	Confounder Adjustment
Okladnikova <i>et al.</i> (2007)	USSR	Cohort	1949-1990s (~1-50+ y)	Occupational – Nuclear Power Workers Mayak; <u>N</u> not reported	External: Gamma	Not reported	Not reported	Not reported	Chronic external gamma- radiation does not cause radiation-induced effects when it does not exceed the limit of the yearly dose for personnel. Consequences of acute radiation disease included radiation- induced cataracts at a dose > 4 Gy	Not reported
Shang and Fu (2007)	China	Case- Cohort	Not reported (~1-35 y)	Occupational – Radiation Workers; <u>N</u> = 584 exposed; <u>N</u> = 340 controls	Not reported	Not reported	Years of radiation work, range 4 mos-35 y, mean 11.6 y	Slit-lamp; Opacities and early changes method not reported	Found increase in more advanced (but still early) opacities with longer radiation working time	Not reported

Table A.7—Exposure to doses of ionizing radiation: Exposures in populations or residentially exposed persons and development of cataract.

Reference: First author (year)	Area of Study	Type of Study	Study Period (follow-up time)	Study population characteristics and study size	Type of ionizing radiation exposed	Estimated Dose	Exposure assessment	Outcome assessment	Results or Risk estimates for cataract (95% CI)	Confounder Adjustment
Chen <i>et al.</i> (2001)	Taiwan	Cohort	1983-1997 (<1->5 y)	Residents – contaminated buildings; $N = 114$	External: Gamma	Cumulative whole body dose range: 1.11 mSv – 1.49 Sv	Taiwan cumulative dose exposure assessment	LOCS III; FLD – minor focal lens defect scores	Increase in FLD in the exposed group found in the anterior cortex, but not the posterior cortex or nucleus	Steroid, Diabetes, Sun, Eye disorder
Day <i>et al.</i> (1995)	Ukraine	Cohort	1991 (5.7 y)	Residents – Chernobyl; $N = 991$ living in high deposition towns/areas; $N = 791$ living in no deposition areas	External: Gamma; Internal: Gamma	Estimates of cumulative whole body doses in exposed area range from 29 – 85.6 mSv depending on the assessment method	Self-reported	LOCS III; If ≥ 2 considered cataract	No differences in cortical opacities. Small excess (3.6 versus 1.1%, $p=0.0005$) of subclinical posterior subcapsular opacities in exposed versus not exposed children	Exposure level, Sex, Age, Diabetes, Radiotherapy and medications
Hourihan <i>et al.</i> (1999)	Australia	Cross- Section	1992-1994 (various)	Residents – urban population, Blue Mountains Eye Study; $N = 3,654$	External: X-rays	Not reported	Self-reported	Wisconsin Cataract Grading System	If history of >1 CT scan: OR = 1.0 (0.4-2.7) for PSC; OR = 1.7 (0.8-3.5) for nuclear cataract; OR = 0.9 (0.5-1.6) for cortical cataract	Age, Sex, Education, Diabetes, Others
Hsieh <i>et al.</i> (2010)	Taiwan	Cohort	1998-2002 (1-5 y)	Residents – contaminated buildings; $N = 84$ (<20 y)	External: Gamma	0.19 +/- 0.36 Sv	Taiwan cumulative dose exposure assessment	LOCS III; FLD – minor focal lens defect scores	For exposed (>50 mSv) versus unexposed, RR = 1.39	Age, Relocation time
Klein <i>et al.</i> (1993)	USA	Cross- Section	09/1987- 05/1988 (various)	Residents – Beaver Dam; Population cross- sectional study – Beaver Dam Eye Study (also assessed medical imaging with X-ray); $N = 4,926$	External: X-rays	Not reported	Self-reported	Wisconsin Cataract Grading System.	History of head CT scan: OR = 1.45 (1.08-1.95) for PSC opacity; OR = 1.28 (1.02-1.61) for nuclear sclerotic opacity; OR = 1.17 (0.88-1.55) for cortical opacity	Age, Sex
Klein <i>et al.</i> (2000)	USA	Cohort 5 y follow- up study	1993-1995 (various)	Residents - Beaver Dam – Beaver Dam Eye Study 5 year(also assessed medical imaging with X- ray); $N = 3,684$	External: X-rays	Not reported	Self-reported	Wisconsin Cataract Grading System	Incidence of PSC with history of head CT: 7.2 versus 4.6% without ($p<0.005$)	Age, Sex, Diabetes

Table A.8—Cataract epidemiology scoring evaluation summary (EPRI, 2014).

Study References	Cataract Type	Study Design	Dosimetry	Age Adjustment	Confounding	Numerical Risk Assessment	exposure-response Analysis	Latency	Reporting Bias	Selection Bias	Pathology Method	Blinded Pathology	Cataract Scoring Type	Total Score	Tier
Albert <i>et al.</i> , 1968	Opacities (Axial/PSC)	0	0	0	-1	0	1	0	1	-1	-1	0	-1	-2	3
Chen <i>et al.</i> , 2001; Hsieh <i>et al.</i> , 2010	Opacities	0	0	0	-1	-1	0	-1	1	-1	1	-1	0	-3	3
Chmelvsky <i>et al.</i> , 1988	Mixed	-1	-1	0	-1	-1	1	0	1	-1	-1	-1	-1	-6	3
Chodick <i>et al.</i> , 2008	Mixed (Clinical)	0	0	0	1	1	1	0	0	1	-1	-1	-1	1	2
Chodick <i>et al.</i> , 2008	Mixed (Occupational)	0	0	0	1	1	1	0	0	1	-1	-1	-1	1	2
Choshi <i>et al.</i> , 1983	Opacities (Axial, PSC)	-1	0	0	-1	-1	0	0	1	-1	1	0	-1	-3	3
Chylack <i>et al.</i> , 2009; 2012	PSC	-1	1	0	1	0	1	-1	1	0	1	0	1	4	1
Ciraj-Bjelac <i>et al.</i> , 2010	Mixed	-1	0	0	-1	0	1	0	1	-1	0	0	0	-1	3

Table A.8–(continued).

Study References	Cataract Type	Study Design	Dosimetry	Age Adjustment	Confounding	Numerical Risk Assessment	Exposure-response	Analysis	Latency	Reporting Bias	Selection Bias	Pathology Method	Blinded Pathology	Cataract Scoring Type	Total Score	Tier
Cogan and Dreisler, 1953	Opacities (Axial)	-1	0	-1	-1	-1	1	0	1	-1	0	-1	-1	-5	3	
Cogan <i>et al.</i> , 1949; Cogan <i>et al.</i> , 1950	Opacities (Axial/PSC)	0	-1	-1	0	-1	0	-1	1	1	0	-1	-1	-4	3	
Cogan <i>et al.</i> , 1952	Opacities	-1	-1	-1	-1	-1	0	-1	1	-1	0	-1	-1	-8	3	
Cucinotta <i>et al.</i> , 2001	Opacities	-1	0	-1	-1	-1	0	-1	1	-1	0	-1	-1	-7	3	
Day <i>et al.</i> , 1995	≥ LOCS 2 Cortical	0	-1	-1	1	1	0	0	1	-1	1	0	0	1	2	
Day <i>et al.</i> , 1995	≥ LOCS 2 PSC	0	-1	-1	1	1	0	0	1	-1	1	0	0	1	2	
Griffith <i>et al.</i> , 1985	Mixed	-1	1	-1	-1	-1	0	-1	1	-1	-1	-1	-1	-7	3	
Hall <i>et al.</i> , 1999	Cortical	-1	0	-1	1	0	1	0	1	-1	1	-1	0	0	2	

Table A.8–(continued).

Study References	Cataract Type	Study Design	Dosimetry	Age Adjustment	Confounding	Numerical Risk Assessment	Exposure-response	Analysis	Latency	Reporting Bias	Selection Bias	Pathology Method	Blinded Pathology	Cataract Scoring Type	Total Score	Tier
Hall <i>et al.</i> , 1999	PSC	-1	0	-1	1	0	1	0	1	-1	1	-1	0	0	2	
Hayes and Fisher, 1979	Mixed	-1	-1	-1	-1	-1	0	0	1	-1	0	-1	-1	-7	3	
Hourihan <i>et al.</i> , 1999	Cataract	0	-1	-1	1	-1	0	-1	-1	1	0	-1	0	-4	3	
Jacob <i>et al.</i> , 2010; 2013	Mixed Opacity	0	-1	0	1	0	0	0	1	-1	1	-1	0	0	2	
Jacobson, 2005	PSC	-1	1	-1	0	0	1	0	1	0	-1	0	-1	1	2	
Junk <i>et al.</i> , 2004; Haskal and Worgul, 2004	Opacities (or PSC)	-1	-1	-1	-1	-1	0	-1	1	-1	0	-1	-1	-8	3	
Kai <i>et al.</i> , 2009	Mixed	-1	0	-1	1	-1	0	-1	0	-1	-1	-1	-1	-7	3	
Kleiman <i>et al.</i> , 2009	Opacities (or PSC)	-1	-1	-1	-1	-1	0	-1	1	-1	0	-1	0	-7	3	

Table A.8–(continued).

Study References	Cataract Type	Study Design	Dosimetry	Age Adjustment	Confounding	Numerical Risk Assessment	Exposure-response	Analysis	Latency	Reporting Bias	Selection Bias	Pathology Method	Blinded Pathology	Cataract Scoring Type	Total Score	Tier
Klein <i>et al.</i> , 1993	Cortical or PSC	0	-1	0	-1	-1	0	-1	1	1	0	-1	0	-3	3	
Meecham <i>et al.</i> , 1994	Cortical or PSC	-1	1	0	1	-1	1	-1	1	-1	-1	-1	-1	-3	3	
Merriam and Focht, 1957	Opacities	-1	1	0	0	-1	1	0	1	0	0	-1	-1	-1	3	
Milacic <i>et al.</i> , 2009	Mixed	-1	-1	0	1	-1	0	0	1	1	-1	-1	-1	-3	3	
Minamoto <i>et al.</i> , 2004	Cortical	-1	0	0	1	0	1	0	1	0	1	0	0	3	1	
Minamoto <i>et al.</i> , 2004	PSC	-1	0	0	1	0	1	0	1	0	1	0	0	3	1	
Mrena <i>et al.</i> , 2011	Non-nuclear (Cortical or PSC)	-1	1	0	1	0	0	0	1	-1	1	-1	0	1	2	
Mrena <i>et al.</i> , 2011	Opacities	-1	1	0	1	0	0	0	1	-1	1	-1	0	1	2	

Table A.8–(continued).

Study References	Cataract Type	Study Design	Dosimetry	Age Adjustment	Confounding	Numerical Risk Assessment	Exposure-response Analysis	Latency	Reporting Bias	Selection Bias	Pathology Method	Blinded Pathology	Cataract Scoring Type	Total Score	Tier
Nadejina <i>et al.</i> , 2002	Mixed	-1	0	-1	-1	-1	0	0	1	-1	-1	-1	-1	-7	3
Nakashima <i>et al.</i> , 2006	Cortical	-1	0	0	1	0	1	0	1	-1	1	-1	0	1	2
Nakashima <i>et al.</i> , 2006	Nuclear Color	-1	0	0	1	0	1	0	1	-1	1	-1	0	1	2
Nakashima <i>et al.</i> , 2006	Nuclear Opacity	-1	0	0	1	0	1	0	1	-1	1	-1	0	1	2
Nakashima <i>et al.</i> , 2006	PSC	-1	0	0	1	0	1	0	1	-1	1	-1	0	1	2
Nakashima <i>et al.</i> , 2013	Mixed (Removal)	-1	0	-1	-1	0	1	0	1	-1	-1	-1	-1	-5	3
Nefzger <i>et al.</i> , 1969; Otake and Schull, 1982; Otake <i>et al.</i> , 1990; 1996	Opacities	-1	0	-1	-1	-1	1	0	1	0	0	-1	-1	-4	3

Table A.8–(continued).

Study References	Cataract Type	Study Design	Dosimetry	Age Adjustment	Confounding	Numerical Risk Assessment	Exposure-response Analysis	Latency	Reporting Bias	Selection Bias	Pathology Method	Blinded Pathology	Cataract Scoring Type	Total Score	Tier
Neriishi <i>et al.</i> , 2007	Mixed	0	0	0	1	0	1	0	-1	0	-1	-1	-1	-2	3
Neriishi <i>et al.</i> , 2012	Mixed (Removal)	-1	0	-1	1	0	1	0	1	-1	-1	-1	-1	-3	3
Neriishi <i>et al.</i> , 2012	Mixed (Removal)	-1	0	-1	1	-1	1	0	1	-1	-1	-1	-1	-4	3
Okladnikova <i>et al.</i> , 2007	Mixed	0	1	0	0	0	0	0	0	0	-1	0	-1	-1	3
Qvist and Zachaue-Christiansen, 1959	Mixed	-1	0	-1	-1	-1	0	0	1	-1	-1	-1	-1	-7	3
Rafnsson <i>et al.</i> , 2005	Nuclear	-1	0	0	1	0	1	0	1	1	0	0	0	3	1
Rastegar <i>et al.</i> , 2002	PSC	-1	-1	0	-1	-1	0	0	0	-1	1	-1	-1	-6	3
Shang and Fu, 2007	Opacities	0	-1	-1	-1	-1	0	-1	1	1	0	-1	-1	-5	3

Table A.8–(continued).

Study References	Cataract Type	Study Design	Dosimetry	Age Adjustment	Confounding	Numerical Risk Assessment	Exposure-response Analysis	Latency	Reporting Bias	Selection Bias	Pathology Method	Blinded Pathology	Cataract Scoring Type	Total Score	Tier
Vano <i>et al.</i> , 1998	Opacities (PSC)	-1	0	-1	-1	-1	0	-1	1	-1	-1	-1	-1	-8	3
Vano <i>et al.</i> , 2010	Mixed (Cardiologists)	-1	0	0	1	0	0	0	1	-1	0	0	0	0	2
Vano <i>et al.</i> , 2010	Mixed (Nurses)	-1	0	0	1	0	0	0	1	-1	0	0	0	0	2
Voelz, 1967	Opacities (Cortical/PSC)	-1	1	0	0	-1	0	-1	1	1	0	-1	-1	-2	3
Whalen <i>et al.</i> , 2010	Mixed	-1	0	0	1	0	1	0	0	1	-1	-1	-1	-1	3
Wilde and Sjostrand, 1997	Mixed	-1	0	-1	-1	-1	1	0	1	-1	1	-1	-1	-4	3
Worgul <i>et al.</i> , 2007; Chumak <i>et al.</i> , 2007	Mixed	-1	0	0	1	1	1	0	1	0	0	-1	0	2	1
Worgul <i>et al.</i> , 2007; Chumak <i>et al.</i> , 2007	Non-nuclear	-1	0	0	1	1	1	0	1	0	0	-1	0	2	1

Table A.8–(continued).

Study References	Cataract Type	Study Design	Dosimetry	Age Adjustment	Confounding	Numerical Risk Assessment	Exposure-response Analysis	Latency	Reporting Bias	Selection Bias	Pathology Method	Blinded Pathology	Cataract Scoring Type	Total Score	Tier
Worgul <i>et al.</i> , 2007; Chumak <i>et al.</i> , 2007	Nuclear	-1	0	0	1	1	1	0	1	0	0	-1	0	2	1
Worgul <i>et al.</i> , 2007; Chumak <i>et al.</i> , 2007	PSC	-1	0	0	1	1	1	0	1	0	0	-1	0	2	1
Worgul <i>et al.</i> , 2007; Chumak <i>et al.</i> , 2007	Superficial Cortical	-1	0	0	1	1	1	0	1	0	0	-1	0	2	1
Yamada <i>et al.</i> , 2004	Non-nuclear	-1	0	0	-1	0	1	0	1	0	0	-1	0	-1	3

2854

2855 **Appendix B**

2856

2857 **Evaluating the Epidemiological Evidence Tables**

2858

2859 Tables B.1 and B.2 support the discussion in Section 5.3.3 and Table B.3 supports the
2860 discussion in Section 5.3.4 of this Commentary.

2861

2862

2863

Table B.1—Cataract epidemiological study: Odds/risk/hazard ratio evaluations.

Tier	Study Reference	Cataract Type	Study Size (N)	Ratio Type	Ratio Value	95% LCL ^a	95% UCL ^b
<u>Risk calculated at 1 Gy</u>							
1	Worgul et al. (2007)	Cortical (superficial)	8,607 total in study	OR at 1 Gy	1.51	1.09	2.10
1	Minamoto et al. (2004)	Cortical	873 total cases	OR at 1 Gy	1.29	1.12	1.49
2	Hall et al. (1999)	Cortical	573 total, 484 exposed	OR at 1 Gy	1.50	1.15	1.95
2	Nakashima et al. (2006)	Cortical	873 total cases	OR at 1 Gy	1.30	1.10	1.53
1	Worgul et al. (2007)	PSC	8,607 total in study	OR at 1 Gy	1.42	1.01	2.00
1	Minamoto et al. (2004)	PSC	873 total cases	OR at 1 Gy	1.41	1.21	1.64
2	Hall et al. (1999)	PSC	573 total, 484 exposed	OR at 1 Gy	1.49	1.07	2.08
2	Nakashima et al. (2006)	PSC	873 total cases	OR at 1 Gy	1.44	1.19	1.73
1	Worgul et al. (2007)	Mixed	8,607 total in study	OR at 1 Gy	1.70	1.22	2.38
2	Chodick et al. (2008)	Mixed	35,705	RR at 1 Gy	2.98	0.31	5.65
3	Yamada et al. (2004)	Mixed	10,339	RR at 1 Gy	1.11	1.03	1.19
3	Neriishi et al. (2007)	Mixed	3,282 controls, 479 cases	OR at 1 Gy	1.39	1.24	1.55
3	Neriishi et al. (2012)	Mixed (removal)	6,066 total, 1,028 surgery	HR at 1 Gy	1.26	1.17	1.52
3	Nakashima et al. (2013)	Mixed (removal)	3,055 total, 685 cases	OR at 1 Gy	1.33	1.28	1.38
1	Worgul et al. (2007)	Non-nuclear	8,607 total in study	OR at 1 Gy	1.65	1.18	2.30
3	Yamada et al. (2004)	Non-nuclear	3,484 cases	OR at 1 Gy	1.06	1.01	1.11
1	Worgul et al. (2007)	Nuclear	8,607 total in study	OR at 1 Gy	1.07	0.5	2.0
2	Nakashima et al. (2006)	Nuclear opacity	873 total cases	OR at 1 Gy	1.07	0.89	1.30
2	Nakashima et al. (2006)	Nuclear color	873 total cases	OR at 1 Gy	1.01	0.83	1.24
<u>Not based on exposure level</u>							
1	Day et al. (1995)	Cortical (>= LOCS 2)	991 cases, 791 controls	OR	1.20	0.50	2.60
1	Day et al. (1995)	PSC (>= LOCS 2)	991 cases, 791 controls	OR	2.80	1.30	6.10
1	Rafnsson et al. (2005)	Nuclear	445 total, 71 cases	OR	3.02	1.44	6.35
1	Chylack et al. (2009/2012)	PSC	171	OR	2.23	1.16	4.26
2	Vano et al. (2010)	Mixed	41	RR	3.20	1.70	6.10
2	Vano et al. (2010)	Mixed	28	RR	1.70	0.80	3.70
2	Jacob et al. (2010/2013)	Mixed opacity	106 cases, 99 controls	OR	3.90	1.30	11.40
2	Mrena et al. (2011)	Non-nuclear	59	OR	1.04	0.80	1.28
2	Mrena et al. (2011)	Opacities	59	OR	1.13	0.98	1.28
2	Jacobson (2005)	PSC	113 total, 97 exposed, 20 PSC	OR	4.05	-	-
3	Albert et al. (1968)	PSC opacities	234 cases, 232 controls	OR	5.90	1.40	24.00
3	Milacic et al. (2009)	Mixed	241	RR	4.60	-	-
3	Whalen et al. (2010)	Mixed	14,362	RR	3.20	2.00	5.20
3	Ciraj-Bjelac et al. (2010)	Mixed	67 total, 34 with lens changes	RR	5.60	1.40	21.00

^aLCL = lower control limit

^bUCL = upper control limit

Table B.2—Results of odds ratio meta-analysis at 1 Gy by cataract type.

Cataract Type	Odds Ratio (1 Gy)	95 % Confidence Interval	Relevant Studies with the Specific
			Cataract Type
Cortical	1.37	1.20 to 1.56	Hall, 1999; Nakashima, 2006;
	1.50 ^a	1.21 to 1.87 ^a	Worgul, 2007
Mixed	1.75	1.26 to 2.46	Chodick, 2008; Worgul, 2007
Nuclear	1.07	0.89 to 1.28	Nakashima, 2006 (nuclear
	1.07 ^a	0.5 to 2.0 ^a	opacity); Worgul, 2007
PSC	1.45	1.25 to 1.68	Hall, 1999; Nakashima, 2006;
	1.45 ^a	1.15 to 1.85 ^a	Worgul, 2007

^aNakashima 2006 excluded.

Table B.3—Cataract epidemiological study: Threshold evaluation.

Tier	Study Reference	Cataract Type	Study Size (N)	Time since exposure	Threshold (Gy)	95% LCL ^a	95% UCL ^b
<u>Thresholds with 95% CI reported</u>							
1	Worgul et al. (2007)	Cortical (superficial)	8,607 total in study	12-14 y	0.34	0.18	0.51
2	Nakashima et al. (2006)	Cortical	873 total cases	56 y	0.6	0.0	1.4
1	Worgul et al. (2007)	PSC	8,607 total in study	12-14 y	0.35	0.19	0.66
2	Nakashima et al. (2006)	PSC	873 total cases	56 y	0.7	0.0	2.9
1	Worgul et al. (2007)	Mixed	8,607 total in study	12-14 y	0.50	0.17	0.65
3	Neriishi et al. (2012)	Mixed (removal)	6,066 total, 1,028 surgery	~60 y	0.50	0.10	0.95
3	Neriishi et al. (2012)	Mixed (removal)	6,066 total, 1,028 surgery	~60 y	0.45	0.10	1.05
3	Nakashima et al. (2013)	Mixed (removal)	Up to 685 cases, 3,055 participants	42-60 y	0.41	0.04	1.03
1	Worgul et al. (2007)	Non-nuclear	8,607 total in study	12-14 y	0.50	0.17	0.69
<u>Thresholds no 95% CI reported</u>							
3	Qvist et al. (1959)	Mixed	56 of 855	~20-40+ y	6.9		
3	Nefzger et al. (1969) Otake and Schull (1982) Otake et al. (1990) Otake et al. (1996)	Mixed opacities	2,125	18-19 y	1.54-1.68		

^aLCL = lower control limit

^bUCL = upper control limit

2889 **Glossary**

2890

2891 **acute radiation exposure:** Radiation exposure received during a short time period (e.g., hours).

2892 **angiography:** The radiographic visualization of blood vessels following introduction of contrast
2893 material.

2894 **as low as reasonably achievable (ALARA):** A principle of radiation protection philosophy that
2895 requires that exposures to ionizing radiation be kept as low as reasonably achievable,
2896 economic and societal factors being taken into account. The ALARA principle is satisfied
2897 when the expenditure of further resources would be unwarranted by the reduction in
2898 exposure that would be achieved.

2899 **ataxia telangiectasia mutated (ATM):** Ataxia telangiectasia (AT) is a rare, hereditary, slowly
2900 progressive multisystem, neurodegenerative disorder that includes dilation of small blood
2901 vessels and recurrent infections. Individuals homozygous defective in the AT mutated
2902 (ATM) gene have cancer predisposition and significantly increased radiosensitivity.

2903 **bystander effect:** In radiobiology, the term is used to describe an effect on cells in which the
2904 energy had not been directly deposited. In most instances, the cells so affected were
2905 neighbors of the cells directly impacted by the radiation.

2906 **cataract:** A cataract is a clouding or opacification that occurs in the normally clear lens of the
2907 eye. Some cataracts are clinically unimportant and do not impair vision in any way. But,
2908 without intervention, cataracts remain the most common cause of blindness.

2909 **confidence interval (CI):** A measure of the extent to which an estimate of risk, dose or other
2910 parameter is expected to lie within a specified interval (e.g., a 95 % confidence interval of a
2911 risk estimate means that, based on available information, the probability is 0.95 that the true
2912 but unknown risk lies within the specified interval).

2913 **cornea:** The transparent epithelial structure forming the anterior part of the external covering of
2914 the eye.

2915 **deoxyribonucleic acid (DNA):** Genetic material of cells; a complex molecule of high molecular
2916 weight consisting of deoxyribose, phosphoric acid, and four bases which are arranged as two
2917 long chains that twist around each other to form a double helix joined by hydrogen bonds
2918 between the complementary components.

2919 **deterministic effects:** Detrimental health effects for which the severity varies with the dose of
2920 radiation (or other toxic substance), and for which a threshold usually exists (i.e., causally
2921 determined by preceding events). ICRP Publication 103 has restated this as: “Injury in a
2922 population of cells, characterized by a threshold dose and an increase in the severity of the
2923 reaction as the dose is increased further. Also termed tissue reactions. In some cases,
2924 deterministic effects are modifiable by post-irradiation procedures including biological
2925 response modifiers.” It is common for deterministic effects to be termed tissue reactions.

2926 **detriment:** Measure of stochastic effects from exposure to ionizing radiation that takes into
2927 account the probability of fatal cancers, probability of severe hereditary effects in future
2928 generations, probability of nonfatal cancers weighted by the lethality fraction, and relative
2929 years of life lost per fatal health effect.

2930 **dose:** General term denoting the mean energy imparted from ionizing radiation to a tissue or
2931 organ from either an external source or from radionuclides in the body. When unspecified,
2932 dose refers to the quantity of absorbed dose, measured in gray ($1 \text{ Gy} = 1 \text{ J}\cdot\text{kg}^{-1}$) or rad (1 rad
2933 $= 100 \text{ ergs}\cdot\text{g}^{-1}$). Depending upon the context in which it is used, the generic term dose may
2934 also refer to equivalent dose, effective dose or other dose-related quantities.

2935 **dose limit:** A limit on radiation dose that is applied for exposure to individuals in order to
2936 prevent the occurrence of radiation-induced deterministic effects or to limit the probability
2937 of radiation-induced stochastic effects to an acceptable level.

2938 **dose rate:** Dose per unit time; often expressed as an average over some time period (e.g., a
2939 year).

2940 **dosimetry:** The science or technique of determining radiation dose.

2941 **electrons:** Subatomic charged particle. Negatively charged particles are parts of atoms. Both
2942 negatively and positively charged electrons may be expelled from a radioactive atom when it
2943 disintegrates.

2944 **exposure:** Most often used in a general sense meaning to be irradiated. When used as the
2945 specifically defined radiation quantity, exposure is a measure of the ionization produced in
2946 air by x or gamma radiation. The unit of exposure is coulomb per kilogram (C kg^{-1}). The
2947 special unit for exposure is roentgen I, where $1 \text{ R} = 2.58 \times 10^{-4} \text{ C kg}^{-1}$.

- 2948 **fluoroscopically-guided interventional (FGI) procedures:** An interventional diagnostic or
2949 therapeutic procedure performed via percutaneous or other access routes, usually with local
2950 anesthesia or intravenous sedation, which uses external ionizing radiation in the form of
2951 fluoroscopy to: localize or characterize a lesion, diagnostic site, or treatment site; monitor
2952 the procedure; and, control and document therapy.
- 2953 **fluoroscopy (fluoro):** The process of producing a real-time image using x rays. The machine
2954 used for visualization, in which the dynamic image appears in real time on a display screen
2955 (usually video) is a fluoroscope.
- 2956 **fractionation:** The delivery of a given total dose of radiation as several smaller doses, separated
2957 by intervals of time.
- 2958 **gamma radiation:** Electromagnetic radiation emitted in de-excitation of atomic nuclei, and
2959 frequently occurring in decay of radionuclides. Also called gamma ray and sometimes
2960 shortened to gamma (e.g., gamma-emitting radionuclides) (see **photon** and **x ray**).
- 2961 **genetic effects:** Changes in reproductive cells that may result in detriment to offspring.
- 2962 **gray (Gy):** The SI special name for the unit of the quantities absorbed dose and air kerma.
2963 $1 \text{ Gy} = 1 \text{ J kg}^{-1}$.
- 2964 **heavy ions:** Synonymous with heavy charged particles, heavy nuclei, high- Z particles, or HZE
2965 particles [see **high atomic number, high-energy (HZE) particles**].
- 2966 **heritable effects:** Changes in reproductive cells that may be passed on to offspring of persons or
2967 animals. Often called genetic effects (see **genetic effects**).
- 2968 **high atomic number, high-energy (HZE) particles:** Heavy ions having an atomic number
2969 greater than that of helium (such as boron, carbon, nitrogen, neon, argon, or iron ions that
2970 are positively charged) and having high kinetic energy.
- 2971 **HZE:** A heavy ion having an atomic number greater than that of helium and having high kinetic
2972 energy.
- 2973 **incidence:** The rate of occurrence of a disease, usually expressed in number of cases per million.
- 2974 **interventionalist:** In this Report, an individual who has been granted clinical privileges to
2975 perform or supervise FGI procedures in the facility, and who is personally responsible for
2976 the use of radiation during a specific FGI procedure in that facility.

- 2977 **ionization:** The process by which a neutral atom or molecule acquires a positive or negative
2978 charge through the loss or gain of an orbital electron.
- 2979 **ionizing radiation:** Any radiation capable of displacing electrons from atoms or molecules,
2980 thereby producing ions. Examples include alpha radiation, beta radiation, gamma or x rays,
2981 and cosmic rays. Minimum energy of ionizing radiation is a few electron volts (eV);
2982 $1 \text{ eV} = 1.6 \times 10^{-19} \text{ J}$.
- 2983 **irradiation:** Exposure to ionizing or nonionizing radiation (see also exposure).
- 2984 **justification:** The part of the decision-making process in which the options that are expected to
2985 do more good than harm are identified.
- 2986 **lifetime risk:** The probability during one's lifetime of expressing a given health outcome.
- 2987 **LET:** Linear-energy transfer, the average amount of energy lost per unit of particle track length
2988 and expressed in $\text{keV } \mu\text{m}^{-1}$.
- 2989 **low-LET:** Radiation having a low linear-energy transfer (e.g., electrons, x rays, and gamma
2990 rays).
- 2991 **high-LET:** Radiation having a high linear-energy transfer (e.g., protons, alpha particles,
2992 heavy ions, and the interaction products of fast neutrons).
- 2993 **meta-analysis:** In statistics evaluating epidemiological studies, this comprises the use of
2994 statistical methods for contrasting and combining results from different studies reported in
2995 the literature in the hope of identifying patterns among study results, sources of
2996 disagreement among those results, or other interesting relationships that may come to light
2997 in the context of multiple studies.
- 2998 **neutrons:** Particles with a mass similar to that of a proton, but with no electrical charge. Because
2999 they are electrically neutral, they cannot be accelerated in an electrical field.
- 3000 **noncancer:** Health effects other than cancer (e.g., cataracts, cardiovascular disease) that occur in
3001 the exposed individual.
- 3002 **occupational dose:** The dose received by an individual in a restricted area, or in the course of
3003 employment in which the individual's duties necessarily involve exposure to radiation
3004 (medical doses involving diagnosis or treatment of the exposed individual that are not
3005 required as a condition of employment are excluded).

- 3006 **odds ratio (OR):** The ratio of the number of people incurring an event to the number of people
3007 having non-events.
- 3008 **optimization:** Although the term ALARA is used as equivalent to or in replacement of the term
3009 optimization used in ICRP Publication 121 (ICRP, 2013), ALARA is only a part of the
3010 concept of optimization. The entire concept implies, more precisely, keeping patient
3011 exposure to the minimum necessary to achieve the required medical objective (either
3012 diagnostic or therapeutic) when applied to the clinical use of ionizing radiation.
- 3013 **photon:** Quantum of electromagnetic radiation, having no charge or mass, that exhibits both
3014 particle and wave behavior, such as a gamma or x ray.
- 3015 **posterior subcapsular (PSC) cataract:** Posterior subcapsular cataracts begin in the back of the
3016 lens, adjacent to the capsule in which the lens is situated. PSC have been associated with
3017 steroids, diabetes and ionizing radiation exposure.
- 3018 **protons:** The nucleus of the hydrogen atom. Protons are positively charged.
- 3019 **radionuclide:** An unstable (*i.e.*, radioactive) nuclide. A species of atom characterized by the
3020 constitution of its nucleus (*i.e.*, the number of protons and neutrons) and the excess energy
3021 available in the unstable nucleus.
- 3022 **relative biological effectiveness (RBE):** For a specific radiation (A), the ratio of absorbed dose
3023 of a reference radiation required to produce a specific level of response in a biological
3024 system to absorbed dose of radiation (A) required to produce an equal response. The
3025 reference radiation normally is x or gamma rays with an average linear energy transfer of
3026 $3.5 \text{ keV } \mu\text{m}^{-1}$ or less. Relative biological effectiveness generally depends on dose, dose per
3027 fraction if the dose is fractionated, dose rate, and biological endpoint.
- 3028 **relative risk:** The ratio of the risk of a given disease in those exposed to the risk of that disease
3029 in those not exposed.
- 3030 **risk:** Probability of harm, combined with potential severity of that harm.
- 3031 **risk coefficient:** The increase in the annual incidence or mortality rate per unit dose: (1) absolute
3032 risk coefficient is the observed minus the expected number of cases per person year at risk
3033 for a unit dose, and (2) the relative risk coefficient is the fractional increase in the baseline
3034 incidence or mortality rate for a unit dose.

3035 **Scheimpflug principle:** Describes an optical imaging condition, which allows documentation of
3036 an obliquely tilted object with the maximally possible depth of focus and minimal image
3037 distortion under given conditions. It is a geometric rule that describes the orientation of the
3038 plane of focus of an optical system (such as a camera) when the lens plane is not parallel to
3039 the image plane. The principle can be applied to images of the eye with a camera at an angle
3040 to a slit-beam creating an optic section of the eye from the anterior corneal surface to the
3041 posterior lens surface..

3042 **sclera:** The tough supporting tunic of the eyeball covering it except for the segment covered by
3043 the cornea.

3044 **severe hazard:** A hazard that has the potential to cause death, severe injury, or occupational
3045 illness, significant risk to the public, extensive environmental harm, or significant property
3046 damage.

3047 **severity:** In the context of this Report, the quality or power of afflicting, distressing, or paining
3048 an individual or organ system from exposure to an environmental insult, such as ionizing
3049 radiation, that in the extreme would cause pain or anguish and possible clinical sequelae in
3050 the individual.

3051 **sievert (Sv):** Special name for the SI unit of dose equivalent, equivalent dose, and effective dose.
3052 $1 \text{ Sv} = 1 \text{ J kg}^{-1}$.

3053 **somatic effect:** Biological effects (of radiation or otherwise) that occur in the exposed
3054 individual, as opposed to genetic (or heritable) effects which occur in the descendants of
3055 exposed individuals due to genetic mutations in the germline.

3056 **stochastic:** Describes random events leading to effects whose probability of occurrence in an
3057 exposed population (rather than severity in an affected individual) is a direct function of
3058 dose; these effects are commonly regarded as having no threshold; cancer and hereditary
3059 effects are regarded as being stochastic.

3060 **telangiectasia:** Dilation of capillary vessels and very small arteries.

3061 **tissue reaction (deterministic effect):** Injury in populations of cells, characterized by a
3062 threshold dose and an increase in the severity of the reaction as the dose is increased further.
3063 In some cases, tissue reactions are modifiable by post-irradiation procedures including

3064 biological response modifiers. Examples for irradiation of the embryo or fetus are radiation-
3065 induced malformations and mental retardation in the live-born child.

3066 **vitreous:** The semifluid, transparent substance which lies between the retina and the lens of the
3067 eye.

3068

3069

3070 **Symbols, Abbreviations and Acronyms**

3071

3072	ALARA	as low as reasonably achievable
3073	AHS	Adult Health Study (RERF)
3074	ALI	annual limit on intake
3075	ANSI	American National Standards Institute
3076	ARS	acute radiation syndrome
3077	ATM	ataxia-telangiectasia mutated gene
3078	EU BSS	European Basic Safety Standard
3079	BWR	boiling water reactor
3080	CED	committed effective dose
3081	ChRS	chronic radiation syndrome
3082	CNS	central nervous system
3083	CT	computed tomography
3084	DDREF	dose and dose-rate effectiveness factor
3085	DSB	double-strand break
3086	EAR	excess absolute risk
3087	EDEX	external dose equivalent from external exposure
3088	EPRI	Electric Power Research Institute
3089	ERR	excess relative risk
3090	FGI	fluoroscopically-guided interventional procedure
3091	HZE	heavy ion ($Z > 2$) that is highly energetic
3092	IAEA	International Atomic Energy Agency
3093	ICRP	International Commission on Radiological Protection
3094	ICRU	International Commission on Radiation Units and Measurements
3095	IR	interventional radiology
3096	LDE	lens of the eye dose equivalent
3097	LET	linear energy transfer
3098	LNT	linear nonthreshold assumption or hypothesis model
3099	NCRP	National Council on Radiation Protection and Measurements

3100	NIR	non-ionizing radiation
3101	PSC	posterior subcapsular
3102	RBE	relative biological effectiveness
3103	REL	recommended exposure limit
3104	RELID	retrospective evaluation of lens injuries and dose
3105	RERF	Radiation Effects Research Foundation
3106	SSB	single strand break
3107	TBI	total body irradiation
3108	TEDE	total effective dose equivalent
3109	VIC	vision-impairing cataract
3110		
3111		

3112 **References**

- 3113
- 3114 ABDELKAWI, S. (2012). “Lens crystallin response to whole body irradiation with single and
3115 fractionated doses of gamma radiation,” *Int. J. Rad. Biol.* **88**(8), 600-606.
- 3116 ABE, T., FURUI, S., SASAKI, H., SAKAMOTO, Y., SUZUKI, S., ISHITAKE, T.,
3117 TERASAKI, K., KOHTAKE, H., NORBASH, A.M., BEHRMAN, R.H. and HAYABUCHI,
3118 N. (2013). “Quantitative evaluation of light scattering intensities of the crystalline lens for
3119 radiation related minimal change in interventional radiologists: A cross-sectional pilot
3120 study,” *J. Radiat. Res.* **54**(2), 315-321.
- 3121 ABS (2014). American Brachytherapy Society-Ophthalmic Oncology Task Force. “The
3122 American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal
3123 melanoma and retinoblastoma,” *Brachytherapy* **13**(1), 1-14.
- 3124 AECL (2013). Atomic Energy of Canada, Ltd. “Submissions received during public consultation
3125 of discussion paper DIS-13-01 – Proposals to amend the radiation protection regulations,”
3126 [http://www.nuclearsafety.gc.ca/eng/pdfs/Discussion-Papers/13-01/RRP-Discussion-Paper-](http://www.nuclearsafety.gc.ca/eng/pdfs/Discussion-Papers/13-01/RRP-Discussion-Paper-Stakeholder-comments.pdf)
3127 [Stakeholder-comments.pdf](http://www.nuclearsafety.gc.ca/eng/pdfs/Discussion-Papers/13-01/RRP-Discussion-Paper-Stakeholder-comments.pdf) (accessed July 23, 2014) (Atomic Energy of Canada, Ltd.,
3128 Ottawa, Canada).
- 3129 AEA (1954). U.S. Atomic Energy Act. Public Law 83-703 (August 30), 68 Stat. 919, as
3130 amended (U.S. Government Printing Office, Washington).
- 3131 AINSBURY, E.A., BOEFFLER, S.D., DORR, W., GRAW, J., MUIRHEAD, C.R., EDWARDS,
3132 A.A. and COOPER, J. (2009). “Radiation cataractogenesis: A review of recent studies,”
3133 *Radiat. Res.* **172**(1), 1-9.
- 3134 AINSBURY, E.A., BOEFFLER, S., COCKER, M., GILVIN, P., HOLT, E., PETERS, S.,
3135 SLACK, K. and WILLIAMSON, A. (2014). “Public Health England survey of eye lens
3136 doses in the UK medical sector,” *J. of Radiol. Prot.* **34**(1), 15-29.
- 3137 ANASTASIAN, Z.H., STROZYK, D., MEYERS, P.M., WANG, S. and BERMAN, M.F.
3138 (2011). “Radiation exposure of the anesthesiologist in the neurointerventional suite,”
3139 *Anesthesiology* **114**(3), 512-520.

- 3140 AUFDERHEIDE, E., RINKS, H., HIEBERT, L. and KRAFT, G. (1987). "Heavy ion effects on
3141 cellular DNA: Strand break induction and repair in cultured diploid lens epithelial cells," *Int.*
3142 *J. Radiat. Biol.* **51**(5), 779-790.
- 3143 AUGUSTEYN, R.C. (2008). "Growth of the lens: in vitro observations," *Clin. Exp. Optom.*
3144 **91**(3), 226-239.
- 3145 AVUNDUK, A., YARDIMCI, S., AVUNDUK, M., KURNAZ, L. and CENGIZ, M. (2000). "A
3146 possible mechanism of x-ray-induced injury in rat lens," *Japan J. Ophthalmol.* **44**(1), 88-91.
- 3147 BABIZHAYEV, M.A. and YEGOROV, Y.E. (2015). "Telomere attrition in human lens
3148 epithelial cells associated with oxidative stress provide a new therapeutic target for the
3149 treatment, dissolving and prevention of cataract with N-acetylcarnosine lubricant eye drops.
3150 Kinetic, pharmacological and activity-dependent separation of therapeutic targeting:
3151 Transcorneal penetration and delivery of L-carnosine in the aqueous humor and hormone-
3152 like hypothalamic antiaging effects of the instilled ophthalmic drug through a safe eye
3153 medication technique," *Recent Pat. Drug Deliv. Formul.* **9**(Epub ahead of print: June 17,
3154 2015; DOI: 10.2174/1872211309666150618104657).
- 3155 BARABINO, S., RAGHAVAN, A., LOEFFLER, J. and DANA, R. (2005). "Radiotherapy-
3156 induced ocular surface disease," *Cornea* **24**(8), 909-914.
- 3157 BASSNETT, S. (2002). "Lens organelle degradation," *Exp. Eye Res.* **74**(1), 1-6.
- 3158 BASSNETT, S. and MATAIC, D. (1997). "Chromatin degradation in differentiating fiber cells
3159 of the eye lens," *J. Cell Biol.* **137**(1), 37-49.
- 3160 BAUMSTARK-KHAN, C., HALBE, E. and RINK, H. (1999). "X-ray sensitivity and DNA
3161 damage in bovine lens epithelial cells in vitro," in Ocular Radiation Risk Assessment in
3162 Populations Exposed to Environmental Radiation Contamination, Junk, A.K., Kundiev, Y.,
3163 Vitte, P. and Worgul, B.V., Eds. (Kluwer Academic Publishers, Netherlands).
- 3164 BEEBE, D.C. (2008). "Maintaining transparency: A review of the developmental physiology and
3165 pathophysiology of two avascular tissues," *J. Ophthalmic Vis. Res.* **3**(1), 52-65.
- 3166 BEEBE, D.C., HOLEKAMP, N.M., SIEGFRIED, C. and SHUI, Y.B. (2011). "Vitreoretinal
3167 influences on lens function and cataract," *Phil. Trans. R. Soc. B* **366**(1568), 1293-1300.
- 3168 BEHRENS, R., DIETZE, G. and ZANKI, M. (2009). "Dose conversion coefficients for electron
3169 exposure of the human eye lens," *Phys. Med. Biol.* **54**(13), 4069-4087.

- 3170 BEHRENS, R. and DIETZE, G. (2010). "Monitoring the eye lens: Which dose quantity is
3171 adequate?" *Phys. Med. Biol.* **55**(14), 4047-4062.
- 3172 BEHRENS, R. and DIETZE, G. (2011). "Dose conversion coefficients for photon exposure of
3173 the human eye lens," *Phys. Med. Biol.* **56**(2), 415-437.
- 3174 BELKACÉMI, Y., OZSAHIN, M., PÈNE, F., RIO, B., LAPORTE, J.P., LEBLOND, V.,
3175 TOUBOUL, E., SCHLIENGER, M., GORIN, N.C. and LAUGIER, A. (1996).
3176 "Cataractogenesis after total body irradiation," *Int. J. Radiat. Oncol. Biol. Phys.* **35**(1), 53-
3177 60.
- 3178 BENDEL, J., SCHUTTMANN, W. and ARNDT, D. (1978). "Cataract of lens as late effect of
3179 ionizing radiation in occupationally exposed persons," page 309, in Late Biological Effects
3180 of Ionizing Radiation (International Atomic Energy Agency, Vienna).
- 3181 BENDER, L., SPALON, D.J., UYANONVARA, B., BOYCE, J., HEATLEY, C., JOSE, R. and
3182 KHAN, J. (2004). "POCOman: New system for quantifying posterior capsule
3183 opacification," *J. Cataract Refract. Surg.* **30**(DOI: 10.1016/j.jcrs.2004.05.010), 2058-2063.
- 3184 BENEDEK, G.B. (1971). "Theory of transparency of eye," *Appl. Opt.* **10**(3), 459-473.
- 3185 BENITEZ DEL CASTILLO, J., DEL RIO, T. and GARCIA-SANCHEZ, J. (1997). "Effects of
3186 estrogen use on lens transmittance in postmenopausal women," *Ophthalmol.* **104**(6), 970-
3187 973.
- 3188 BERLINER, M.L. (1966). Biomicroscopy of the Eye (Hafner, New York).
- 3189 BERTHOUD, V.M. and BEYER, E.C. (2009). "Oxidative stress, lens gap junctions, and
3190 cataracts," *Antioxidants and Redox Signaling* **11**(2), 339-353.
- 3191 BEYER, E.C., EBIHARA, L. and BERTHOUD, V.M. (2013). "Connexin mutants and
3192 cataracts," *Frontiers in Pharmacology* **4**(43), 1-14.
- 3193 BIGSBY, R.M., VALLURI, S., LOPEZ, J., MENDONCA, M.S., CAPERELL-GRANT, A.,
3194 DESROSIERS, C. and DYNLACHT, J.R. (2009). "Ovarian hormone modulation of
3195 radiation-induced cataractogenesis: Dose-response studies," *Investigative Ophth. Vis. Sci.*
3196 **50**(7; doi: 10.1167/iovs.08-3262), 3304-3310.
- 3197 BLAKELY, E.A., KLEIMAN, N.J., NERIISHI, K., CHODICK, G., CHYLACK, L.T.,
3198 CUCINOTTA, F.A., MINAMOTO, N.E., KUMGAMI, T., KITAOKA, T., KANAMOTO,

- 3199 T., KIUCHE, Y., CHANG, P., FUJII, N. and SHORE, R.E. (2010). "Radiation
3200 cataractogenesis: Epidemiology and biology," *Radiation Research* **173**(5), 709-717.
- 3201 BLAKELY, E.A. (2012). "Lauriston S. Taylor Lecture on radiation protection and
3202 measurements: What makes particle radiation so effective?" *Health Phys.* **103**(5), 508-528.
- 3203 BOUFFLER, S., AINSBURY, E., GILVIN, P. and HARRISON, J. (2012). "Radiation-induced
3204 cataracts: The Health Protection Agency's response to the ICRP statement on tissue
3205 reactions and recommendation on the dose limit for the eye lens," *J. Radiol. Prot.* **32**(4),
3206 479-488.
- 3207 BOURNE, W.M. and ENOCH, J.M. (1976). "Some optical principles of the clinical specular
3208 microscope," *Inv. Ophthalmol.* **15**(1), 29-32.
- 3209 BRACCIO, L., CAMPIRINI, M., GRAZIOSI, P., BARATTA, G., FERRIGNO, L., WILLIAMS,
3210 S.L., ROSMINI, F. SPERDUTO, R.D. and MARAINI, G. (1998). "An independent
3211 evaluation of the age related disease study (AREDS) cataract grading system," *Curr. Eye*
3212 *Res.* **17**(1), 53-59.
- 3213 BRADY, L.W. (1996). "Ocular complications of high-dose radiotherapy," *Oncology* **10**(7), 981-
3214 984.
- 3215 BRADY, L.W. and YAEGER, T.E. (2001). "Radiation effects on the eye," in Age-related
3216 Macular Degeneration, Alberti, W.E., Richard, G. and Sagerman, R.H., Eds. (Springer,
3217 Berlin, Heidelberg).
- 3218 BRENNER, L.W., SHIELDS, J., AUGUSBURGER, J., MARKOE, A. and KARLSSON, U.L.
3219 (1989). "Complications from radiation therapy to the eye," *Front. Radiat. Ther. Oncol.* **23**,
3220 238-250.
- 3221 BRENNER, D.J., MEDVEDOVSKY, C., HUANG, Y. and WORGUL, B.V. (1993).
3222 "Accelerated heavy particles and the lens VIII. Comparisons between the effects of iron ions
3223 (190 keV/m) and argon ions (88 keV/m)," *Radiat. Res.* **133**(2), 198-203.
- 3224 BRENNER, D., HALL, E., RANDERS-PEHRSON, G., HUANG, Y., JOHNSON, G., MILLER,
3225 R., WU, B., VAZQUEZ, M., MEDVEDOVSKY, C. and WORGUL, B. (1996).
3226 "Quantitative comparisons of continuous and pulsed low dose rate regimens in a model late-
3227 effect system," *Int. J. Radiat. Onc. Biol. Phys.* **34**(4), 905-910.

- 3228 BRITTEN, M.J.A., HALNAN, K.E. and MEREDITH, W.J. (1966). "Radiation cataract – new
3229 evidence on radiation dosage to the lens," *Br. J. Radiol.* **39**(464), 612-617.
- 3230 BROUGHTON, J., CANTONE, M.C., GINJAUME, M. and SHAH, B. (2013). "Report of Task
3231 Group on the implications of the implementation of the ICRP recommendations for a revised
3232 dose limit to the lens of the eye," *J. Radiat. Prot.* **33**(4), 855-868.
- 3233 BROWN, N. (1974). "The change in lens curvature with age," *Exp. Eye Res.* **19**(2), 175-183.
- 3234 BSS (2014). European Directive 2013/59. "Euratom on basic safety standards for protection
3235 against the dangers arising from exposure to ionising radiation and repealing Directives
3236 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom,"
3237 *Off. J. Eur. Commun.* **57**(L13), 1-73.
- 3238 BURNS, S., THORNTON, R., DAUER, L.T., QUINN, B., MIODOWNIK, D. and HAK, D.J.
3239 (2013). "Leaded eyeglasses substantially reduce radiation exposure of the surgeon's eyes
3240 during acquisition of typical fluoroscopic views of the hip and pelvis," *J. Bone Joint Surg.*
3241 *Am.* **95**(14; doi: 10.2106/JBJS.L.00893), 1307-1311.
- 3242 CHANG, J.R., KOO, E., AGRON, E., HALLAK, J., CLEMONS, T., AZAR, D., SPERDUTO,
3243 R.D., FERRIS, F.L. and CHEW, E.Y. (2011). "Risk factors associated with incident
3244 cataracts and cataract surgery in the Age Related Eye Disease Study (AREDS). AREDS
3245 Report Number 32," *Ophthalmology* **118**(11), 2113-2119.
- 3246 CHANG, P.Y., BJORNSTAD, K.A., CHANG, E., MCNAMARA, M.P., BARCELLOS-HOFF,
3247 M.H., LIN, S.P., ARAGON, G., POLANSKY, J.R., LUI, G.M. and BLAKELY, E.A.
3248 (2000). "Particle irradiation induces FGF-2 expression in normal human lens cells," *Radiat.*
3249 *Res.* **154**(5), 477-484.
- 3250 CHANG, P.Y., BJORNSTAD, K.A., ROSEN, C.J., MCNAMARA, M.P., MANCINI, R.,
3251 GOLDSTEIN, L.E., CHYLACK, L.T. and BLAKELY, E.A. (2005). "Effects of iron ions,
3252 protons and x rays on human lens cell differentiation," *Radiat. Res.* **164**(4), 531-539.
- 3253 CHANG, P.Y., BJORNSTAD, K.A., ROSEN, C.R., LIN, S. and BLAKELY, E.A. (2007).
3254 "Particle radiation alters expression of matrix metalloproteases resulting in ECM remodeling
3255 in human lens cells," *Radiat. Environ. Biophys.* **46**(2), 187-194.

- 3256 CHARAKIDAS, A., KALOGERAKI, A., TSILIMBARIS, M., KOUKOULOMATIS, P.,
3257 BROUZAS, D. and DELIDES, G., (2005). "Lens epithelial apoptosis and cell proliferation
3258 in human age-related cortical cataract," *Eur. J. Ophthalmol.* **15**(2), 213-220.
- 3259 CHEN, W.L., HWANG, J.S., HU, T.H., CHEN, M.S. and CHANG, W.P. (2001). "Lenticular
3260 opacities in populations exposed to chronic low-dose-rate gamma radiation from
3261 radiocontaminated buildings in Taiwan," *Radiat. Res.* **156**(1), 71-77.
- 3262 CHEW, E.Y., KIM, J., SPERDUTO, R.D., DATILES, M.B., III, COLEMAN, H.R.,
3263 THOMPSON, D.J.S., MILTON, R.C., CLAYTON, J.A., HUBBARD, L.D., DANIS, R.P.
3264 and FERRIS, F.L., III (2010). "Evaluation of the Age-Related Eye Disease Study clinical
3265 lens grading system AREDS Report No. 31," *Ophthalmology* **117**(11), 2112-2119.
- 3266 CHODICK, G., BEKIROGLU, N., HAUPTMANN, M., ALEXANDER, B.H., FREEDMAN,
3267 D.M., DOODY, M.M., CHEUNG, L.C., SIMON, S.L., WEINSTOCK, R.M., BOUVILLE,
3268 A. and SIGURDSON, A.J. (2008). "Risk of cataract after exposure to low doses of ionizing
3269 radiation: A 20-year prospective cohort study among US radiologic technologists," *Am. J.*
3270 *Epidemiol.* **168**(6), 620-630.
- 3271 CHOSHI, K., TAKAKU, I., MISHIMA, H., TAKASE, T., NERIISHI, S., FINCH, S.C. and
3272 OTAKE, M. (1983). "Ophthalmologic changes related to radiation exposure and age in
3273 Adult Health Study sample, Hiroshima and Nagasaki," *Radiat. Res.* **96**(3), 560-579.
- 3274 CHUMAK, V.V., WORGUL, B.V., KUNDIYEV, Y.I., SEGIYENKO, N.M., VITTE, P.M.,
3275 MEDVEDOVSKY, C., BAKHANOVA, E.V., JUNK, A.K., KYRYCHENKO, O.Y.,
3276 MUSIJACHENKO, N.V., SHOLOM, S.V., SHYLO, S.A., VITTE, O.P., XU, S., XUE, X.
3277 and SHORE, R.E. (2007). "Dosimetry for a study of low-dose radiation cataracts among
3278 Chernobyl clean-up workers," *Radiat. Res.* **167**(5), 606-614.
- 3279 CHYLACK, L.T., LESKE, C., SPERDUTO, R., SPERDUTO, R., KHU, P. and MCCARTHY,
3280 D. (1988). "Lens opacities classification system," *Arch. Ophthalmol.* **106**(3), 330-334.
- 3281 CHYLACK, L.T., LESKE, C., MCCARTHY, D., KHU, P., KASHIWAGI, T. and SPERDUTO,
3282 R. (1989). "Lens opacities classification system II (LOCS II)," *Arch. Ophthalmol.* **107**(7),
3283 991-997.

- 3284 CHYLACK, L.T. JR., WOLFE, J.K., SINGER, D.M., LESKE, M.C., BULLIMORE, M.A.,
3285 BAILEY, I.L., FRIEND, J., MCCARTHY, D. and WU, S.-Y. (1993). "The Lens Opacities
3286 Classification System III," Arch. Ophthalmol. **111**(6), 831-836.
- 3287 CHYLACK, L.T. JR., PETERSON, L.E., FEIVESON, A.H., WEAR, M.L., MANUEL, F.K.,
3288 TUNG, W.H., HARDY, D.S., MARAK, L.J. and CUCINOTTA, F.A. (2009). "NASA study
3289 of cataracts in astronauts (NASCA). Report 1: Cross-sectional study of the relationship of
3290 exposure to space radiation and risk of lens opacity," Radiat. Res. **172**(1), 10-20.
- 3291 CIRAJ-BJELAC, O., REHANI, M.M., SIM, K.H., LIEW, H.B., VANO, E. and KLEIMAN, N.J.
3292 (2010). "Risk for radiation-induced cataract for staff in interventional cardiology: Is there
3293 reason for concern?" Catheter Cardiovasc. Interv. **76**(6), 826-834.
- 3294 CNSC (2013). Canadian Nuclear Safety Commission. Proposals to Amend the Radiation
3295 Protection Regulations. Discussion Paper DIS-13-01. (Canadian Nuclear Safety
3296 Commission, Ottawa, Ontario, Canada).
- 3297 COLLMAN, G.W., SHORE, D.L., SHY, C.M., CHECKOWAY, H. and LURIA, A.S. (1988).
3298 "Sunlight and other risk factors for cataracts: An epidemiologic study," American J. Public
3299 Health **78**(11), 1459-1462.
- 3300 COMSG (2007). Collaborative Ocular Melanoma Study Group. "Incidence of cataract and
3301 outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the
3302 collaborative ocular melanoma study," COMS Report No. 27, Ophthalmol. **114**(7), 1363-
3303 1371.
- 3304 COOK, C.A. and KORETZ, J.F. (1998). "Methods to obtain quantitative parametric descriptions
3305 of the optical surfaces of the human crystalline lens from Scheimpflug slit-lamp images. I.
3306 Image processing methods," J. Opt. Soc. Am. A **15**(6), 1473-1485.
- 3307 COOPER, J.R. (2009). Application of the 2007 recommendation of the ICRP to the UK: Advice
3308 from the Health Protection Agency, Vol. 12, Health Protection Agency.
- 3309 COX, J.D. and ANG, K.K. (2010). Radiation Oncology: Rationale, Technique, Results, 9th
3310 Edition (Elsevier, Philadelphia).
- 3311 CRUICKSHANKS, K.J., KLEIN, B.E. and KLEIN, R. (1992). "Ultraviolet light exposure and
3312 lens opacities in the Beaver Dam eye study," Am. J. Public Health **82**(12), 1658-1662.

- 3313 CUCINOTTA, F.A., MANUEL, F.K., JONES, J., ISZARD, G., MURREY, J., DJOJONEGRO,
3314 B. and WEAR, M. (2001). "Space radiation and cataracts in astronauts," *Radiat. Res.* **156**(5
3315 Pt 1), 460-466.
- 3316 CUMMING, R. and MITCHELL, P. (1997). "Hormone replacement therapy, reproductive
3317 factors, and cataract. The Blue Mountain Eye Study," *Am. J. Epidemiol.* **145**(3), 242-249.
- 3318 DATILES, M.B., III and ANSARI, R.R. (2006). "Clinical evaluation of cataracts," Chapter 73B
3319 in *Duane's Ophthalmology* on CD-ROM (Lippincott Williams and Wilkins, Philadelphia,
3320 Pennsylvania).
- 3321 DATILES, M.B., MAGNO, B.V. and FREIDLIN, V. (1995). "Study of nuclear cataract
3322 progression using the National Eye Institute Scheimpflug system," *Br. J. Ophthalmol.* **79**(6),
3323 527-534.
- 3324 DATILES, M.B., ANSARI, R.R., SUH, K.I., VITALE, S., REED, G.F., ZIGLER, J.S. and
3325 FERRIS, F.L. (2008). "Clinical detection of early pre-cataractous lens protein changes using
3326 dynamic light scattering," *Arch. Ophthalmol.* **126**(12), 1687-1693.
- 3327 DAUER, L.T., THORNTON, R.H., SOLOMON, S.B. and ST. GERMAIN, J. (2010).
3328 "Unprotected operator eye lens doses in oncologic interventional radiology are clinically
3329 significant: Estimation from patient kerma-area-product data," *J. Vasc. Interv. Radiol.*
3330 **21**(12), 1859-1869.
- 3331 DAUER, L.T. (2014). "Exposed medical staff: Challenges, available tools, and opportunities for
3332 improvement," *Health Phys.* **106**(2), 217-224.
- 3333 DAURES, J., GOURIOU, J. and BORDY, J.M. (2011). "Monte Carlo determination of the
3334 conversion coefficients $H_p(3)/K_a$ in a right cylinder phantom with 'PENELope' code.
3335 Comparison with 'MCNP' simulations," *Radiat. Prot. Dosim.* **144**(1-4), 37-42.
- 3336 DAY, R., GORIN, M.B. and ELLER, A.W. (1995). "Prevalence of lens changes in Ukrainian
3337 children residing around Chernobyl," *Health Phys.* **68**(5), 632-642.
- 3338 DE WAARD, P.W.T., IJSPEERT, J.K., VAN DEN BERG, J.T.P. and DE JONG, P.T.V.M.
3339 (1992). "Intraocular light scattering in age-related cataracts," *Inv. Ophthalmol. Vis. Sci.*
3340 **33**(3), 618-625.
- 3341 DEEG, H.J., FLOURNOY, N., SULLIVAN, K.M., SHEEHAN, K., BUCKNER, C.D.,
3342 SANDERS, J.E., STORB, R., WITHERSPOON, R.P. and THOMAS, E.D. (1984).

- 3343 “Cataracts after total body irradiation and marrow transplantation: A sparing effect of dose
3344 fractionation,” *Int. J. Radiat. Oncol. Biol. Phys.* **10**(7), 957-964.
- 3345 DHIR, S., JOSHI, A. and BANERJEE, A. (1982). “Radiation retinopathy in diabetes mellitus,”
3346 *Acta Radiol. Oncol.* **21**(2), 111-113.
- 3347 DI PAOLA, M., BIANCHI, M. and BAARLI, J. (1978). “Lens opacification in mice exposed to
3348 14-MeV neutrons,” *Radiat. Res.* **73**(2), 340-350.
- 3349 DI PAOLA, M., COPPOLA, M., BAARLI, T., BIANCHI, M. and SULLIVAN, A.H. (1980).
3350 “Biological responses to various neutron energies from 1 to 600 MeV. A II. Lens
3351 opacification in mice,” *Radiat. Res.* **84**(3), 453-461.
- 3352 DOE (2008). U.S. Department of Energy. “Occupational Radiation Protection,” 10 CFR 835
3353 (revised January 1) (U.S. Government Printing Office, Washington).
- 3354 DOMIENIK, J., BRODECKI, M., CARINOU, E., DONADILLE, L., JANKOWSKI, J.,
3355 KOUKORAVA, C., KRIM, S., NIKODEMOVA, D., RUIZ-LOPEZ, N., SANS-MERCE,
3356 M., STRUELENS, L. and VANHAVERE, F. (2011). “Extremity and eye lens doses in
3357 interventional radiology and cardiology procedures: First results of the ORAMED project,”
3358 *Radiat. Prot. Dosimetry* **144**(1-4), 442-447.
- 3359 DUKE-ELDER, S. (1962). *System of Ophthalmology*, pp. 233-237 (Kimpton, London).
- 3360 DURAN, A., HIAN, S.K., MILLER, D.L., LE HERON, J., PADOVANI, R. and VANO, E.
3361 (2013). “Recommendations for occupational radiation protection in interventional
3362 cardiology. Endorsed by the Asian Pacific Society of Interventional Cardiology, the
3363 European Association of Percutaneous Cardiovascular Interventions, the Latin American
3364 Society of Interventional Cardiology, and the Society for Cardiovascular Angiography and
3365 Interventions,” *Catheter Cardiovasc. Interv.* **82**(1), 29-42.
- 3366 DURKIN, S.R., ROOS, D., HIGGS, B., CASSON, R.J. and SELVA, D. (2007). “Ophthalmic
3367 and adnexal complications of radiotherapy,” *Acta Ophthalmol. Scand.* **85**(3), 240-250.
- 3368 DYNLACHT, J.R., VALLURI, S., GARRETT, J. MENDONCA, M.S., LOPEZ, J.T.,
3369 CAPERELL-GRANT, A. and BIGSBY, R.M. (2011). “Age and hormonal status as
3370 determinants of cataractogenesis induced by ionizing radiation. I. Densely ionizing (high-
3371 LET) radiation,” *Radiat. Res.* **175**(1), 37-43.

- 3372 DYNLACHT, J.R. (2013). “The role of age, sex and steroid sex hormones in radiation
3373 cataractogenesis,” *Radiat. Res.* **180**(6), 559-566.
- 3374 EPRI (2013). Electric Power Research Institute. Lens of Eye Dose Limit Changes, Technical
3375 Report 3002000486 (Electric Power Research Institute, Palo Alto, California).
- 3376 EPRI (2014). Electric Power Research Institute. Epidemiology and Mechanistic Effects of
3377 Radiation on the Lens of the Eye: Review and Scientific Appraisal of the Literature, EPRI
3378 Publication Number 3002003162,
3379 <http://www.epri.com/abstracts/Pages/ProductAbstract.aspx?productId=000000003002003162>
3380 [2](http://www.epri.com/abstracts/Pages/ProductAbstract.aspx?productId=000000003002003162) (accessed December 22, 2015) (Electric Power Research Institute, Palo Alto, California).
- 3381 EPRI (2015). Electric Power Research Institute. Guidance for Improved Lens Dose Monitoring
3382 and Protection at Nuclear Power Plants, Technical Report (in press) (Electric Power
3383 Research Institute, Palo Alto, California).
- 3384 ESHAGHIAN, J. and STREETEN, B.W. (1980). “Human posterior subcapsular cataract. An
3385 ultrastructural study of the posteriorly migrating cells,” *Arch. Ophthalmol.* **98**(1; doi:
3386 10.1001/archophth.1980.01020030136016), 134-143.
- 3387 EURADOS (2014). European Radiation Dosimetry Group. Visions for Radiation Dosimetry over
3388 the Next Two Decades – Strategic Research Agenda of the European Radiation Dosimetry
3389 Group, EURADOS Report 2014-01,
3390 http://www.eurados.org/~media/Files/Eurados/documents/EURADOS_Report_2014_01.pdf
3391 [f](http://www.eurados.org/~media/Files/Eurados/documents/EURADOS_Report_2014_01.pdf) (accessed November 29, 2014) (Braunschweig, Germany).
- 3392 FAJARDO, L.F., BERTHRONG, M. and ANDERSON, R.E. (2001). “Eye and its adnexa,” in
3393 Radiation Pathology (Oxford University Press, New York).
- 3394 FARAH, J., STRUELENS, L., DABIN, J., KOUKORAVA, C., DONADILLE, L., JACOB, S.,
3395 SCHNIEIZER, M., AUVINEN, A., VANHAVERE, F. and CLAIRAND, I. (2013). “A
3396 correlation study of eye lens doses and personal dose equivalent for interventional
3397 cardiologists,” *Rad. Prot. Dosim.* **157**(4), 561-569.
- 3398 FAULKNER, K. and MARSHALL, N.W. (1993). “The relationship of effective dose to
3399 personnel and monitor reading for simulated fluoroscopic irradiation conditions,” *Health*
3400 *Phys.* **64**(5), 502-508.

- 3401 FIFE, K., MILAN, S., WESTBROOK, K., POWLES, R. and TAIT, D. (1994). "Risk factors for
3402 requiring cataract surgery following total body irradiation," *Radiotherapy Oncol.* **33**(2), 93-
3403 98.
- 3404 FINGER, P.T. (2009). "Radiation therapy for orbital tumors: Concepts, current use, and
3405 ophthalmic radiation side effects," *Surv. Ophthalmol.* **54**(5), 545-568.
- 3406 FREEMAN, E.E., MUNOZ, B., SCHEIN, O.D. and WEST, S.K. (2001). "Hormone replacement
3407 therapy and lens opacities: The Salisbury Eye Evaluation project," *Arch. Ophthalmol.*
3408 **119**(11), 1687-1692.
- 3409 FREEMAN, E.E., MUNOZ, B., SCHEIN, O.D. and WEST, S.K. (2004). "Incidence and
3410 progression of lens opacities: Effect of hormone replacement therapy and reproductive
3411 factors," *Epidemiology* **15**(4), 451-457.
- 3412 FUJIMICHI, Y. and HAMADA, N. (2014). "Ionizing irradiation not only inactivates clonogenic
3413 potential in primary human diploid lens epithelial cells but also stimulates cell proliferation
3414 in a subset of this population," *PLoS ONE* 9(5; DOI: 10.1371/journal.pone.0098154).
- 3415 GALSTYAN, I., GUSHKOVA, A. and NADEJINA, N. (2007). "Consequences of radiation
3416 exposure during the accident at the Chernobyl Nuclear Power Plant (analysis of data by the
3417 clinical department of the State Research Centre-Institute of Biophysics, Moscow and the
3418 Ukranian Research Centre of Radiation Medicine," *Medical Radiol. Radiat. Safety* **54**(4), 5-
3419 13 (In Russian).
- 3420 GAO, Y. and SPRAY, D.C. (1998). "Structural changes in lenses of mice lacking the gap
3421 junction protein connexin43," *Invest. Ophthalmol. Vis. Sci.* **39**(7), 1198-1209.
- 3422 GERSHENZON, A. and ROBMAN, L.D. (1999). "New software for lens retro-illumination
3423 digital image analysis," *Aust. New Zeal. J. Ophthalmol.* **27**(xx), 170-172.
- 3424 GOLDSTEIN, L.E., MUFFAT, J.A., CHERRY, R.A., MOIR, R.D., ERICSSON, M.H.,
3425 HUANG, X., MAVROS, C., COCCIA, J.A., FAGET, K.Y., FITCH, K.A., MASTERS,
3426 C.L., TANZI, R.E., CHYLACK, JR., L.T. and BUSH, A.I. (2003). "Cytosolic β -amyloid
3427 deposition and supranuclear cataracts in lenses from people with Alzheimer's disease,"
3428 *Lancet* **361**(9365), 1258-1265.
- 3429 GORDON, K.B., CHAR, D.H. and SAGERMAN, R.H. (1995). "Late effects of radiation on the
3430 eye and ocular adnexa," *Int. J. Radiat. Oncol. Biol. Phys.* **31**(5), 1123-1139.

- 3431 GRAGOUDAS, E.S., EGAN, K.M., WALSH, S.M., REGAN, S., MUNZENRIDER, J.E. and
3432 TARATUTA, V. (1995). “Lens changes after proton beam irradiation for uveal melanoma,”
3433 Am. J. Ophthalmol. **119**(2), 157-164.
- 3434 GRAW, J., WELZL, G., AHMAD, N., KLOPP, N., HEIER, M., WULFF, A., HEINRICH, J.,
3435 DÖRING, A., KARRASCH, S., NOWAK, D., SCHULZ, H., RATHMANN, W., ILLIG, T.,
3436 PETERS, A., HOLLE, R., MEISINGER, C. and WICHMANN, H.E. (2011). “The KORA
3437 eye study: A population-based study on eye diseases in southern Germany (KORA F4),”
3438 Invest. Ophthalmol. Vis. Sci. **52**(10), 7778-7786.
- 3439 GUALDRINI, G., MARIOTTI, F., WACH, S., BILSKI, P., DENOZIERE, M., DAURES, J.,
3440 BORDY, J.M., FERRARI, P., MONTEVENTI, F. and FANTUZZI, E. (2011). “Eye lens
3441 dosimetry: Task 2 within the ORAMED project,” Radiat. Prot. Dosim. **144**(1-4), 473-477.
- 3442 GUPTA, M., RAM, J., JAIN, A., SUKHIJA, J. and CHAUDHARY, M. (2013). “Correlation of
3443 nuclear density using the Lens Opacity Classification System III versus Scheimpflug
3444 imaging with phacoemulsification parameters,” J. Cataract Refract. Surg. **39**(12), 1818-
3445 1823.
- 3446 HALL, E.J. and GIACCIA, A.J. (2012). Radiobiology for the Radiologist, Seventh Edition
3447 (Lippincott Williams & Wilkins, Philadelphia).
- 3448 HALL, E.J., BRENNER, D.J., WORGUL, B. and SMILENOV, L. (2005). “Genetic
3449 susceptibility to radiation,” Adv. Space Res. **35**(2), 249–253.
- 3450 HALL, E.J., WORGUL, B.V., SMILENOV, L., ELLISTON, C.D. and BRENNER, D.J. (2006).
3451 “The relative biological effectiveness of densely ionizing heavy-ion radiation for inducing
3452 ocular cataracts in wild type versus mice heterozygous for ATM gene,” Radiat. Environ.
3453 Biophys. **45**(2; doi: 10.1007/s00411-006-0052-5), 99-104.
- 3454 HALL, M.D., SCHULTHEISS, T.E., SMITH, D.D., NGUYEN, K.H. and WONG, J.Y.C.
3455 (2015). “Dose response for radiation cataractogenesis: A meta-regression of hematopoietic
3456 stem cell transplantation regimens,” Intl. J. Radiat. Oncol. Biol. Phys. **91**(1), 22-29.
- 3457 HALL, P., GRANATH, F., LUNDELL, M., OLSSON, K. and HOLM, L.E. (1999). “Lenticular
3458 opacities in individuals exposed to ionizing radiation in infancy,” Radiat. Res. **152**(2), 190-
3459 195.

- 3460 HAMADA, N. and FUJIMICHI, Y. (2014). "Classification of radiation effects for dose
3461 limitation purposes: History, current situation and future prospects," *J. Radiat. Res.* **55**(doi:
3462 10.1093/jrr/rru019), 629-640.
- 3463 HAMADA, N., FUJIMICHI, Y., IWASAKI, T., FUJII, N., FURUHASHI, M., KUBO, E.,
3464 MINAMINO, T., NOMURA, T. and SATO, H. (2014). "Emerging issues in radiogenic
3465 cataracts and cardiovascular disease," *J. Radiat. Res.* **55**(doi: 10.1093/jrr/rru036), 831-846.
- 3466 HAMADA, N. and FUJIMICHI, Y. (2015). "Role of carcinogenesis related mechanisms in
3467 cataractogenesis and its implications for ionizing radiation cataractogenesis," *Cancer Letters*
3468 (doi: 10.1016/j.canlet.2015.02.017).
- 3469 HAMMER, G.P., SCHEIDEMANN-WESP, U., SAMKANGE-ZEEB, F., WICKE, H.,
3470 NERIISHI, K. and BLETTNER, M. (2013). "Occupational exposure to low doses of
3471 ionizing radiation and cataract development: A systematic literature review and perspectives
3472 on future studies," *Radiat. Environ. Biophys.* **52**(3), 303-319.
- 3473 HARDING, J.J. and CRABBE, M.J.C. (1984). "The Lens: Development, Proteins, Metabolism
3474 and Cataract," Chapter 3, pp. 207-492, in *The Eye*, Vol. 1B, Ed. H. Davson (Academic
3475 Press, London).
- 3476 HARDING, J.J. and VAN HEYNINGEN, R.B. (1989). "Beer, cigarettes and military work as
3477 risk factors for cataract," *Dev. Ophthalmol.* **17**, 13-16.
- 3478 HASANOVA, N., KUBO, E., KUMAMOTO, Y., TAKAMURA, Y. and AKAGI, Y. (2009).
3479 "Age-related cataracts and Prdx6: Correlation between severity of lens opacity, age, and the
3480 level of Prdx6 expression," *Br. J. Ophthalmol.* **93**(8; doi: 10.1136/bjo.2008.152272), 1081-
3481 1084.
- 3482 HASHEMI, H., JABBARVAND, M. and MOHAMMADPOUR, M. (2008). "Bilateral electric
3483 cataracts: Clinicopathologic report," *J. Cataract Refract. Surg.* **34**(8), 1409-1412.
- 3484 HEIDBUCHEL, H., WITTKAMPF, F.H., VANO, E., ERNST, S., SCHILLING, R., PICANO,
3485 E. and MONT, L. (2014). "Practical ways to reduce radiation dose for patients and staff
3486 during device implantations and electrophysiological procedures," *Europace* eut409.
- 3487 HENDERSON, K.H., LU, J.K., STRAUSS, K.J., TREVES, S.T. and ROCKOFF, M.A. (1994).
3488 "Radiation exposure of anesthesiologists," *J. Clin. Anesth.* **6**(1), 37-41.

- 3489 HENDERSON, M.A., VALLURI, S., DESROSIERS, C., LOPEZ, J.T., BATUELLO, C.N.,
3490 CAPERELL-GRANT, A., MENDONCA, M.S., POWERS, E-M., BIGSBY, R.M. and
3491 DYNLACHT, J.R. (2009). "Effect of gender on radiation-induced cataractogenesis," *Radiat.*
3492 *Res.* **172**(1), 129-133.
- 3493 HENDERSON, M.A., VALLURI, S., DESROSIERS, C., LOPEZ, J.T., BATUELLO, C.N.,
3494 CAPERELL-GRANT, A., MENDONCA, M.S., POWERS, E-M., BIGSBY, R.M. and
3495 DYNLACHT, J.R. (2010). "Effects of estrogen and gender on cataractogenesis induced by
3496 high linear energy transfer radiation," *Radiat. Res.* **173**(2), 191-196.
- 3497 HENK, J.M., WHITELOCKE, R.A.F., WARRINGTON, A.P. and BESSELL, E.M. (1993).
3498 "Radiation dose to the lens and cataract formation," *Int. J. Radiat. Oncol. Biol. Phys.* **25**(5),
3499 815-820.
- 3500 HEWITT, G., JURK, D., MARQUES, F., CORREIA-MELO, C., HARDY, T., GACKOWSKA,
3501 A., ANDERSON, R., TASCHUK, M., MANN, J. and PASSOS, J. (2012). "Telomeres are
3502 favoured targets of a persistent DNA damage response in ageing and stress-induced
3503 senescence," *Nat. Commun.* **3**(708; DOI: 10.1038/ncomms1708).
- 3504 HILLER, R., SPERDUTO, R.D. and EDERER, F. (1986). "Epidemiologic associations with
3505 nuclear, cortical and posterior subcapsular cataracts," *Am. J. Epidemiol.* **124**(6), 916-925.
- 3506 HOCKWIN, O., (1994-1995). "Cataract classification," *Doc. Ophthalmol.* **88**(3-4), 263-275.
- 3507 HOCKWIN, O., DRAGONMIRESCU, V. and LASER, H. (1982). "Measurements of lens
3508 transparency or its disturbances by densitometric image analysis of Scheimpflug
3509 photographs," *Graefe's Arch. Clin. Exp. Ophthalmol.* **219**(6), 255-262.
- 3510 HORWATH-WINTER, J., SCHNEIDER, M.R., WACKERNAGEL, W., RABENSTEINER, D.,
3511 BOLDIN, I., HALLER-SCHOBBER, E-M. and LANGMANN, G. (2013). "Influence of
3512 single-fraction Gamma-Knife radiosurgery on ocular surface and tear function in choroidal
3513 melanoma patients," *Br. J. Ophthalmol.* **97**(4), 466-470.
- 3514 HOURIHAN, F., MITCHELL, P. and CUMMING, R.G. (1999). "Possible associations between
3515 computed tomography scan and cataract: The Blue Mountains Eye Study," *Amer. J. Public*
3516 *Hea.* **89**(12; doi: 10.2105/AJPH.89.12.1864), 1864-1866.

- 3517 IAEA (2004). International Atomic Energy Agency. Methods for Assessing Occupational
3518 Radiation Doses Due to Intakes of Radionuclides, IAEA Safety Report Series No. 37
3519 (International Atomic Energy Agency, Vienna, Austria).
- 3520 IAEA (2011). International Atomic Energy Agency. Radiation Protection and Safety of
3521 Radiation Sources: International Basic Safety Standards: General Safety Requirements, Part
3522 3. Interim Edition, (International Atomic Energy Agency, Vienna, Austria).
- 3523 IAEA (2012). International Atomic Energy Agency. Report of the Technical Meeting: The New
3524 Dose Limit for the Lens of the Eye – Implications and Implementation, Vienna, 2-4 October
3525 (International Atomic Energy Agency, Vienna, Austria).
- 3526 IAEA (2013). International Atomic Energy Agency. Implications for Occupational Radiation
3527 Protection of the New Dose Limit for the Lens of the Eye – Interim Guidance for Use and
3528 Comment, IAEA-TECDOC-1731 (International Atomic Energy Agency, Vienna, Austria).
- 3529 IAEA (2014a). International Atomic Energy Agency. “IAEA cataract study,”
3530 <https://rpop.iaea.org/rpop/rpop/content/news/reliid-cataract-study.htm> (accessed June 16,
3531 2014) (International Atomic Energy Agency, Vienna, Austria).
- 3532 IAEA (2014b). International Atomic Energy Agency. “What is RELID,”
3533 <https://rpop.iaea.org/RPOP/RPoP/Content/News/des-reliid.htm> (accessed June 16, 2014)
3534 (International Atomic Energy Agency, Vienna, Austria).
- 3535 IAEA (2014c). International Atomic Energy Agency. “Radiation and cataract: Patient
3536 protection,”
3537 https://rpop.iaea.org/RPOP/RPoP/Content/InformationFor/HealthProfessionals/6_OtherClinicalSpecialities/radiation-cataract/radiation-cataract-patient-protection.htm (accessed June
3538 16, 2014) (International Atomic Energy Agency, Vienna, Austria).
- 3539
3540 IAEA (2014d). International Atomic Energy Agency. “The Statute of the IAEA,”
3541 <http://www.iaea.org/About/statute.html#A1.2> (accessed June 26, 2014) (International
3542 Atomic Energy Agency, Vienna, Austria).
- 3543 IAEA (2014e). International Atomic Energy Agency. The Information System on Occupational
3544 Exposure in Medicine, Industry and Research (ISEMIR): Industrial Radiography, IAEA-
3545 TECDOC-1747 (International Atomic Energy Agency, Vienna, Austria).

- 3546 ICRP (1969). International Commission on Radiological Protection. Radiosensitivity and Spatial
3547 Distribution of Dose, ICRP Publication 14 (Pergammon Press, New York).
- 3548 ICRP (1977). International Commission on Radiological Protection. Recommendations of the
3549 ICRP, ICRP Publication 26, Ann. ICRP **1**(3) (Elsevier, New York).
- 3550 ICRP (1984). International Commission on Radiological Protection. Non-stochastic Effects of
3551 Irradiation, ICRP Publication 41, Ann. ICRP **14**(3) (Elsevier, New York).
- 3552 ICRP (1987). International Commission on Radiological Protection. Radiation Dose to Patients
3553 from Radiopharmaceuticals, ICRP Publication 53, Ann. ICRP **18**(1–4) (Elsevier, New
3554 York).
- 3555 ICRP (1989a). International Commission on Radiological Protection. Optimization and
3556 Decision-Making in Radiological Protection, ICRP Publication 55, Ann. ICRP **20**(1)
3557 (Elsevier, New York).
- 3558 ICRP (1989b). International Commission on Radiological Protection. RBE for Deterministic
3559 Effects, ICRP Publication 58, Ann. ICRP **20**(4) (Elsevier, New York).
- 3560 ICRP (1991a). International Commission on Radiological Protection. 1990 Recommendations of
3561 the International Commission on Radiological Protection, ICRP Publication 60, Ann. ICRP
3562 **21**(1–3) (Elsevier, New York).
- 3563 ICRP (1991b). International Commission on Radiological Protection. Radiation Dose to Patients
3564 from Radiopharmaceuticals. Addendum 1 to ICRP Publication 53, in: Radiological
3565 Protection in Biomedical Research, ICRP Publication 62, Ann. ICRP **22**(3) (Elsevier, New
3566 York).
- 3567 ICRP (1998). International Commission on Radiological Protection. Radiation Dose to Patients
3568 from Radiopharmaceuticals (Addendum 2 to ICRP Publication 53), ICRP Publication 80,
3569 Ann. ICRP **28**(3) (Elsevier, New York).
- 3570 ICRP (1999). International Commission on Radiological Protection. Genetic Susceptibility to
3571 Cancer, ICRP Publication 79, Ann. ICRP **28**(1-157) (Elsevier, New York).
- 3572 ICRP (2000). International Commission on Radiological Protection. Radiopathology of Skin and
3573 Eye and Radiation Risk, ICRP Publication 85, Ann. ICRP **30**(2) (Elsevier, New York).

- 3574 ICRP (2003). International Commission on Radiological Protection. Relative Biological
3575 Effectiveness (RBE), Quality Factor (Q), and Radiation Weighting Factor (w_R), ICRP
3576 Publication 92, Ann. ICRP **33**(4) (Elsevier, New York).
- 3577 ICRP (2007). International Commission on Radiological Protection. The 2007
3578 Recommendations of the International Commission on Radiological Protection, ICRP
3579 Publication 103, Ann. ICRP **37**(2-4) (Elsevier, New York).
- 3580 ICRP (2008). International Commission on Radiological Protection. Radiation Dose to Patients
3581 from Radiopharmaceuticals. Addendum 3 to ICRP Publication 53, in: Radiological
3582 Protection in Biomedical Research, ICRP Publication 106, Ann. ICRP **38**(1-2) (Elsevier,
3583 New York).
- 3584 ICRP (2009). International Commission on Radiological Protection. Education and Training in
3585 Radiological Protection for Diagnostic and Interventional Procedures, ICRP Publication
3586 113, Ann. ICRP **39**(5) (Elsevier, New York).
- 3587 ICRP (2010). International Commission on Radiological Protection. Conversion Coefficients for
3588 Radiological Protection Quantities for External Radiation Exposures, ICRP Publication 116,
3589 Ann. ICRP **40**(2-5) (Elsevier, New York).
- 3590 ICRP (2012). International Commission on Radiological Protection. ICRP Statement on Tissue
3591 Reactions / Early and Late Effects of Radiation in Normal Tissues and Organs – Threshold
3592 Doses for Tissue Reactions in a Radiation Protection Context, ICRP Publication 118, Ann.
3593 ICRP **41**(1-2) (Elsevier, New York).
- 3594 ICRP (2013). International Commission on Radiological Protection. Radiological Protection in
3595 Paediatric Diagnostic and Interventional Radiology, ICRP Publication 121, Ann. ICRP **42**(2)
3596 (Elsevier, New York).
- 3597 ICRU (1993a). International Commission on Radiation Units and Measurements. Prescribing,
3598 Recording, and Reporting Photon Beam Therapy, ICRU Report 50, J. ICRU (Oxford
3599 University Press, Oxford, United Kingdom).
- 3600 ICRU (1993b). International Commission on Radiation Units and Measurements. Quantities and
3601 Units in Radiation Protection Dosimetry, ICRU Report 51, J. ICRU (Oxford University
3602 Press, Oxford, United Kingdom).

- 3603 ICRU (1999). International Commission on Radiation Units and Measurements. Prescribing,
3604 Recording, and Reporting Photon Beam Therapy (supplement to ICRU Report 50), ICRU
3605 Report 62, J. ICRU (Oxford University Press, Oxford, United Kingdom).
- 3606 ICRU (2002). International Commission on Radiation Units and Measurements. Absorbed-Dose
3607 Specification in Nuclear Medicine, ICRU Report 67, J. ICRU **2**(1) (Oxford University Press,
3608 Oxford, United Kingdom).
- 3609 JAIN, R. and GREWAL, S.P.S. (2009). "Pentacam: Principle and clinical applications," J. Curr.
3610 Glaucoma Pract. **3**(2), 20-32.
- 3611 JAVADI, M. and ZAREI-GHANA VATI, S. (2008). "Cataracts in diabetic patients: A review
3612 article," J. Ophthalmic Vis. Res. **3**(1), 52-65.
- 3613 JEGANATHAN, V.S.E., WANG, J.J. and WONG, T.Y. (2008). "Ocular associations of diabetes
3614 other than diabetic retinopathy," Diabetes Care **31**(9), 1905-1912.
- 3615 JEGANATHAN, V.S.E., WIRTH, A. and MACMANUS, M.P. (2011). "Ocular risks from
3616 orbital and periorbital radiation therapy: A critical review," Int. J. Radiat. Oncol. Biol. Phys.
3617 **79**(3), 650-659.
- 3618 JI, Y., CAI, L., ZHENG, T., YE, H., RONG, X., RAO, J. and LU, Y. (2015). "The mechanism of
3619 UVB irradiation induced-apoptosis in cataract," Mol. Cell Biochem. **401**(1-2; DOI:
3620 10.1007/s11010-014-2294-x), 87-95.
- 3621 JIANG, G.L., TUCKER, S.L., GUTTENBERGER, R., PETERS, L.J., MORRISON, W.H.,
3622 GARDEN, A.S., HA, C.S. and ANG, K.K. (1994). "Radiation-induced injury to the visual
3623 pathway," Radiotherapy & Oncol. **30**(1), 17-25.
- 3624 JONES, C.E., ATCHISON, D.A., MEDER, R. and POPE, J.M. (2005). "Refractive index
3625 distribution and optical properties of the isolated human lens measured using magnetic
3626 resonance imaging (MRI)," Vision Res. **45**(18; doi: 10.1016/j.visres.2005.03.008), 2352-
3627 2366.
- 3628 JOSE, J.G. (1978). "The role of DNA damage, its repair and its misrepair in the etiology of
3629 cataract: A review," Ophthalmol. Res. **10**(1), 52-62.
- 3630 JOSE, J.G. and AINSWORTH, E.J. (1983). "Cataract production in mice by heavy charged
3631 argon, neon, and carbon particles," Radiat. Res. **94**(3), 513-528.

- 3632 KAL, H.B. and VAN KEMPEN-HARTEVELD, M.L. (2009). "Induction of severe cataract and
3633 late renal dysfunction following total body irradiation: Dose-effect relationships,"
3634 *Anticancer Res.* **29**(8), 3305-3309.
- 3635 KARP, L.A., STREETEN, B.W. and COGAN, D.G. (1979). "Radiation-induced atrophy of the
3636 Meibomian glands," *Arch. Ophthalmol.* **97**(2), 303-305.
- 3637 KASSOFF, A., KASSOFF, J. and MEHU, M. (2001). "The age-related eye disease study
3638 (AREDS) system for classifying cataracts from photographs: AREDS Report No. 4," *Am. J.*
3639 *Ophthalmol.* **131**(2; doi: 10.1016/S0002-9394(00)00732-7), 167-175.
- 3640 KASTHURIRAGAN, S., MARKWELL, E.L., ATCHINSON, D.A. and POPE, J.M. (2011).
3641 "MRI study of the changes in crystalline lens shape with accommodation and aging in
3642 humans," *J. of Vision* **11**(3), 19, 1-16.
- 3643 KENNERDELL, J.S., JOHNSON, B.L. and DEUTSCH, H.M. (1992). "Radiation treatment of
3644 orbital lymphoid hyperplasia," *Ophthalmol.* **86**(5), 942-947.
- 3645 KESAVACHANDRAN, C.N., HAAMANN, F. and NIENHAUS, A. (2012). "Radiation
3646 exposure of eyes, thyroid gland and hands in orthopaedic staff: A systematic review,"
3647 *European J. Med. Res.* **17**(<http://www.eurjmedres.com/content/17/1/28>), 28-37.
- 3648 KIM, K.P., MILLER, D.L., BALTER, S., KLENERMAN, R.A., LINET, M.S., KWON, D. and
3649 SIMON, S.L. (2008). "Occupational radiation doses to operators performing cardiac
3650 catheterization procedures," *Health Phys.* **94**(3), 211-227.
- 3651 KIM, K.P., MILLER, D.L., BERRINGTON DE GONZALEZ, A., BALTER, S.,
3652 KLENERMAN, R.A., OSTROUMOVA, E. SIMON, S.L. and LINET, M.S. (2012).
3653 "Occupational radiation doses to operators performing fluoroscopically-guided procedures,"
3654 *Health Phys.* **103**(1), 80.
- 3655 KIRKWOOD, B.J., HENDICOTT, P.L., READ, S.A. and PESUDOVA, K. (2009).
3656 "Repeatability and validity of lens densitometry measured with Scheimpflug imaging," *J.*
3657 *Cataract Refract. Surg.* **35**(7; doi: 10.1016/j.jcrs.2009.03.017), 1210-1215.
- 3658 KLEIMAN, N.J. and SPECTOR, A. (1993). "DNA single strand breaks in human lens epithelial
3659 cells from patients with cataract," *Curr. Eye Res.* **12**(5), 423-431.
- 3660 KLEIMAN, N.J., DAVID, J., ELLISTON, C.D., HOPKINS, K.M., SMILENOV, L.B.,
3661 BRENNER, D.J., WORGUL, B.V., HALL, E.J. and LIEBERMAN, H.B. (2007). "Mrad9

- 3662 and Atm haploinsufficiency enhance spontaneous and x-ray-induced cataractogenesis in
3663 mice,” *Radiation Research* **168**(5), 567-573.
- 3664 KLEIN, B.E. and KLEIN, R. (1982). “Cataracts and macular degeneration in older Americans,”
3665 *Arch Ophthalmol.* **100**(4), 571-573.
- 3666 KLEIN, B.E., KLEIN, R., LINTON, K.L., MAGLI, Y.L. and NEIDER, M.W. (1990).
3667 “Assessment of cataracts from photographs in the Beaver Dam Eye Study,” *Ophthalmology*
3668 **97**(11; doi: 10.1016/S0161-6420(90)32391-6), 1428-1433.
- 3669 KLEIN, B.E., KLEIN, R. and LINTON, K.L. (1992). “Prevalence of age-related lens opacities in
3670 a population. The Beaver Dam eye study,” *Ophthalmol.* **99**(4), 546-552.
- 3671 KLEIN, B.E., KLEIN, R., LINTON, K.L. and FRANKE, T. (1993a). “Diagnostic x ray exposure
3672 and lens opacities: The Beaver Dam eye study,” *Am. J. Public Health* **83**(4), 588-590.
- 3673 KLEIN, B.E., KLEIN, R., LINTON, K.L. and FRANKE, T. (1993b). “Cigarette smoking and
3674 lens opacities: The Beaver Dam eye study,” *Am. J. Prev. Med.* **9**(1), 27-30.
- 3675 KLEIN, B., KLEIN, R. and RITTER, L. (1994). “Is there evidence of an estrogen effect on age-
3676 related lens opacities? The Beaver Dam Eye Study,” *Arch. Ophthalmol.* **112**(1; doi:
3677 10.1001/archophth.1994.01090130095025), 85-91.
- 3678 KLEIN, B.E.K., KLEIN, R., WANG, Q. and MOSS, S.E. (1995a). “Older-onset diabetes and
3679 lens opacities. The Beaver Dam eye study,” *Ophthalmic Epidemiology* **2**(1), 49-55.
- 3680 KLEIN, B.E., KLEIN, R., JENSEN, S.C. and LINTON, K.L. (1995b). “Hypertension and lens
3681 opacities from the Beaver Dam eye study,” *Am. J. Ophthalmol.* **119**(5), 640-646.
- 3682 KLEIN, B.E.K., KLEIN, R. and MOSS, S.E. (2000). “Exposure to diagnostic x-rays and incident
3683 age-related eye disease,” *Ophthalmic Epidemiology* **7**(1), 61-65.
- 3684 KOPEC, R., BUDZANOWSKI, M., BUDZYNSKA, A., CZEPZYNSKI, R., DZIUK, M.,
3685 SOWINSKI, J. and WYSZOMIRSKA, A. (2011). “On the relationship between whole body,
3686 extremity and eye lens doses for medical staff in the preparation and application of
3687 radiopharmaceuticals in nuclear medicine,” *Radiat. Meas.* **46**(11), 1295-1298.
- 3688 KORETZ, J.F., STRENK, S.A., STRENK, L.M. and SEMMLOW, J.L. (2004). “Scheimpflug
3689 and high-resolution magnetic resonance imaging of the anterior segment: A comparative
3690 study,” *J. Opt. Soc. Am. A.* **21**(3), 346-354.

- 3691 KORN, B.S. and KIKKAWA, D.O. (2014). "Images in clinical medicine. Ocular manifestation
3692 of electrical burn," *N. Engl. J. Med.* **370**(4) DOI: 10.1056/NEJMicm1213581.
- 3693 KREMA, H., XU, W., PAYNE, D., VAZQUEZ, L.M., PAVLIN, C.J. and SIMPSON, R. (2011).
3694 "Factors predictive of radiation retinopathy post ¹²⁵Iodine brachytherapy for uveal
3695 melanoma," *Can. J. Ophthalmol.* **46**(2), 158-163.
- 3696 KUSZAK, J.R., PETERSON, K.L., SIVAK, J.G. and HERBERT, K.L. (1994). "The
3697 interrelationship of lens anatomy and optical quality. II. Primate lenses," *Exp. Eye Res.*
3698 **59**(5), 521-534.
- 3699 LE HERON, J., PADOVANI, R., SMITH, I. and CZARWINSKI, R. (2010). "Radiation
3700 protection of medical staff," *European J. of Radiology* **76**(1; doi:
3701 10.1016/j.ejrad.2010.06.034), 20-23.
- 3702 LESKE, M.C., CHYLACK, L.T. and WU, S-Y. (1991). "The lens opacity case-control study
3703 group," *Arch. Ophthalmol.* **109**, 244-251.
- 3704 LETT, J.T., COX, A.B. and LEE, A.C. (1985). "Some perspectives on cataractogenesis from
3705 heavy charged particles," *Radiat. Res.* **104**(2s), S201-S207.
- 3706 LEUSCHEN, J., MORTENSEN, E.M., FREI, C.R., MANSI, E.A., PANDAY, V. and MANSI, I.
3707 (2013). "Association of statin use with cataracts: A propensity score-matched analysis,"
3708 *JAMA Ophthalmol.* **131**(11), 1427-1434.
- 3709 LIAO, J., SU, X., CHEN, P., WANG, X., XU, L., LI, X., THEAN, L., TAN, C., TAN, A.G.,
3710 TAY, W-T., JUN, G., ZHENG, Y., CHEW, M., WANG, Y.X., TAN, Q.S., BARATHI,
3711 V.A., KLEIN, B.E., SAW, S-M., VITHANA, E.N., TAI, E-S., IYENHAR, S.K.,
3712 MITCHELL, P., KHOR, C-C., AUNG, T., WANG, J.J., JONAS, J.B., TEO, Y-Y., WONG,
3713 T.Y. and CHENG, C-Y. (2014). "Meta-analysis of genome-wide association studies in
3714 multiethnic Asians identifies two loci for age-related nuclear cataract," *Human Molecular*
3715 *Genetics* **23**(22; doi: 10.1093/hmg/ddu315), 6119-6128.
- 3716 LIM, D.H., KIM, T.H., CHUNG, E-S. and CHUNG, T-Y. (2014). "Measurement of lens density
3717 using Scheimpflug imaging system as a screening test in the field of health examination for
3718 age-related cataract," *Br. J. Ophthalmol.* 1(doi: 10.1136/bjophthalmol-2014-305632).

- 3719 LOVICU, F.J., ANG, S., CHORAZYCZEWSKA, M. and MCAVOY, J.W. (2004).
3720 “Deregulation of lens epithelial cell proliferation and differentiation during the development
3721 of TGF beta-induced anterior subcapsular cataract,” *Dev. Neurosci.* **26**(5-6), 446-457.
- 3722 LYLE, B.J., MARES-PERLMAN, J.A., KLEIN, B.E.K., KLEIN, R. and GREGER, J.L. (1999).
3723 “Antioxidant intake and risk of incident age-related nuclear cataracts in the Beaver Dam Eye
3724 Study,” *Am. J. Epidemiol.* **149**(9), 801-809.
- 3725 MAKLEY, L.N., MCMENIMEN, K.A., DEVREE, B.T., GOLDMAN, J.W., MCGLASSON,
3726 B.N., RAJAGOPAL, P., DUNYAK, B.M., MCQUADE, T.J., THOMPSON, A.D.,
3727 SUNAHARA, R., KLEVIT, R.E., ANDLEY, U.P. and GESTWICKI, J.E. (2015).
3728 “Pharmacological chaperone for α -crystallin partially restores transparency in cataract,”
3729 *Science* **350**(6261; DOI: 10.1126/science.aac9145), 674-677.
- 3730 MALMSTRÖM, T. and KRÖGER, R.H.H. (2006). “Pupil shapes and lens optics in the eyes of
3731 terrestrial vertebrates,” *J. Exp. Biol.* **209**(doi: 10.1242/jeb.01959), 18-25.
- 3732 MARKIEWICZ, E., BARNARD, S., HAINES, J., COSTER, M., VAN GEEL, O., WU, W.,
3733 RICHARDS, S., AINSBURY, E., ROTHKAMM, K., BOUFFLER, S. and QUINLAN, R.A.
3734 (2015). “Nonlinear ionizing radiation-induced changes in eye lens cell proliferation, cyclin
3735 D1 expression and lens shape,” *Open Biol.* **5**(4; DOI: 10.1098/rsob.150011).
- 3736 MARTIN, C.J. (2011). “A 20 mSv dose limit for the eye: Sense or no sense?” *J. Radiol. Prot.*
3737 **31**(4), 385-387.
- 3738 MASTERS, B.R. (1996). “Three-dimensional visualization of human cataract in vivo,” *Ger. J.*
3739 *Ophthalmol.* **5**(6), 532-536.
- 3740 MASTERS, B.R. (1998). “Three-dimensional microscopic tomographic imaging of the cataract
3741 in a human lens in vivo image,” *Optical Express* **3**(9), 332-338.
- 3742 MASTERS, B.R. and BOHNKE, M. (2002). “Three-dimensional confocal microscopy of the
3743 living human eye,” *Ann. Rev. Biomed. Eng.* **4**(PMID: 12117751), 69-91.
- 3744 MCCART, C.A.I., NANJAN, M.B. and TAYLOR, H.R. (2000). “Attributable risk estimate for
3745 cataract to prioritize medical and public health action,” *Inv. Ophthalmol. Vis. Sci.* **41**(12),
3746 3720-3725.

- 3747 MCLAREN, J.W., DINSLAGE, S., DILLON, J.P., ROBERTS, J.E. and BRUBAKER, R.F.
3748 (1999). "Measuring oxygen tension in the anterior chamber of rabbits," *Amer. J.*
3749 *Ophthalmol.* **127**, 249.
- 3750 MCNAMARA, M.P.J., BJORNSTAD, K.A., CHANG, P.Y., CHOU, W., LOCKETT, S.J. and
3751 BLAKELY, E.A. (2001). "Modulation of lens cell adhesion molecules by particle beams,"
3752 *Physica Medica* **17**(Suppl. 1), 247-248.
- 3753 MEECHAM, W.J., KROLL, S.M., CHAR, D.H., CASTRO, J.R. and BLAKELY, E.A. (1994).
3754 "Anterior segment complications after helium ion radiation therapy for uveal melanoma: I.
3755 Radiation cataract," *Arch. Ophthalmol.* **112**(2), 197-203.
- 3756 MEHRA, V. and MINASSIAN, D.C. (1988). "A rapid method of grading cataract in
3757 epidemiological studies and eye surveys," *Br. J. Ophthalmol.* **72**(11), 801-803.
- 3758 MERRIAM, G.R., JR. (1956). "A clinical study of radiation cataracts," *Trans. Am. Ophthalmol.*
3759 *Soc.* **54**, 611-653.
- 3760 MERRIAM, G.R., JR. and FOCHT, E.F. (1957). "A clinical study of radiation cataracts and the
3761 relationship to dose," *Am. J. Roentgenol. Rad. Ther. Nucl. Med.* **77**, 759-784.
- 3762 MERRIAM, G.R., JR. and FOCHT, E.F. (1962). "A clinical and experimental study of the effect
3763 of single and divided doses of radiation on cataract production," *Trans. Am. Ophthalmol.*
3764 *Soc.* **60**, 35-52.
- 3765 MERRIAM, G.R., JR. and SZECHTER, A. (1975). "The relative radiosensitivity of rat lenses as
3766 a function of age," *Radiat. Res.* **62**(3), 488-497.
- 3767 MERRIAM, G.R., JR., SZECHTER, A. and FOCHT, E.F. (1972). "The effects of ionizing
3768 radiations on the eye," *Front. Rad. Ther. Oncol.* **6**, 346-385.
- 3769 MEWIS, L., TANG, R. and SALMONSEN, P. (1982). "Radiation retinopathy after 'safe' levels
3770 of irradiation," *Invest. Ophthalmol. Vis. Sci.* **22**, 222.
- 3771 MICHAEL, R. and BRON, A.J. (2010). "The ageing lens and cataract: A model of normal and
3772 pathological ageing," *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **366**(1568), 1278-1292.
- 3773 MICHEL, M., JACOB, S., ROGER, G., PELOSSE, B., LAURIER, D., LE POINTE, H.D. and
3774 BERNIER, M.O. (2012). "Eye lens radiation exposure and repeated CT scans: A problem to
3775 keep in mind," *Eur. J. Radiol.* **81**(8), 1896-1900.

- 3776 MILACIC, S. (2009). "Risk of occupational radiation-induced cataract in medical workers,"
3777 Med. Lav. **100**(3), 178-186.
- 3778 MILLER, D.L., VANO, E., BARTAL, G., BALTER, S., DIXON, R., PADOVANI, R.,
3779 SCHUELER, B., CARDELLA, J.F. and DE BAERE, T. (2010). "Occupational radiation
3780 protection in interventional radiology: A joint guideline of the Cardiovascular and
3781 Interventional Radiology Society of Europe and the Society of Interventional Radiology," J.
3782 Vasc. Interv. Radiol. **21**(5), 607-615.
- 3783 MILLER, R.W., FUJINO, T. and NEFZGER, M.D. (1967). "Lens findings in atomic bomb
3784 survivors. A review of major ophthalmic surveys at the Atomic Bomb Casualty Commission
3785 (1949-1962)," Arch. Ophthalmol. **78**, 697-704.
- 3786 MILLER, R.W., FUJINO, T. and NEFZGER, M.D. (1968). "Eye findings in atomic bomb
3787 survivors, 1963-1964, Hiroshima-Nagasaki," Atomic Bomb Casualty Commission
3788 Technical Report 9-68 (Radiation Effects Research Foundation, Hiroshima).
- 3789 MINAMOTO, A., TANIGUCHI, H., YOSHITANI, N., MUKAI, S., YOKOYAMA, T.,
3790 KUMAGAMI, T., TSUDA, Y., MISHIMA, H.K., AMEMIUA, T., NAKASHIMA, E.,
3791 NERIISHI, K., HIDA, A., FUJIWARA, S., SUZUKI, G. and AKAHOSHI, M. (2004).
3792 "Cataract in atomic bomb survivors," Int. J. Radiat. Biol. **80**(5), 339-345.
- 3793 MINAMOTO, A., NERIISHI, K. and NAKASHIMA, E. (2011). "UV radiation may explain
3794 intercity difference for cataract in A-bomb survivors," J. Photochem. Photobiol. B **103**(2),
3795 105-110.
- 3796 MONCASTER, J.A., PINEDA, R., MOIR, R.D., LU, S., BURTON, M.A., GHOSH, J.G.,
3797 ERICSSON, M., SOSCIA, S.J., MOCOFANESCU, A., FOLKERTH, R.D., ROBB, R.M.,
3798 KUSZAK, J.R., CLARK, J.I. and GOLSTEIN, L.E. (2010). "Alzheimer's Disease amyloid-
3799 b links lens and brain pathology in Down Syndrome," PLOS One **5**(5); DOI:
3800 10.1371/journal.pone.0010659).
- 3801 MOREAU, K.L. and KING, J.A. (2012). "Protein misfolding and aggregation in cataract disease
3802 and prospects for prevention," Trends in Molecular Medicine **18**(5), 273-283.
- 3803 MORGAN, W.F. (2003a). "Non-targeted and delayed effects of exposure to ionizing radiation: I.
3804 Radiation-induced genomic instability and bystander effects in vitro," Radiat. Res. **159**(5),
3805 567-580.

- 3806 MORGAN, W.F. (2003b). “Non-targeted and delayed effects of exposure to ionizing radiation:
3807 II. Radiation-induced genomic instability and bystander effects in vivo, clastogenic factors
3808 and transgenerational effects,” *Radiat. Res.* **159**(5), 581-596.
- 3809 MORITA, K. and KAWABE, Y. (1979). “Late effects on the eye of conformation radiotherapy
3810 for carcinoma of the paranasal sinuses and nasal cavity,” *Radiology* **130**(1), 227-232).
- 3811 MRENA, S., KIVELA, T., KURTTIO, P. and AUVINEN, A. (2011). “Lens opacities among
3812 physicians occupationally exposed to ionizing radiation – a pilot study in Finland,”
3813 *Scand. J. Work Environ. Health* **37**(3), 237-243.
- 3814 MURANOV, K.O., POLIANSKI, N.B., KUROVA, V.S., RIABOKON, A.M., SHEREMET,
3815 N.L., FEDOROV, A.A., BANNIK, K.I., ABROSIMOVA, A.N. and OSTROVSKI, M.A.
3816 (2010). “Comparative study of aging, UV treatment, and radiation on cataract formation,”
3817 *Biophys.* **55**(5), 870-877.
- 3818 NAKASHIMA, E., NERIISHI, K. and MINAMOTO, A. (2006). “A reanalysis of atomic-bomb
3819 cataract data, 2000-2002: A threshold analysis,” *Health Phys.* **90**(2), 154-160.
- 3820 NAKISSA, N., RUBIN, P. STROHL, R. and KEYS, H. (1983). “Ocular and orbital
3821 complications following radiation therapy of paranasal sinus malignancies and review of
3822 literature,” *Cancer* **51**(6), 980-986.
- 3823 NA/NRC (1972). National Academies/National Research Council. Report of the Advisory
3824 Committee on the Biological Effects of Ionizing Radiations (BEIR I) (National Academies
3825 Press, Washington).
- 3826 NA/NRC (1980). National Academies/National Research Council. The Effects on Populations of
3827 Exposure to Low Levels of Ionizing Radiation: 1980, BEIR III (National Academies Press,
3828 Washington).
- 3829 NA/NRC (1990). National Academies/National Research Council. Health Effects of Exposure to
3830 Low Levels of Ionizing Radiation, BEIR V (National Academies Press, Washington).
- 3831 NA/NRC (2006). National Academies/National Research Council. Health Risks from Exposure
3832 to Low Levels of Ionizing Radiation: BEIR VII Phase 2 (National Academies Press,
3833 Washington).

- 3834 NASA (2014). National Aeronautics and Space Administration. “International space station,”
3835 http://www.nasa.gov/mission_pages/station/research/experiments/1043.html (accessed
3836 November 14, 2014) (National Aeronautics and Space Administration, Washington).
- 3837 NCRP (1987). National Council on Radiation Protection and Measurements. Recommendations
3838 on Limits for Exposure to Ionizing Radiation, NCRP Report No. 91 (National Council on
3839 Radiation Protection and Measurements, Bethesda, Maryland).
- 3840 NCRP (1989a). National Council on Radiation Protection and Measurements. Guidance on
3841 Radiation Received in Space Activities, NCRP Report No. 98 (National Council on
3842 Radiation Protection and Measurements, Bethesda, Maryland).
- 3843 NCRP (1989b). National Council on Radiation Protection and Measurements. Limit for
3844 Exposure to “Hot Particles” on the Skin, NCRP Report No. 106 (National Council on
3845 Radiation Protection and Measurements, Bethesda, Maryland).
- 3846 NCRP (1993a). National Council on Radiation Protection and Measurements. Risk Estimates for
3847 Radiation Protection, NCRP Report No. 115 (National Council on Radiation Protection and
3848 Measurements, Bethesda, Maryland).
- 3849 NCRP (1993b). National Council on Radiation Protection and Measurements. Limitation of
3850 Exposure to Ionizing Radiation, NCRP Report No. 116 (National Council on Radiation
3851 Protection and Measurements, Bethesda, Maryland).
- 3852 NCRP (1995a). National Council on Radiation Protection and Measurements. Use of Personal
3853 Monitors to Estimate Effective Dose Equivalent and Effective Dose to Workers for External
3854 Exposure to Low-LET Radiation, NCRP Report No. 122 (National Council on Radiation
3855 Protection and Measurements, Bethesda, Maryland).
- 3856 NCRP (1995b). National Council on Radiation Protection and Measurements. Radiation
3857 Exposure and High-Altitude Flight, NCRP Commentary No. 12 (National Council on
3858 Radiation Protection and Measurements, Bethesda, Maryland).
- 3859 NCRP (1997). National Council on Radiation Protection and Measurements. Uncertainties in
3860 Fatal Cancer Risk Estimates Used in Radiation Protection, NCRP Report No. 126 (National
3861 Council on Radiation Protection and Measurements, Bethesda, Maryland).

- 3862 NCRP (1998a). National Council on Radiation Protection and Measurements. Operational
3863 Radiation Safety Program, NCRP Report No. 127 (National Council on Radiation Protection
3864 and Measurements, Bethesda, Maryland).
- 3865 NCRP (1998b). National Council on Radiation Protection and Measurements. Radionuclide
3866 Exposure of the Embryo/Fetus, NCRP Report No. 128 (National Council on Radiation
3867 Protection and Measurements, Bethesda, Maryland).
- 3868 NCRP (1999). National Council on Radiation Protection and Measurements. Biological Effects
3869 and Exposure Limits for “Hot Particles”, NCRP Report No. 130 (National Council on
3870 Radiation Protection and Measurements, Bethesda, Maryland).
- 3871 NCRP (2000a). National Council on Radiation Protection and Measurements. Radiation
3872 Protection Guidance for Activities in Low-Earth Orbit, NCRP Report No. 132 (National
3873 Council on Radiation Protection and Measurements, Bethesda, Maryland).
- 3874 NCRP (2000b). National Council on Radiation Protection and Measurements. Operational
3875 Radiation Safety Training, NCRP Report No. 134 (National Council on Radiation Protection
3876 and Measurements, Bethesda, Maryland).
- 3877 NCRP (2001). National Council on Radiation Protection and Measurements. Evaluation of the
3878 Linear-Nonthreshold Dose-Response Model for Ionizing Radiation, NCRP Report No. 136
3879 (National Council on Radiation Protection and Measurements, Bethesda, Maryland).
- 3880 NCRP (2006a). National Council on Radiation Protection and Measurements. Information
3881 Needed to Make Radiation Protection Recommendations for Space Missions Beyond Low-
3882 Earth Orbit, NCRP Report No. 153 (National Council on Radiation Protection and
3883 Measurements, Bethesda, Maryland).
- 3884 NCRP (2006b). National Council on Radiation Protection and Measurements. Management of
3885 Radionuclide Therapy Patients, NCRP Report No. 155 (National Council on Radiation
3886 Protection and Measurements, Bethesda, Maryland).
- 3887 NCRP (2008). National Council on Radiation Protection and Measurements. Risk to the Thyroid
3888 from Ionizing Radiation, NCRP Report No. 159 (National Council on Radiation Protection
3889 and Measurements, Bethesda, Maryland).

- 3890 NCRP (2009). National Council on Radiation Protection and Measurements. Ionizing Radiation
3891 Exposure of the Population of the United States, NCRP Report No. 160 (National Council
3892 on Radiation Protection and Measurements, Bethesda, Maryland).
- 3893 NCRP (2010a). National Council on Radiation Protection and Measurements. Potential Impact
3894 of Individual Genetic Susceptibility and Previous Radiation Exposure on Radiation Risk for
3895 Astronauts, NCRP Report No. 167 (National Council on Radiation Protection and
3896 Measurements, Bethesda, Maryland).
- 3897 NCRP (2010b). National Council on Radiation Protection and Measurements. Radiation Dose
3898 Management for Fluoroscopically-guided Interventional Medical Procedures, NCRP Report
3899 No. 168 (National Council on Radiation Protection and Measurements, Bethesda,
3900 Maryland).
- 3901 NCRP (2011). National Council on Radiation Protection and Measurements. Second Primary
3902 Cancers and Cardiovascular Disease After Radiation Therapy, NCRP Report No. 170
3903 (National Council on Radiation Protection and Measurements, Bethesda, Maryland).
- 3904 NCRP (2012). National Council on Radiation Protection and Measurements. Uncertainties in the
3905 Estimation of Radiation Risks and Probability of Disease Causation, NCRP Report No. 171
3906 (National Council on Radiation Protection and Measurements, Bethesda, Maryland).
- 3907 NCRP (2013). National Council on Radiation Protection and Measurements. Preconception and
3908 Prenatal Radiation Exposure: Health Effects and Protective Guidance, NCRP Report No.
3909 174 (National Council on Radiation Protection and Measurements, Bethesda, Maryland).
- 3910 NERIISHI, K., NAKASHIMA, E., MINAMOTO, A., FUJIWARA, S., AKAHOSHI, M.,
3911 MISHIMA, H.K., KITAOKU, T. and SHORE, R.E. (2007). "Post-operative cataract cases
3912 among atomic bomb survivors: Radiation dose response and threshold," *Radiat. Res.* **168**(4),
3913 404-408.
- 3914 NERIISHI, K., HAYASHI, T., NAKASHIMA, E., IMAI, K. and NAKACHI, K. (2009). "ATM
3915 haplotypes and radiosensitivity in A-bomb survivors-Preliminary trial using existing data at
3916 RERF," in Abstract Book of Radiation Cataractogenesis Workshop.
- 3917 NERIISHI, K., NAKASHIMA, E., AKAHOSHI, M., HIDA, A., GRANT, E.J., MASUNARI,
3918 N., FUNAMOTO, S., MINAMOTO, A., FUJIWARA, S. and SHORE, R.E. (2012).

- 3919 “Radiation dose and cataract surgery incidence in atomic bomb survivors, 1986–2005,”
3920 Radiology **265**(1), 167–174.
- 3921 NISHIMOTO, S., KAWANE, K., WATANABE-FUKUNAGA, R., FUKUYAMA, H.,
3922 OHSAWA, Y., UCHIYAMA, Y., HASHIDA, N., OHGURO, N., TANO, Y., MORIMOTO,
3923 T., FUKUDA, Y. and NAGATA, S. (2003). “Nuclear cataract caused by a lack of DNA
3924 degradation in the mouse eye lens,” Nature **424**(6952), 1071-1074.
- 3925 NRC (1994). U.S. Nuclear Regulatory Commission. “The Health Physics Positions (HPPOS)
3926 Database (NUREG/CR-5569, Rev. 1, 1994)” [http://www.nrc.gov/about-](http://www.nrc.gov/about-nrc/radiation/protects-you/hppos/qa386.html)
3927 [nrc/radiation/protects-you/hppos/qa386.html](http://www.nrc.gov/about-nrc/radiation/protects-you/hppos/qa386.html) (accessed September 23, 2014) (U.S.
3928 Government Printing Office, Washington).
- 3929 NRC (2008). U.S. Nuclear Regulatory Commission. “Part 20 Standards For Protection Against
3930 Radiation,” Title 10 Code of Federal Regulations Part 20 [http://www.nrc.gov/reading-](http://www.nrc.gov/reading-rm/doc-collections/cfr/part020/)
3931 [rm/doc-collections/cfr/part020/](http://www.nrc.gov/reading-rm/doc-collections/cfr/part020/) (accessed July 23, 2014) (U.S. Government Printing Office,
3932 Washington).
- 3933 NRC (2010). U.S. Nuclear Regulatory Commission. Methods for Measuring Effective Dose
3934 Equivalent from External Exposure, Office of Nuclear Regulatory Research, Regulatory
3935 Guide 8.40, <http://pbadupws.nrc.gov/docs/ML1006/ML100610534.pdf> (accessed July 23,
3936 2014) (U.S. Government Printing Office, Washington).
- 3937 NRC (2011). U.S. Nuclear Regulatory Commission. Occupational Radiation Exposure at
3938 Commercial Nuclear Power Reactors and Other Facilities 2011 – Forty-Fourth Annual
3939 Report, Office of Nuclear Regulatory Research, NUREG-0713, Volume 33,
3940 <http://pbadupws.nrc.gov/docs/ML1309/ML13095A191.pdf> (accessed July 16, 2014) (U.S.
3941 Government Printing Office, Washington).
- 3942 OKLADNIKOVA, N.D., PESTERNIKOVA, V.S., SUMINA, M.V. and DOSHCENKO, V.N.
3943 (1994). “Occupational diseases from radiation exposure at the first nuclear plant in the
3944 USSR,” Science of the Total Environment **142**(1), 9-17.
- 3945 OKLADNIKOVA, N.D., SUMINA, M.V., PESTERNIKOVA, V.S., AZIZOVA, T. and
3946 KABASHEVA, N. (2007). “Long-term consequences of external gamma-radiation
3947 according to the results of the observation of the personnel of the first atomic power plant in
3948 the country,” Kinicheskaiia Meditsina, **85**(100), 21-26 [in Russian].

- 3949 OTAKE, M. and SCHULL, W.J. (1982). "The relationship of gamma and neutron radiation to
3950 posterior lenticular opacities among atomic bomb survivors," *Radiat. Res.* **92**(3), 574-595.
- 3951 PARSONS, J.T., BOVA, F.J., FITZGERALD, C.R., MENDENHALL, W.M. and MILLION,
3952 R.R. (1994a). "Radiation retinopathy after external-beam irradiation: Analysis of time-dose
3953 factors," *Intl. J. Radiat. Oncol. Biol. Phys.* **30**(4), 765-773.
- 3954 PARSONS, J.T., BOVA, F.J., FITZGERALD, C.R., MENDENHALL, W.M. and MILLION,
3955 R.R. (1994b). "Radiation optic neuropathy after megavoltage external-beam irradiation:
3956 Analysis of time-dose factors," *Intl. J. Radiat. Oncol. Biol. Phys.* **30**(4), 755-763.
- 3957 PENDERGRASS, W., PENN, P., POSSIN, D. and WOLF, N. (2005). "Accumulation of DNA,
3958 nuclear and mitochondrial debris and ROS at sites of age-related cortical cataract in mice,"
3959 *Inv. Ophthalmol. Vis. Sci.* **46**(12), 4661-4670.
- 3960 PENDERGRASS, W., ZITNIK, G., TSAI, R. and WOLF, N. (2010). "X-ray induced cataract is
3961 preceded by LEC loss, and coincidence with accumulation of cortical DNA, and ROS;
3962 similarities with age-related cataracts," *Mol. Vis.* **16**, 1496-1513.
- 3963 PICANO, E., VANO, E., DOMENICI, L., BOTTAI, M. and THIERRY-CHEF, I. (2012).
3964 "Cancer and non-cancer brain and eye effects of chronic low-dose ionizing radiation
3965 exposure," *BMC Cancer* **12**(157), DOI: 10.1186/1471-2407-12-157.Review.
- 3966 POTTS, A.M. (1979). "Cataract – A semantic trap," in *Progress Anterior Eye Segment Research*,
3967 *Doc. Ophthalmol. Proc. Ser.* **18**(xx), 229-233.
- 3968 PRINS, R., DAUER, L.T., COLOSI, D.C., QUINN, B., KLEIMAN, N.J., BOHLE, G.C.,
3969 HOLOHAN, B., AL-NAJJAR, A., FERNANDEZ, T., BONVENTO, M., FABER, R.D.,
3970 CHING, H. and GOREN, A.D. (2011). "Significant reduction in dental cone beam
3971 computed tomography (CBCT) eye dose through the use of leaded glasses," *Oral Surg. Oral*
3972 *Med. Oral Pathol. Oral Radiol. Endod.* **112**(4), 502-507.
- 3973 PRYOR, K. (2011). Communication to Cindy Bladey. Docket ID NRC-2009-0279
3974 Recommendations on the Annual Dose Limit to the Lens of the Eye. Health Physics Society
3975 to U.S. Nuclear Regulatory Commission, October 31, 2011 (Health Physics Society,
3976 Richland, Washington).

- 3977 PUK, O. and HARABE DE ANGELIS, M. (2013). “Lens density tracking in mice by
3978 Scheimpflug imaging,” *Mamm. Genome* **24**(7-8; doi: 10.1007/s00335-013-9470-2), 295-
3979 302.
- 3980 QUINN, B., AIME, J., HUMM, J., ST. GERMAIN, J. and DAUER, L.T. (2012). “Measured
3981 dose rate constant from oncology patients administered ¹⁸F for positron emission
3982 tomography,” *Med. Phys.* **39**(10), 6071-6079.
- 3983 RAFNSSON, V., OLAFSDOTTIR, E., HRAFNKELSSON, J., SASAKI, H., AMARSSON, A.
3984 and JONASSON, F. (2005). “Cosmic radiation increases the risk of nuclear cataract in
3985 airline pilots: A population-based case-control study,” *Arch. Ophthalmol.* **123**(8), 1102-
3986 1105.
- 3987 RERF (2013a). Radiation Effects Research Foundation. “The 40th meeting of the RERF
3988 Scientific Advisory Committee,” Press Conference Material
3989 <http://www.rerf.jp/news/pdf/40sace.pdf> (accessed February 20, 2015) (Radiation Effects
3990 Research Foundation, Hiroshima, Japan).
- 3991 RERF (2013b). Radiation Effects Research Foundation. “Report of the 40th meeting of the RERF
3992 Scientific Advisory Committee,” Annual Report 2012-2013
3993 http://www.rerf.jp/library/AnnualReport_e/2012/index_e.html (accessed February 20, 2015)
3994 (Radiation Effects Research Foundation, Hiroshima, Japan).
- 3995 RERF (2014a). Radiation Effects Research Foundation. “The 41st meeting of the RERF
3996 Scientific Advisory Committee,” Press Conference Material
3997 <http://www.rerf.jp/news/pdf/41sace.pdf> (accessed February 20, 2015) (Radiation Effects
3998 Research Foundation, Hiroshima, Japan).
- 3999 RERF (2014b). Radiation Effects Research Foundation. “Report of the 41st meeting of the RERF
4000 Scientific Advisory Committee,” Annual Report 2013-2014
4001 http://www.rerf.jp/library/AnnualReport_e/2013/index_e.html (accessed February 20, 2015)
4002 (Radiation Effects Research Foundation, Hiroshima, Japan).
- 4003 RESTE, J., ZVIGULE, G., ZVAGULE, T., KURJANE, N., EGLITE, M., GABRUSEVA, N.,
4004 BERZINA, D., PLONIS, J. and MIKLASEVICS, E. (2014). “Telomere length in Chernobyl
4005 accident recovery workers in the late period after the disaster,” *J. Radiat. Res.* **55**(6; DOI:
4006 10.1093/jrr/rru060), 1089-100.

- 4007 RICHTER-MUESCH, S., SACU, S., WEINGESSEL, B., VECSEI-MARLOVITS, V.P. and
4008 SCHMIDT-ERFUTH, U. (2011). "The influence of cortical, nuclear, subcortical posterior,
4009 and mixed cataract on the results of microperimetry," *Eye (Lond.)* **25**(10), 1317-1321.
- 4010 RILEY, E.F., LINDGREN, A.L., ANDERSEN, A.L., MILLER, R.C. and AINSWORTH, E.J.
4011 (1991). "Relative cataractogenic effects of x rays, fission-spectrum neutrons, and ⁵⁶Fe
4012 particles: A comparison with mitotic effects," *Radiat. Res.* **125**(3), 298-305.
- 4013 RINGELSTEIN, A., LEHEL, U., FAHRENDORF, D.M., ALTENBERND, J.C., FORSTING,
4014 M. and SCHLAMANN, M. (2014). "Radiation exposure in perfusion CT of the brain," *J.*
4015 *Comput. Assist. Tomogr.* **38**(1), 25-28.
- 4016 RITTER, L.L., KLEIN, B.E.K., KLEIN, R. and MARES-PERLMAN, J.A. (1993). "Alcohol use
4017 and lens opacities in the Beaver Dam eye study," *Arch Ophthalmol.* **111**(1), 113-117.
- 4018 ROBERTS, J.E. (2001). "Ocular phototoxicity," *J. Photochem. Photobiology B: Biol.* **64**(2-3),
4019 136-143.
- 4020 ROBERTS, J.E. (2011). "Photobiology of the Human Lens," Original research article (Fordham
4021 University, Department of Natural Sciences, New York, New York).
- 4022 ROBMAN, L. and TAYLOR, H. (2005). "External factors in the development of cataract," *Eye*
4023 **19**(xx), 1074-1082.
- 4024 ROHRSCHEIDER, W. (1929). "Experimentelle untersuchungen über die veränderungen
4025 normaler augengewebe nach röntgenbestrahlung: III. Mittelilung: Veränderungen der lines
4026 der netzhaut und des sehnerven nach röntgenbestrahlung," *Graefes. Arch. Ophthalmol.*
4027 **122**(2-3), 282-298.
- 4028 RYAN, E.R., THORNTON, R., SOFOCLEOUS, C.T., ERINJERI, J.P., HSU, M., QUINN, B.
4029 and DAUER, L.T. (2013). "PET/CT-guided interventions: Personnel radiation dose,"
4030 *Cardiovasc. Intervent. Radiol.* **36**(4), 1063-1067.
- 4031 SAGERMAN, R. and ALBERTI, W.E. (2003). "Radiosensitivity of ocular and orbital
4032 structures," pp. 269-280 in Radiotherapy of Intraocular and Orbital Tumors, Sagerman, R.H.
4033 and Alberti, W.E., Eds. (Springer, Berlin).
- 4034 SANCHEZ, R.M., VANO, E., FERNANDEZ, J.M., GINJAUME, M. and DUCH, M.A. (2014).
4035 "Measurements of eye lens doses in interventional cardiology using OSL and electronic
4036 dosimeters," *Radiat. Prot. Dosimetry* DOI: 10.1093/rpd/nct368.

- 4037 SANDBORG, M., ROSSITTI, S. and PETTERSSON, H. (2010). "Local skin and eye lens
4038 equivalent doses in interventional neuroradiology," *Eur. Radiol.* **20**(3), 725-733.
- 4039 SASAKI, K. and NAKAMURA, F. (1978). "Rotating photo-slit lamp based on Scheimpflug's
4040 principle and its clinical application," *J. Ophthalmol. Photogr. Soc.* **1**(1), 20-22.
- 4041 SASAKI, K., OISHI, T., YAMAACKI, H. and NAKAMURA, F. (1979). "Documentation of
4042 human lens by rotating photo-slit-lamp. Clinical applications and examinations for the
4043 reproducibility of obtained photographs," *Japan J. Ophthalmol.* **33**, 621-627.
- 4044 SASAKI, K., SHIBATA, T., OBAZAWA, H., FUJIWARA, T., KOGURE, F., OBARA, Y.
4045 ITOI, M., KATOU, K., AKIYAMA, K. and OKUYAMA, S. (1990). "Classification system
4046 for cataracts. Application by the Japanese Cooperative Cataract Epidemiology Study
4047 Group," *Ophthalmic Res.* **22**(Suppl. 1), 46-50.
- 4048 SCHWARTZ, D.L., KIM, S.K. and ANG, K.K. (2010). "The orbit," Chapter 14 in Radiation
4049 Oncology: Rational, Technique, Results, 9th Edition, Cox, J.D. and Ang, K.K., Eds.
4050 (Elsevier, Philadelphia).
- 4051 SHAH, M. SHAH, S., UPADHYAY, P. and AGRAWAL, R. (2013). "Controversies in traumatic
4052 cataract classification and management: A review," *Can. J. Ophthalmol.* **48**(4), 251-258.
- 4053 SHIELS, A. and HEJTMANCIK, J.F. (2013). "Genetics of human cataract," *Clin. Genet.* **84**(2),
4054 120-127.
- 4055 SHORE, R.E. (2014). "Radiation impacts on human health: Certain, fuzzy, and unknown,"
4056 *Health Phys.* **106**(2), 196-205.
- 4057 SHORE, R.E., NERIISHI, J. and NAKASHIMA, E. (2010). "Epidemiological studies of cataract
4058 risk at low to moderate radiation doses: (Not) seeing is believing," *Radiat. Res.* **174**(6b),
4059 889-894.
- 4060 SMILENOV, L.B., BRENNER, D.J. and HALL, E.J. (2001). "Modest increased sensitivity to
4061 radiation oncogenesis in ATM heterozygous versus wild-type mammalian cells," *Cancer*
4062 *Res.* **61**(15), 5710-5713.
- 4063 SMILENOV, L.B., KLEIMAN, N.J., LIEBERMAN, H.B., ZHOU, G. and HALL, E.J. (2008).
4064 "Individual genetic susceptibility," Presented at the DOE/BER Low Dose Radiation
4065 Research Investigators Workshop VII (Washington, DC, January 21, 2008).

- 4066 SPARROW, J.M. (1990). "Methods of clinical cataract grading: Two systems compared," Arch.
4067 Ophthalmol. **108**(9), 1209.
- 4068 SPARROW, J.M., BRON, A.J., BROWN, N.A.P., AYLIFF, W. and HILL, A.R. (1986). "The
4069 Oxford Clinical Cataract Classification and Grading System," Int. Ophthalmol. **9**(4), 207-
4070 225.
- 4071 SPENCER, R.W. and ANDELMAN, S.Y. (1965). "Steroid cataracts; posterior subcapsular
4072 formation in rheumatoid arthritis patients on long term steroid therapy," Arch. Ophthalmol.
4073 **74**(1), 38-41.
- 4074 STEIN, J. (2012). "Serious adverse events after cataract surgery," Curr. Opin. Ophthalmol.
4075 **23**(3), 219-225.
- 4076 STRAHLENSCHUTZKOMMISSION (2010). Monitoring the Eye Lens Dose, Statement by the
4077 German Commission on Radiological Protection with Scientific Reasoning, adapted at the
4078 240th meeting of the German Commission on Radiological Protection,
4079 [http://www.ssk.de/SharedDocs/Beratungsergebnisse_PDF/2010/2010_01e.pdf?__blob=publi](http://www.ssk.de/SharedDocs/Beratungsergebnisse_PDF/2010/2010_01e.pdf?__blob=publicationFile)
4080 [cationFile](http://www.ssk.de/SharedDocs/Beratungsergebnisse_PDF/2010/2010_01e.pdf?__blob=publicationFile) (accessed November 29, 2014) (Geschäftsstelle der Strahlenschutzkommission,
4081 Bonn, Germany).
- 4082 STRENK, S.A., STRENK, L.M., SEMMLOW, J.L. and DEMARCO, J.K. (2004). "Magnetic
4083 resonance imaging study of the effects of age and accommodation on the human lens cross-
4084 sectional area," Invest. Ophthalmol. Vis. Sci. **45**(2), 539-545.
- 4085 SULOCHANA, K.N., PUNITHAM, R. and RAMAKRISHNAN, S. (2002). "Effect of cigarette
4086 smoking on cataract: Antioxidant enzymes and constituent minerals in the lens and blood of
4087 humans," Indian J. Pharmacol. **34**, 428-431.
- 4088 SWETHA, V., JEGANATHAN, E., ANDREWWIRTH, Y. and MACMANUS, M.P. (2011).
4089 "Ocular risks from orbital and periorbital radiation therapy: A critical review," Int. J. Radiat.
4090 Oncol. Biol. Phys. **79**(3), 650-659.
- 4091 TAN, A.C.S., WANT, J.J., LAMOUREUX, E.L., WONG, W., MITCHELL, P., LI, J., TAN,
4092 A.G. and WONG, T.Y. (2011). "Cataract prevalence varies substantially with assessment
4093 systems: Comparison of clinical and photographic grading in a population-based study,"
4094 Ophthalmic Epidemiol. **18**(4), 164-170.

- 4095 TATE, G., JR. and SAFIR, A. (1991). "The slit lamp history, principles and practice," pages 1-
4096 44 in Duane's Clinical Ophthalmology, Ed. Tasman, W. and Jaeger, E.A. (1:1-44).
- 4097 TAYLOR, H.R. and WEST, S.K. (1989). "The clinical grading of lens opacities," Aust. NZ J.
4098 Ophthalmol. **17**(1; doi: 10.1111/j.1442-9071.1989.tb00492.x), 81.
- 4099 TAYLOR, H.R., WEST, S.K., ROSENTHAL, F.S., MUNOZ, B., NEWLAND, H.S., ABBEY,
4100 H. and EMMETT, E.A. (1988). "Effect of ultraviolet radiation on cataract formation," N.
4101 Engl. J. Med. **319**(22), 1429-1433.
- 4102 TAYSI, S., UCUNCU, H., ELMASTAS, M., AKTAN, B. and EMIN-BUYUKOKUROGLU, M.
4103 (2005). "Effect of melatonin on lipid peroxidation, glutathione and glutathione-dependent
4104 enzyme activities in experimental otitis media with effusion in guinea pigs," J. Pineal Res.
4105 **39**(3), 238-242.
- 4106 TETZ, M.R., AUFFARTH, G.U., SPERKER, M., BLUM, M. and VOLCHER, H.E. (1997).
4107 "Photographic image analysis system of posterior capsule opacification," J. Cataract Refract.
4108 Surg. **23**(10), 1515-1520.
- 4109 THOMAS, B.C., MINOGUE, P.J., VALIUNAS, V., KANAPORIS, G., BRINK, P.R.,
4110 BERTHOUD, V.M. and BEYER, E.C. (2008). "Cataracts are caused by alterations of a
4111 critical N-terminal positive charge in connexin50," Invest. Ophthalmol. Vis. Sci. **49**(6),
4112 2549-2556.
- 4113 THOMPSON, K.M., SIMONS, E.A., BADIZADEGAN, K. and REEF, S.E. (2014).
4114 "Characterization of the risks of adverse outcomes following rubella infection in
4115 pregnancy," Risk Anal. DOI: 10.1111/risa.12264.
- 4116 THYLEFLORS, B., CHYLACK, L., KONYAMA, K., SASAKI, K., SPERDUTO, R.,
4117 TAYLOR, H.R. and WEST, S. (2002). "A simplified cataract grading system: The WHO
4118 cataract grading group," Ophthalmic Epidemiol. **9**(2), 83-95.
- 4119 TRUSCOTT, R.J.W. (2005). "Age-related nuclear cataract-oxidation is the key," Exp. Eye Res.
4120 **80**(5), 709-725.
- 4121 UNSCEAR (1972). United Nations Scientific Committee on the Effects of Atomic Radiation.
4122 Ionizing Radiation: Levels and Effects, 1972 Report to the General Assembly with Annexes,
4123 Publication E.72.IX.17 (United Nations Publications, New York).

- 4124 UNSCEAR (1977). United Nations Scientific Committee on the Effects of Atomic Radiation.
4125 Sources and Effects of Ionizing Radiation, 1977 Report to the General Assembly with
4126 Annexes, Publication E.77.IX.1 (United Nations Publications, New York).
- 4127 UNSCEAR (1982). United Nations Scientific Committee on the Effects of Atomic Radiation.
4128 Ionizing Radiation: Sources and Biological Effects, UNSCEAR 1982 Report to the General
4129 Assembly, with Annexes, Publication No. E.82.IX.8 (United Nations Publications, New
4130 York).
- 4131 UNSCEAR (1986). United Nations Scientific Committee on the Effects of Atomic Radiation.
4132 Genetic and Somatic Effects of Ionizing Radiation, 1986 Report to the General Assembly
4133 with Annexes, Publication E.86.IX.9 (United Nations Publications, New York).
- 4134 UNSCEAR (1988). United Nations Scientific Committee on the Effects of Atomic Radiation.
4135 “Annex F: Radiation carcinogenesis in man,” pages 405 to 543 in Sources and Risks of
4136 Ionizing Radiation, 1988 Report to the General Assembly with Annexes, Publication
4137 E.88.IX.7 (United Nations Publications, New York).
- 4138 UNSCEAR (1994). United Nations Scientific Committee on the Effects of Atomic Radiation.
4139 Sources and Effects of Ionizing Radiation, Publication No. E.94.IX.11 (United Nations
4140 Publications, New York).
- 4141 UNSCEAR (2000). United Nations Scientific Committee on the Effects of Atomic Radiation.
4142 Sources and Effects of Ionizing Radiation: UNSCEAR 2000 Report, Volume II Effects -
4143 Report to the General Assembly, with Scientific Annexes, Sales Number 00.IX.4 (United
4144 Nations Publications, New York).
- 4145 UNSCEAR (2001). United Nations Scientific Committee on the Effects of Atomic Radiation.
4146 Hereditary Effects of Radiation: UNSCEAR 2001 Report to the General Assembly, with
4147 Scientific Annex, Sales Number 01.1X.2 (United Nations Publications, New York).
- 4148 UNSCEAR (2008). United Nations Scientific Committee on the Effects of Atomic Radiation.
4149 Effects of Ionizing Radiation: UNSCEAR 2006 Report, Volume 1 - Report to the General
4150 Assembly, with Scientific Annexes A and B, Sales Number 08.IX.6 (United Nations
4151 Publications, New York).

- 4152 UNSCEAR (2011a). United Nations Scientific Committee on the Effects of Atomic Radiation.
4153 Sources of Ionizing Radiation, Volume I: Report to the General Assembly, Scientific
4154 Annexes A and B, Sales Number 10.IX.3 (United Nations Publications, New York).
- 4155 UNSCEAR (2011b). United Nations Scientific Committee on the Effects of Atomic Radiation.
4156 Report of the United Nations Scientific Committee on the Effects of Atomic Radiation 2010.
4157 Fifty-seventh Session, Scientific Report: Summary of Low-Dose Radiation Effects on
4158 Health, Sales Number M.11.IX.4 (United Nations Publications, New York).
- 4159 UNSCEAR (2013a). United Nations Scientific Committee on the Effects of Atomic Radiation.
4160 Sources, Effects and Risks of Ionizing Radiation, Volume I: 2013 Report to the General
4161 Assembly, [http://www.unscear.org/docs/reports/2013/13-](http://www.unscear.org/docs/reports/2013/13-85418_Report_2013_GA_Report.pdf)
4162 [85418_Report_2013_GA_Report.pdf](http://www.unscear.org/docs/reports/2013/13-85418_Report_2013_GA_Report.pdf) (accessed November 29, 2014) (United Nations
4163 Publications, New York).
- 4164 UNSCEAR (2013b). United Nations Scientific Committee on the Effects of Atomic Radiation.
4165 Sources, Effects and Risks of Ionizing Radiation, Volume I: 2013 Report to the General
4166 Assembly Scientific Annex A: Levels and Effects of radiation exposure due to the nuclear
4167 accident after the 2011 great east-Japan earthquake and tsunami, Sales No. E.14.IX.1,
4168 [http://www.unscear.org/docs/reports/2013/14-](http://www.unscear.org/docs/reports/2013/14-06336_Report_2013_Annex_A_Ebook_website.pdf)
4169 [06336_Report_2013_Annex_A_Ebook_website.pdf](http://www.unscear.org/docs/reports/2013/14-06336_Report_2013_Annex_A_Ebook_website.pdf) (accessed November 29, 2014) (United
4170 Nations Publications, New York).
- 4171 UNSCEAR (2013c). United Nations Scientific Committee on the Effects of Atomic Radiation.
4172 Sources, Effects and Risks of Ionizing Radiation, Volume II: 2013 Report to the General
4173 Assembly Scientific Annex B, Sales Number 14.IX.2 (United Nations Publications, New
4174 York).
- 4175 VAN SONSBEEK, R. (2012). “New dose limits for the lens of the eye implications and
4176 implementation industrial radiography,” presentation at the Technical Meeting in ‘The New
4177 Dose Limit for the Lens of the Eye – Implications and Implementation,’
4178 [https://gnssn.iaea.org/RTWS/general/Shared%20Documents/Radiation%20Protection/TM%](https://gnssn.iaea.org/RTWS/general/Shared%20Documents/Radiation%20Protection/TM%20on%20the%20New%20Dose%20Limit%20to%20the%20Lens%20of%20the%20Eye/REPORT%20OF%20THE%20TM.pdf)
4179 [20on%20the%20New%20Dose%20Limit%20to%20the%20Lens%20of%20the%20Eye/RE](https://gnssn.iaea.org/RTWS/general/Shared%20Documents/Radiation%20Protection/TM%20on%20the%20New%20Dose%20Limit%20to%20the%20Lens%20of%20the%20Eye/REPORT%20OF%20THE%20TM.pdf)
4180 [PORT%20OF%20THE%20TM.pdf](https://gnssn.iaea.org/RTWS/general/Shared%20Documents/Radiation%20Protection/TM%20on%20the%20New%20Dose%20Limit%20to%20the%20Lens%20of%20the%20Eye/REPORT%20OF%20THE%20TM.pdf) (accessed February 20, 2015) (Vienna, Austria).

- 4181 VON SALLMANN, L., TOBIAS, C.A., ANGER, H.O., WELCH, C., KIMURA, S.F., MUNOZ,
4182 C.M. and DRUNGIS, A. (1955). "Effects of high energy particles, x-rays, and aging on lens
4183 epithelium," *Arch. Ophthalmol.* **54**(4), 489-514.
- 4184 VANO, E., GONZALEZ, B.F. and MORENO, F. (1998). "Lens injuries induced by occupational
4185 exposure in non-optimized interventional radiology laboratories," *Br. J. Radio.* **71**(847),
4186 728-733.
- 4187 VANO, E., GONZALEZ, L., FERNANDEZ, J.M. and HASKAL, Z.J. (2008). "Eye lens
4188 exposure to radiation in interventional suites: Caution is warranted," *Radiology* **248**(3), 945-
4189 953.
- 4190 VANO, E., KLEIMAN, N.J., DURAN, A., REHANI, M.M., ECHEVERRI, D. and CABRERA,
4191 M. (2010). "Radiation cataract risk in interventional cardiology personnel," *Radiat. Res.*
4192 **174**(4), 490-495.
- 4193 VANO, E., KLEIMAN, N.J., DURAN, A., ROMANO-MILLER, M. and REHANI, M.M.
4194 (2013a). "Radiation-associated lens opacities in catheterization personnel: Results of a
4195 survey and direct assessments," *J. Vasc. Interv. Radiol.* **24**(2), 197-204.
- 4196 VANO, E., FERNANDEZ, J.M., SANCHEZ, R.M. and DAUER, L.T. (2013b). "Realistic
4197 approach to estimate lens doses and cataract radiation risk in cardiology when personal
4198 dosimeters have not been regularly used," *Health Phys.* **105**(4), 330-339.
- 4199 VASAVADA, A.R., RAJ, S.M., VASAVADA, V. and SHRIVASTAV, S. (2012). "Surgical
4200 approaches to posterior polar cataract: A review," *Eye (Lond.)* **26**(6), 761-770.
- 4201 VAVVAS, D. AZAR, N.F. and AZAR, D.T. (2002). "Mechanisms of disease: Cataracts,"
4202 *Ophthalmol. Clin. North Am.* **15**(1), 49-60.
- 4203 VIEBAHN, M., BARRICKS, M. and OSTERLOH, M. (1991). "Synergism between diabetic and
4204 radiation retinopathy: Case report and review," *Br. J. Ophthalmol.* **75**(10), 629-632.
- 4205 VIVINO, M.A., CHINTALAGIRI, S., TRUS, B.L. and DATILES, M.B. (1993). "Development
4206 of a Scheimpflug slit lamp camera system for quantitative densitometric analysis," *Eye* **7**(Pt
4207 6), 791-798.
- 4208 WANG, K., CHENG, C., LI, L., LIU, H., HUANG, Q., XIA, C.H., YAO, K., SUN, P.,
4209 HORWITZ, J. and GONG, X. (2007). "GammaD-crystallin associated protein aggregation
4210 and lens fiber cell denucleation," *Invest. Ophthalmol. Vis. Sci.* **48**(8), 3719-3728.

- 4211 WANG, Y., LI, F., ZHANG, G., KANG, L., QIN, B. and GUAN, H. (2014). “Altered DNA
4212 methylation and expression profiles of 8-oxoguanine DNA glycosylase 1 in lens tissue from
4213 age-related cataract patients,” *Curr. Eye Res.* **13**(PMID: 25310012), 1-7.
- 4214 WEGENER, A., KAEGLER, M. and STINN, W. (2002). “Age-related light scattering in rat
4215 lenses observed in a 2-year inhalation toxicity study,” *Ophthalmic Res.* **34**(5), 273-280.
- 4216 WEGENER, A. and LASER-JUNGA, H. (2009). “Photography of the anterior eye segment
4217 according to Scheimpflug’s principle: Options and limitations – a review,” *Clin. Experiment
4218 Ophthalmol.* **7**(1), 144-154.
- 4219 WEIKEL, K.A., GARBER, C., BABURINS, A. and TAYLOR, A. (2014). “Nutritional
4220 modulation of cataract,” *Nutr. Rev.* **72**(1), 30-47.
- 4221 WEST, S., MUNOZ, B., EMMETT, E.A. and TAYLOR, H.R. (1989). “Cigarette smoking and
4222 risk of nuclear cataracts,” *Arch. Ophthalmol.* **107**(8), 1166-1169.
- 4223 WHELAN, K.F., STRATTON, K., KAWASHIMA, T., WATERBOR, J.W., CASTLEBERRY,
4224 R.P., STOVALL, M., SKLAR, C.A., PACKER, R.J., MITBY, P., AITKEN, C.L., BLATT,
4225 J., ROBISON, L.L. and MERTENS, A.C. (2010). “Ocular late effects in childhood and
4226 adolescent cancer survivors: A report from the childhood cancer survivor study,” *Pediatr.
4227 Blood Cancer* **54**(1), 103-109.
- 4228 WHO (2010). World Health Organization. The International Statistical Classification of Diseases
4229 and Related Health Problems. Chapter VII “Diseases of the eye and adnexa (H00-H59)”
4230 <http://apps.who.int/classifications/icd10/browse/2010/en#/H2> (accessed June 29, 2014)
4231 (World Health Organization, Geneva, Switzerland).
- 4232 WIKI (2014). Wikipedia. “Schematic diagram of the human eye,”
4233 [http://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Schematic diagram of the hu
4234 man_eye_en.svg/508px-Schematic diagram of the human_eye_en.svg.png](http://upload.wikimedia.org/wikipedia/commons/thumb/1/1e/Schematic_diagram_of_the_human_eye_en.svg/508px-Schematic_diagram_of_the_human_eye_en.svg.png) (accessed
4235 November 14, 2014).
- 4236 WILEY, L.A., RAJAGOPAL, R., DATTILO, L.K. and BEEBE, D.C. (2011). “The tumor
4237 suppressor gene Trp53 protects the mouse lens against subcapsular cataracts and the BMP
4238 receptor Acvr1 acts as a tumour suppressor in the lens,” *Dis. Model. Mech.* **4**(4), 484-495.

- 4239 WNA (2012). World Nuclear Association. “The Nuclear Fuel Cycle,” [http://www.world-](http://www.world-nuclear.org/info/Nuclear-Fuel-Cycle/Introduction/Nuclear-Fuel-Cycle-Overview/)
4240 [nuclear.org/info/Nuclear-Fuel-Cycle/Introduction/Nuclear-Fuel-Cycle-Overview/](http://www.world-nuclear.org/info/Nuclear-Fuel-Cycle/Introduction/Nuclear-Fuel-Cycle-Overview/) (accessed
4241 July 16, 2014) (World Nuclear Association, London, United Kingdom).
- 4242 WOLF, N., PENDERGRASS, W., SINGH, N., SWISSHELM, K. and SCHWARTZ, J. (2008).
4243 “Radiation cataracts: Mechanisms involved in their long delayed occurrence but then rapid
4244 progression,” *Mol. Vis.* **14**, 274-285.
- 4245 WORGUL, B.V. (1988). “Accelerated heavy particles and the lens. V. Theoretical basis of
4246 cataract enhancement by dose fractionation,” *Ophthalmol. Res.* **20**(3), 143-148.
- 4247 WORGUL, B.V. and ROTHSTEIN, H. (1975). “Radiation cataract and mitosis,” *Ophthalmic*
4248 *Res.* **7**(1; doi: 10.1159/000264731), 21-32.
- 4249 WORGUL, B.V., DAVID, J., ODRICH, S., MERRIAM, G.R., JR., MEDVEDOVSKY, C.,
4250 MERRIAM, J.C., TROKEL, S.L. and GEARD, C.R. (1991). “Evidence of genotoxic
4251 damage in human cataractous lenses,” *Mutagenesis* **6**(6), 495-499.
- 4252 WORGUL, B.V., SMILENOV, L., BRENNER, D.J., JUNK, A., ZHOU, W. and HALL, E.J.
4253 (2002). “Atm heterozygous mice are more sensitive to radiation-induced cataracts than are
4254 their wild-type counterparts,” *Proc. Natl. Acad. Sci. USA* **99**(15), 9836-9839.
- 4255 WORGUL, B.V., KUNDIYEV, Y.I., SERGIYENKO, N.M., CHUMAK, V.V., VITTE, P.M.,
4256 MEDVEDOVSKY, C., BAKHANOVA, E.V., JUNK, A.K., KYRYCHENKO, O.Y.,
4257 MUSIJACHENKO, N.V., SHYLO, S.A., VITTE, O.P., XU, S., XUE, X. and SHORE, R.E.
4258 (2007). “Cataracts among Chernobyl clean-up workers: Implications regarding permissible
4259 eye exposures,” *Radiat. Res.* **167**(2), 233-243.
- 4260 WORZALA, K., HILLER, R., SPERDUTO, R.D., MUTALIK, K., MURABITO, J.M.,
4261 MOSKOWITZ, M., D’AGOSTINO, R.B. and WILSON, P.W. (2001). “Postmenopausal
4262 estrogen use, type of menopause, and lens opacities: The Framingham studies,” *Arch. Intern.*
4263 *Med.* **161**(11), 1448-1454.
- 4264 YAMADA, M., WONG, F.L., FUJIWARA, S., AKAHOSHI, M. and SUZUKI, G. (2004).
4265 “Noncancer disease incidence in atomic bomb survivors, 1958-1998,” *Radiat. Res.* **161**(6),
4266 622-632.
- 4267 YANOFF, M. (2008). *Yanoff & Duker’s Ophthalmology*, 3rd Edition (Mosby, Saint Louis,
4268 Missouri).

- 4269 YI, J., YUN, J., LI, Z., XU, C. and PAN, B. (2011). “Epidemiology and molecular genetics of
4270 congenital cataracts,” *Int. J. Ophthalmol.* **4**(4), 422-432.
- 4271 ZEITLIN, C., HASSLER, D.M., CUCINOTTA, F.A., EHRESMANN, B., WIMMER-
4272 SCHWEINGRUBER, R.F., BRINZA, D.E., KANG, S., WEIGLE, G., BÖTTCHER, S.,
4273 BÖHM, E., BURMEISTER, S., GUO, J., KÖHLER, J., MARTIN, C., POSNER, A.,
4274 RAFKIN, S. and REITZ, G. (2013). “Measurements of energetic particle radiation in transit
4275 to Mars on the Mars Science Laboratory,” *Science* **340**(6136), 1080-1084.
- 4276 ZHANG, Y., GONG, J.Y., ZHANG, L., XUE, D.-X., Liu, H.-R. and Liu, P. (2013). “Genetic
4277 polymorphisms of HSP70 in age-related cataract,” *Cell Stress Chaperones* **18**(6), 703-709.
- 4278 ZHAO, L., CHEN, X-J., ZHU, J., XI, Y-B., YANG, X., HU, L-D., OUYANG, H., PATEL, S.H.,
4279 JIN, X., LIN, D., WU, F., FLAGG, K., CAI, H., LI, G., CAO, G., LIN, Y., CHEN, D.,
4280 WEN, C., CHUNG, C., WANG, Y., QIU, A., YEH, E., WANG, W., HU, X, GROB, S.,
4281 ABAGYAN, R., SU, Z., TJONDRO, H.C., ZHAO, X-J., LUO, H., HOU, R., JEFFERSON,
4282 J., PERRY, P., GAO, W., KOZAK, I., GRANET, D., LI, Y., SUN, X., WANG, J., ZHANG,
4283 L., LIU, Y., YAN, Y-B. and ZHANG, K. (2015). “Lanosterol reverses protein aggregation
4284 in cataracts,” *Nature* **523**(7562; DOI: 10.1038/nature14650), 607-611.
- 4285 ZIERHUT, D., LOHR, F., SCHRAUBE, P., HUBER, P., WENZ, F., HAAS, R., FEHRENTZ,
4286 D., FLENTJE, M., HUNSTEIN, W. and WANNENMACHER, M. (2000). “Cataract
4287 incidence after total-body irradiation,” *Int. J. Radiat. Oncol. Biol. Phys.* **46**(1), 131-135.
4288
4289

4290

4291 **Scientific Committee**



Eleanor A. Blakely, Co-Chair, is a Senior Staff Biophysicist at the Lawrence Berkeley National Laboratory with more than 38 y of professional experience in molecular, cellular and animal radiobiological research directed at studying the basic mechanisms of radiation responses, with an emphasis on charged particle radiation effects. She also holds a Faculty Affiliate Appointment in the Department of Radiological Health Sciences at Colorado State University, Fort Collins, and is a Clinical Professor of Radiation Medicine (nontenured) at Loma Linda University, School of Medicine, Loma Linda, California. Dr. Blakely earned a PhD in Physiology from the University of Illinois at Champaign-Urbana as a U.S. Atomic Energy Commission Special Fellow in Radiation Science and Protection. Her professional activities have included service on advisory panels for several hospitals, universities, and numerous federal agencies including the U.S. Department of Energy, the National Institutes of Health (NIH), and the National Aeronautics and Space Administration (NASA); on Editorial Boards for several journals: Space Power, Radiation Research, and Journal of Radiation Research; Appointed Member, Diagnostic Radiology Study Section-Division of Research Grants, NIH; Advisory Committee Member, International Atomic Energy Agency; Scientific Director, NASA Space Research Summer School; and Elected Officer of the Radiation Research Society: Biology Councilor and Secretary-Treasurer. In 2000 she was elected to NCRP, and has served on Scientific Committee (SC) 75 that produced NCRP Report No. 132, Radiation Protection Guidance for Activities in Low-Earth Orbit; and SC 1-7 that produced NCRP Report No. 153, Information Needed to Make Radiation Protection Recommendations for Space Missions Beyond Low-Earth Orbit. She has received several awards including the Robert Emerson Graduate Teaching Award, School of Life Sciences, University of Illinois, the Lawrence Berkeley Laboratory Outstanding Performance Award, the DOE Office of Science Outstanding Mentor Award, the Lawrence Berkeley Laboratory Technology Transfer Award, and a RD100 award from Research and Development Magazine. In 2011, she was chosen to give the NCRP 35th Lauriston S. Taylor Lecture. She serves as consultant in support of clinical radiotherapy trials, and of issues pertinent to radiation protection.



Lawrence T. Dauer, Co-Chair, is Associate Attending Physicist, and Associate Clinical Member in the Departments of Medical Physics and Radiology at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City. He earned an MS in Health Physics and a PhD in Adult Education. He is certified in comprehensive health physics by the American Board of Health Physics and is past chair of the Radiation Safety Committee of the American Association of Physicists in Medicine (AAPM), past President of the Greater New York Chapter of the Health Physics Society (HPS), Executive Council Member of the Medical Physics Section of the HPS, a Member of the

joint Safety Committee of the Society for Interventional Radiology and the American College of Radiology, past council member of the Radiological and Medical Physics chapter of the AAPM, and a member of editorial and review boards of several scientific journals. He serves as the Chair of the MSKCC Emergency Management Committee, a member of the Radiation Injury Treatment Network. In 2005, he received the Elda E. Anderson Award from the Health Physics Society. He is currently a Council member of the NCRP. He also serves as a member of International Commission on Radiological Protection Committee 3 on protection in medicine, a member of the science council for the International Organization for Medical Physics, and was on the program committee for the International Atomic Energy Agency's International Conference on Radiation Protection in Medicine—Setting the Scene for the Next Decade. He has several publications in the topical areas of radiation protection and risks in the fields of detection, radiology, interventional radiology, x-ray imaging, nuclear medicine, and radiation oncology, as well as surgery and medicine.



Elizabeth Ainsbury is a Principal Radiation Protection Scientist at the Public Health England (PHE) Centre for Radiation, Chemical and Environmental Hazards, with 7 y of experience in the field of biomarkers of radiation exposure, in particular in mathematical and statistical analysis of data. In recent years, Dr. Ainsbury has taken a growing interest in radiation induced cataracts and has helped to initiate a growing scientific and public health policy research program at PHE, with the core aim of contributing both to scientific understanding of the mechanisms of cataract induction and providing the context for appropriate translation of the basic research to current and future radiation protection policy and practise. Recent work includes publishing a comprehensive review of the current status of knowledge in the field, completing a survey of occupational lens doses for U.K. medical sector workers, reviewing the implications of the International Commission on Radiological Protection's recent proposals for U.K. stakeholders. Dr. Ainsbury is also participating in a number of ongoing collaborative research projects focussed on low dose-induced early lens changes.



Joseph R. Dynlacht is an Associate Professor in the Department of Radiation Oncology at the Indiana University School of Medicine and a member of the Experimental Therapeutics Division of the Indiana University Simon Cancer Center. He received a BS degree in Biology from Florida State University and a PhD in Cellular and Molecular Radiobiology from Colorado State University before completing a post-doctoral fellowship at the University of California, San Francisco. Dr. Dynlacht teaches a course entitled "Radiation and Cancer Biology" to radiation oncology residents and radiation therapy students annually, and is Co-director of the School of Medicine's Clinical Problem Solving course for first year medical students. He received a Trustee Award for his teaching efforts and involvement in resident training in 2012. Dr. Dynlacht's research interests include the development of agents that reduce normal tissue damage after irradiation (specifically damage to the lens),

development of radiation countermeasures, mechanisms of heat- and radiation-induced cell killing, and development of thermally-activated chemotherapeutic compounds. He has served on advisory panels for several organizations, including Brookhaven National Laboratory, the National Institutes of Health, and the National Aeronautics and Space Administration, and is currently an Associate Editor for the journal Radiation Research.

Lee Goldstein, Consultant,



Nobuyuki Hamada, Consultant, is a Research Scientist at the Radiation Safety Research Center in the Central Research Institute of Electric Power Industry (CRIEPI). For over 16 y, he has conducted a series of radiobiological studies. His past projects include nontargeted effects and heavy-ion effects. His ongoing projects aim to elucidate the radiation response of primary normal human lens epithelial cells and to establish a mouse model system allowing a life-long chase of damaged cells. He has also been involved in several health physics studies.

Currently, Dr. Hamada is Assistant Scientific Secretary of the International Commission on Radiological Protection (ICRP), a member of Expert Group on Radiation Protection Science for the Organization for Economic Co-operation and Development/Nuclear Energy Agency/Nuclear Energy Agency/Committee on Radiation Protection and Public Health, Consultant for NCRP Scientific Committee 1-23 on Guidance on Radiation Dose Limits for the Lens of the Eye, and a member of Expert Committee on Radiation Protection of the Ocular Lens for Japan Health Physics Society. He serves as Associate Editor for the Annals of the ICRP and editorial board members for several scientific journals.

Dr. Hamada received a BSc in radiological sciences from Ibaraki Prefectural University of Health Sciences, and his MSc and PhD in pharmaceutical sciences from Nagasaki University. He was also a visiting PhD student at the Gray Cancer Institute. He was a postdoctoral fellow at the National Institute of Radiological Sciences and in Tohoku University Institute of Development, Aging and Cancer, and a COE Associate Professor in Gunma University Graduate School of Medicine. He joined CRIEPI in 2010. Since 2001, he has published 77 papers in peer-reviewed international journals, which have gained over 1,600 citations. Since 2006, he has received 16 awards, including the Michael Fry Research Award of the Radiation Research Society.



David G. Hoel is a Distinguished University Professor in the Department of Medicine at the Medical University of South Carolina in Charleston and Principal Scientist at Exponent, Inc. He received an AB in mathematics and statistics from University of California at Berkeley, a PhD in mathematical statistics from University of North Carolina in Chapel Hill, and was a post-doctoral fellow in preventive medicine at Stanford University. Prior to joining the Medical University of South Carolina Dr. Hoel was Division Director for Risk Assessment at the National Institute of Environmental Health Sciences in North Carolina. Dr. Hoel is a Fellow of the American Academy of Arts and Sciences, a member of the Institute of Medicine of the National Academies, and a National Associate of the National Academies. His awards include the Spiegleman Gold Medal in Public Health and the Ramazzini Award in Environmental and Occupational Health. He has served on numerous governmental and National Academy committees including the EHC and RAC of U.S. Environmental Protection Agency's Science Advisory Board and the BEIR V committee of the National Academy of Sciences. He was a member of International Agency for Research on Cancer's committee on ionizing radiation (report 100D) and contributed to the United Nations Scientific Committee on the Effects of Atomic Radiation 2006 report. Dr. Hoel's research has focused on risk assessment methods with particular interest in low-dose radiation exposures and cancer. This work has included stays in Hiroshima as a Director at Radiation Effects Research Foundation (RERF) and currently is a member of RERF's Scientific Advisory Committee. Until a year ago, he was a member of National Academies' Board on Nuclear and Radiation Studies. Finally he has testified several times in both the House and Senate on human health issues.



Barbara E.K. Klein graduated from Brooklyn College with BS in 1965 and from New York University School of Medicine in 1969. She then completed a medical internship and Master of Public Health before completing ophthalmologic training with a subspecialty in glaucoma. She has been involved in population based studies of age-related eye disease and of diabetes and complications since 1978. She is Professor of Ophthalmology and Visual Sciences at the University of Wisconsin-Madison having been on the faculty there since 1980.



Don Mayer serves at Indian Point Energy Center as Director of Indian Point Unit 1 and Special Projects. Mr. Mayer has more than 30 y of experience in the nuclear power industry. He joined the New York Power Authority (NYPA) in 1982 as a radiological engineer at Indian Point Unit 3 and worked in the radiation protection field for 20 y, including as Radiation Protection Manager. Mr. Mayer also spent approximately 2 y as General Manager of Unit 3 plant services under NYPA where he was responsible for site security, emergency planning, radiation protection licensing and corrective action programs. Since that time Mayer has lead various major projects for Entergy including site integration after Entergy's plant acquisition of Unit 2 and led the Unit 1 project culminating in the removal and dry storage of the spent fuel.

Mr. Mayer was named Director of Unit 1 in 2007. In 2008, at the culmination of the Indian Point Independent Safety Evaluation, he was named as the senior management sponsor for the response and implementation of recommendations.

Mr. Mayer holds a BS in Biology from Syracuse University, an MS in Radiological Science from the University of Lowell; a Master's in Business Administration from Mt. St. Mary's College and is a Certified Health Physicist.



Christina R. Prescott is an assistant professor at the Wilmer Eye Institute of Johns Hopkins School of Medicine. She specializes in medical and surgical management of complex cataracts and serious corneal diseases. She is active in teaching the Wilmer residents and fellows both clinically and surgically and has developed and implemented a new surgical curriculum utilizing surgical simulators, laboratory training, and checklists. Her own surgical practice focuses on cataract surgery, including laser-assisted cataract surgery and specialty lenses, and modern forms of corneal transplants such as Descemet's stripping endothelial keratoplasty and deep anterior lamellar keratoplasty.

Dr. Prescott received her BA in biophysics from Columbia University and earned her MD and PhD (neuroscience) from the University of Colorado Health Sciences Center. She completed an internship at the Hospital of St. Raphael in New Haven, Connecticut, and her ophthalmology residency at Yale University. Dr. Prescott then completed a fellowship in cornea, refractive surgery and external disease at the Massachusetts Eye and Ear Infirmary of Harvard University.



Raymond H. Thornton is Vice Chair for Quality, Safety, and Performance Improvement, Department of Radiology at Memorial Sloan Kettering Cancer Center (MSKCC).



Eliseo Vano is full Professor of Medical Physics at the Faculty of Medicine of the Complutense University in Madrid and head of the Medical Physics Service at the San Carlos University Hospital. He is Chairman of the Medical Working Party on Medical Exposures of the Article 31 Group of Experts of the European Atomic Energy Community Treaty and Chairman of the Committee on Protection in Medicine of the International Commission on Radiological Protection.



Gayle E. Woloschak is a Professor of Radiation Oncology and Radiology at Northwestern University Feinberg School of Medicine in Chicago. She and her group have been involved in studies of molecular consequences of radiation exposure, late tissue effects associated with radiation, and the use of radiation-inducible nanomaterials for cancer imaging and therapy. Dr. Woloschak also teaches radiation biology to radiation oncology and radiology residents, cardiology trainees, and graduate students and manages the Advanced Grant Writing Workshop for the Radiological Society of North America (RSNA). She earned her PhD in medical sciences from the University of Toledo (Ohio) and did post-doctoral studies in molecular biology at the Mayo Clinic. She has served on review panels for various federal agencies including the National Institutes of Health, the National Aeronautics and Space Administration, the U.S. Department of Energy, RSNA, the U.S. Army Medical Research and Materiel Command, and others. She is currently an associated editor for Radiation Research, the International Journal of Radiation Biology, PLOS One, and Nanomedicine. She is a member of NCRP Program Area Committee 1, has served on organizational committees for several NCRP meetings, and has been involved in committees for several NCRP reports. She is currently Vice-President Elect for the Radiation Research Society.



Cindy Flannery is a Senior Health Physicist in the Office of Federal and State Materials and Environmental Management Programs at the U.S. Nuclear Regulatory Commission (NRC). In this position, she serves as office lead for safety culture activities and is also a member of the working group tasked with developing the regulatory basis for the revisions to the radiation protection regulations (10 CFR Part 20). She joined NRC in 2004 and served as the Team Leader of the Medical Radiation Safety Team for 5 y. Ms. Flannery has 20 y experience as a health physicist in the medical industry as well as in military and research organizations. Prior to NRC, she served as Branch Chief and Radiation Safety Officer for the Defense Threat Reduction Agency and as the Radiation Safety Officer/Health Physicist at the Food and Drug Administration. Before her employment by the federal government, she worked as a Health Physics Consultant and as a Nuclear Medicine Technologist. Ms. Flannery graduated from Georgetown University with an MS in Health Physics and from the University of Wisconsin with a BS in Nuclear Medicine Technology. She was certified by the American Board of Health Physics in 2001. She currently serves as Chair of the American Board of Health Physics Part I Examination Panel.



Phung Tran, Consultant, is currently a Senior Project Manager and the Radiation Management Program Lead for the Electric Power Research Institute (EPRI). She has been working for EPRI since 2003, managing research and development projects in the areas of Water Chemistry Control, Low Level Waste, and Radiation Management. Her main responsibilities now include overseeing the Radiation Management Program, which includes projects in source term reduction, dose reduction, radiation protection optimization, and investigation of health risks from low dose ionizing

radiation exposures. She has an MS in health sciences from Johns Hopkins University and BS in chemical engineering from Stanford University where she was a Merck Engineering and Technology Fellow.



Michael P. Grissom, Staff Consultant, is a Technical Staff Consultant for NCRP and is the President of MPG-HP, Inc., Riverside, California a private consulting firm. He is a recognized authority on operational health physics issues, particularly related to radiation protection in management, military, reactor, medical, and accelerator operations. During 20 y of service in the U.S. Navy, Mr. Grissom served as a Radiation Safety/Laser Safety Officer (hospital) and provided Radiation Health Officer support to the Naval Radiological Controls Program (propulsion, industrial and weapons). Mr. Grissom conducted research in biophysics and radiobiological effects at the Armed Forces Radiobiology Research Institute, Bethesda, Maryland as a junior then senior scientist and served as the Director of Medical Records Search for the Navy Nuclear Test Personnel Review, Office of the Chief of Naval Operations, Washington, DC. Mr. Grissom provided support to the Effluent and Dose Assessment Group, Three Mile Island Unit 2 Recovery Team in 1979 to 1980. He has delivered numerous presentations at scientific and professional society meetings. In 2012, Mr. Grissom became a Fellow of the Health Physics Society (HPS). He previously received the HPS Volunteer Award for services associated with the Medical Health Physics Section and is a Past President of the HPS Accelerator Section. He also served in a number of positions for Stanford University over a period of 16 y at the Stanford Linear Accelerator Center National Accelerator Laboratory, Menlo Park, California including Department Head, Operational Health Physics, and Assistant Associate Director for Environment, Safety and Health.

4292

4293

4294